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ABSTRACT

OPTIMIZATION OF RADIATION THERAPY IN TIME DEPENDENT ANATOMY
William Tyler Watkins, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Medical Physics at

Virginia Commonwealth University, 2013.
Major Director: Jeffrey V. Siebers, Ph.D.
Professor and Director, Medical Physics Graduate Program
Department of Radiation Oncology

The objective of this dissertation is to develop treatment planning techniques that have the
potential to improve radiation therapy of time-dependent (4D) anatomy. Specifically, this study
examines dose estimation, dose evaluation, and decision making in the context of optimizing
lung cancer radiation therapy.
Two methods of dose estimation are compared in patients with locally advanced and early
stage lung cancer: dose computed on a single image (3D-dose) and deformably registered,
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accumulated dose (or 4D-dose). The results indicate that differences between 3D- and 4Ddose are not significant in organs at risk (OARs), however, 4D-dose to a moving lung cancer
target can deviate from 3D-dose. These differences imply that optimization of the 4D-dose
through multiple-anatomy optimization (MAO) can improve radiation therapy in 4D-anatomy.
MAO incorporates time-dependent target and OAR geometry while enabling a simple, clinically
realizable delivery. MAO has the potential to enhance the therapeutic ratio in terms of target
coverage and OAR sparing in 4D-anatomy.
In dose evaluation within 4D-anatomy; dose-to-mass is a more intuitive and precise metric in
estimating the effects of radiation in tissues. Assuming physical density is proportional to
functional tissue density, dose-to-mass has a 1-1 correspondence with radiation damage. Doseto-mass optimization boosts dose in massive regions of lung cancer targets and can reduce
integral dose to lung by preferentially treating through regions of low-density lung tissue.
Finally, multi-criteria optimization (MCO) is implemented in order to clarify decision making
during plan design for lung cancer treatment. An MCO basis set establishes a patient-specific
decision space which reveals trade-offs in OAR-dose at a fixed, constrained target dose. By
interpolating the MCO basis set and evaluating the plan on 4D-anatomy, patient- and organspecific conservatism in plan design can be expressed in real time.
Through improved methods of dose estimation, dose evaluation, and decision making, this
dissertation will positively impact radiation therapy of time-dependent anatomy.

1

1 Introduction

Chapter 1 list of abbreviations:
DNA - deoxyribonucleic acid
RT – radiation therapy
LINAC – linear accelerator
MLC- multi-leaf collimator
3DCRT – 3D conformal radiation therapy
IMRT – intensity modulated radiation therapy
beamlet – (radiation) beam element
CT – computed tomography
OAR – organ at risk

Radiation therapy is a mainstay in the treatment of cancer. Radiation damages cells through
ionization with the potential to alter atomic and molecular bonds including bonds in
deoxyribonucleic acid (DNA). With sufficient radiation dose (energy imparted per unit mass), a
loss of cell-functionality will occur which often includes impaired cell ability to repair and
reproduce. The potential to impair harmful cells (i.e. cancer) with radiation is the basis of
radiation therapy (RT). The goal of RT is to destroy cancer cells while minimizing damage to
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healthy, normal tissue; in other words to maximize radiation’s therapeutic ratio. The overall
objective of this work is to develop and investigate methods which, when implemented, will
improve the therapeutic ratio of radiation therapy for lung cancer.
One premise of RT is that cancer can be identified and localized (including delineation from
healthy, normal tissue). Assuming this premise is met, collimation of radiation from an external
source allows design of an RT plan which specifically targets tumors and avoids healthy tissue.
Specifically, external beam RT utilizing photons produced from a linear accelerator (LINAC),
shaped with a multi-leaf collimator (MLC), and delivered from multiple beam angles have
enabled design of RT-dose distributions which conform to patient-specific anatomy. This
specialized, highly conformal treatment is called 3D-conformal radiation therapy (3DCRT).
3DCRT has since evolved into intensity modulated radiation therapy (IMRT) where each beam
element (beamlet) is modulated according to patient-specific anatomy to maximize dose to
tumors while minimizing dose to normal tissues. In order to design (or plan) an IMRT
treatment, several postulates are necessary including (but not limited to) a sufficiently accurate
patient representation through imaging such as computed tomography (CT), accurate dose
estimation in the simulated anatomy, well-defined evaluation metrics and objectives, and
prudent decision making in plan design.
This dissertation focuses on RT for treatment of lung cancer. While the methods apply to other
cancer sites, fulfilling the preconditions of IMRT for planning and treatment of lung cancer is
particularly challenging. Lung cancer RT is complicated by many factors including large
heterogeneities in lung tissue, respiratory motion, and high-incidence of complications in
surrounding organs at risk (OARs). These challenges may be relevant to poor survival rates in
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lung cancer patients, but there are too many confounding factors in lung cancer survival to
make such a claim. According to the National Cancer Institute, overall five year relative survival
of lung cancer patients (all types and stages) is 15.9%.1 Competing mortality combined with
complications in detection and diagnosis make drawing conclusions about the efficacy of RT for
long-term survival of patients with lung cancer very challenging. However, by increasing the
therapeutic ratio an increase in RT efficacy can be inferred.

1.1 SPECIFIC AIMS
The objective of this work is to implement and develop techniques which have the potential to
improve the therapeutic ratio of radiation therapy in time-dependent (4D) anatomy. These
techniques address the preconditions of IMRT treatment in time-dependent anatomy.
Specifically, this dissertation focuses on (1) dose estimation within simulated anatomy, (2)
evaluation metrics used to determine the quality of treatment and (3) decision making during
plan design, including plan-optimization.
In order to describe the three specific aims of this work with added detail in Chapter 3, Chapter
2 introduces basic concepts in RT and summarizes current techniques for lung cancer RT. The
planning process includes patient simulation, treatment planning, treatment evaluation,
inclusion of uncertainty, and plan optimization. Chapter 2 also describes the patient cohort
used in this dissertation and resulting publications and manuscripts (included in Appendices AE). Chapters 4-7 are dedicated to the specific aims of this work; Chapter 8 draws conclusions
and describes future work.
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2 Radiation Therapy Planning for Lung Cancer

Chapter 2 list of abbreviations:
4DCT – four dimensional computed tomography
aCT – average CT image
MIP – maximum intensity projection image
RPM™- Varian Medical Systems, Palo Alto, CA
RTP – radiation therapy planning
GTV – gross tumor volume
CTV – clinical tumor volume
ITV – internal target volume
PTV – planning target volume
OAR – organ at risk
MAO – multiple anatomy optimization
LQ – linear quadratic
Gy – Grey (1 Joule / kilogram)
Dtot – total physical dose
Nfx – number of fractions
BED – biologic equivalent dose
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SBRT – stereotactic body radiation therapy
RTOG – radiation therapy oncology group
DVH – dose volume histogram
TCP – tumor control probability
NTCP – normal tissue complication probability
QUANTEC - quantitative analysis of normal tissue effects in the clinic
IGRT – image guided radiation therapy
CBCT – cone beam computed tomography
SM – setup margin
IM – internal margin
RTV – representative target volume
ROI – region of interest
TPS – treatment planning system
BFGS – Broyden-Fletcher-Goldfarb-Shanno
LA – locally advanced
NSCLC – non-small cell lung cancer
MCO – multi-criteria optimization
DMH – dose-mass histogram

The purpose of this Chapter is to introduce relevant methods in the practice of radiation
therapy (RT) for lung cancer. The sections are divided according to different stages of the RT
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process. Simulation imaging allows for computerized treatment planning. Plan evaluation and
incorporation of uncertainty allows for plan optimization. Finally, a group of lung cancer
patients is described in Section 2.6, these patients’ image-sets are utilized throughout this
document and related publications.

2.1 SIMULATION IMAGING
The current standard for CT-simulation of lung cancer patients is four-dimensional computed
tomography (4DCT).2,3 X-ray projections are acquired throughout the respiratory cycle in order
to capture patient-specific, time-dependent anatomic features including the tumor boundaries.
The projections are sorted and reconstructed into phase images (labeled by a percentage) and
each phase image represents a portion of the breathing period; common breathing periods
range from 3-6 seconds (s)4,5. If the breathing cycle is divided into 10-phase images the
temporal resolution of each phase image is approximately 0.3-0.6 s, depending on the patient
specific breathing pattern. The 4DCT image set is composed of 3D-images which, when
considered together, represent a 4D-model of patient anatomy and its motion during
respiration.
4DCT image sets are susceptible to image artifacts due to many factors including breathing
irregularities and intra-phase residual motion. Yamamoto et al.6 examined 50 4DCT image sets
and found that approximately half contained blurring and/or sorting artifacts. Some level of
blurring always exists in 4DCT phase images due to intra-phase residual motion. The extent of
intra-phase residual motion is patient-specific but can be minimized through proper acquisition
techniques including minimizing gantry rotation speed.7 4DCT projections (or slices) are sorted
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based on signals acquired during image acquisition. One common signal is a breathing trace
acquired through an infrared camera, e.g. the real-time position management (RPM) camera
(RPM™, Varian Medical Systems, Palo Alto, CA). Others have reported using spirometers (e.g.
Lu et al.8), compression belts (e.g. Werner et al.9), or internal anatomy.10 Irregular or erratic
breathing can cause incorrect or inconsistent phase labeling and can result in sorting artifacts.
One cycle of a breathing pattern is shown in Figure 1 with the approximate respiratory phases
labeled according to assignment from the RPM system.

Figure 1. An example of a breathing cycle acquired
from an infrared camera recording a marker block
placed on a patient’s chest. The approximate
respiratory phases are labeled as a percentage, with
maximum inhale phase labeled 00%, exhale is 50%.
In this dissertation, the 4DCT image set is assumed to
be a sufficiently accurate representation of the patient
anatomy in order to perform RT treatment planning. Clinically, if plan-limiting artifacts are
detected during the planning process a new simulation set (through re-acquisition or alternate
reconstruction methods) is necessary in order to implement the methods described herein. In
Chapter 6, an automated method of identifying image artifacts through evaluation of interphase mass conservation is developed.
For the most part, current clinical radiation therapy planning (RTP) software is designed to
handle a single image for dose calculation and plan optimization. Despite the availability of
4DCT image sets for lung cancer patients, a single image is often used to approximate the
moving anatomy in RTP. The chosen, single image is designated the planning image. Common
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planning images used for clinical RT of lung cancer include a single phase image (e.g. midventilation, 30% phase) or a composite image such as the average CT (aCT) density11 or the
maximum intensity projection (MIP).12,13 Figure 2 shows a coronal slice of each of these images
for one patient included in this dissertation; the 30% phase (left), aCT (middle), and MIP (right)
have different density information resulting in different targets delineated on each image.

Figure 2. Images commonly used for radiation therapy planning of lung cancer include the
30% phase image (left), the average 4DCT density (middle), or the maximum intensity
projection (right). Physician delineations of the tumor (red) differ between the image sets.
Approximating 4D-anatomy with a single image may have an effect on RT treatment; this
approximation introduces uncertainty in structure definition, in dose-estimation, and in plan
optimization. One hypothesis of this work is that inclusion of the entire 4DCT image-set will
improve dose estimation, plan evaluation, and plan optimization in RTP of lung cancer. This
hypothesis is examined for dose calculation in Chapter 4, for plan evaluation in Chapter 6-7, and
for plan optimization in Chapters 5.
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2.2 PLANNING TECHNIQUES
Several methods have been introduced for RT of lung cancer which specifically account for
respiratory motion and lung tissue heterogeneities. Motion management techniques are
summarized in the American Association of Physicists in Medicine (AAPM) task-group report 76
(TG-76)14 and are summarized in the following paragraphs.
In order to accurately identify the moving lung-cancer target the gross tumor volume (GTV) is
delineated on all phases of the 4DCT-image set by an expert physician. As described in ICRU
report 6215, the GTV is expanded to account for microscopic disease into a clinical target
volume (CTV). The union of phase-based CTVs is defined as the lung cancer internal target
volume (ITV)15–17 which is used as a surrogate for the actual, moving CTV. The ITV-method is
the most common approach in designing a lung-cancer target surrogate. An ITV-plan is
designed to deliver uniform dose to the entire ITV to while the patient breathes freely (freebreathing treatment) and/or consistently with breathing captured during 4DCT acquisition.
Figure 3 shows a coronal slice of an aCT-image with a dose distribution designed to deliver
uniform dose to the ITV.
The ITV is expanded into a planning target
volume (PTV) in order to account for interFigure 3. A coronal slice of an average-CT
(aCT) image with an ITV (black)
delineated. The dose distribution intends
to treat 95% of the ITV to 70 Gy. The
motion of the diaphragm can be inferred
from the blurred density in the inferior
lung.
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fraction geometric deviations (or set-up error) between the LINAC and the ITV coordinate
systems. Uncertainty in lung cancer RT and PTV design is described in more detail in section
2.4. The assumption of the ITV-planning approach is that a uniform dose to the entire ITV will
result in a uniform dose to the moving CTV which, by definition, is always contained within the
ITV. This dissertation examines this assumption in Chapter 4.
When motion of the GTV is large (e.g. >1 cm) and respiratory motion is quasi-periodic and
predictable, respiratory gating is an option.18,19 Gating attempts to exploit breathing periodicity
by triggering the LINAC on and off in order to treat only during a pre-specified portion of the
breathing cycle, when the target is assumed to be at a known position. The beam on/off trigger
is often based on the position of a surrogate on the patient surface. The 4DCT simulation
images used for planning establish a correlation between surrogate and tumor locations. The
validity of this correlation, however, has slowed universal implementation of gating.
Specifically, the reproducibility of the phase images as a function of surrogate position over the
course of RT is cause for concern. If the tumor location, as a function of surrogate position,
deviates from the information conveyed from 4DCT images there is a possibility of target miss.
Prohibitively long treatment times limit the minimum gating window (composed of the number
of phases treated during each beam-on cycle) resulting in residual motion during beam-on
times. Reducing the gating window reduces residual motion and increases treatment time. The
beam-on window necessitates construction of a gated-ITV; a union of CTVs defined in phases
designated for beam-on. Both free-breathing and gated RT use a union of phase-based CTVs to
form an ITV on a single planning image which is used for dose computation and plan design (or
optimization).20
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Similar to gating, breath-hold RT attempts to treat in a portion of the breathing cycle while the
patient, either voluntarily21 or through active control22, holds their breath. Breath-hold RT is a
viable method of motion management for patients comfortable with holding their breath or
using an active-control device. This limits the applicability in lung cancer RT due to diseaserelated difficulty in breathing.14 Similar to gating, efficient delivery may depend on the ability
of the patient to hold their breath. However, if the breath-hold technique is well-tolerated
during simulation and/or training, it is a reasonable solution for minimizing (or more ideally,
eliminating) respiratory motion during RT. Determining the uncertainties associated with the
technique, and specifically the reproducibility of individual breath holds remains an active area
of interest.23,24
Another option for treating a moving target is tracking. Target tracking designs time-dependent
MLC apertures which follow the moving target in real time; it is an idealized solution for
treating a moving target.25–27 The tracking plan is designed on multiple phase images and
considers the actual target (not an ITV). However, target tracking requires real time knowledge
of tumor position (e.g. through imaging or a surrogate) in order to synchronize delivery with
motion. System latency between tracked positions and delivery necessitates prediction28,29, but
the predictability of respiration is also a cause for concern. If a prediction model relies on prior
information, inter-fraction breathing variations must be minimized which may be possible with,
e.g., breath coaching.30 Tracking is not implemented clinically due to these (and other)
concerns, but may be in the future.
There is evidence that gating, breath-hold, and tracking have the potential to increase the
therapeutic ratio compared to ITV planning.19,21,22,27,31–33 However, these methods involve
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complicated deliveries, new technology, and may create patient discomfort. This dissertation
attempts to improve on the ITV method of RTP for lung cancer by utilizing a 4D-optimization
which designs plans that can be delivered during free breathing. The method inherently
includes all information available in 4DCT and is evaluated on a patient cohort representative of
a large population of lung cancer patients and potential advantages are discussed. The method
is termed multiple anatomy optimization (MAO) and is discussed in Chapter 5.

2.3 EVALUATION OF RADIOTHERAPY PLANS
Most often, an optimized RT dose distribution is delivered to the patient in multiple treatment
sessions, termed fractions. Ideally, the number of fractions is determined from biologic
differences in repair and repopulation of tumors and normal tissues which can be estimated
from the linear-quadratic (LQ) model of cell survival.34 However, the historic treatment of 2 Gy
per day (1 Gy = 1 Joule/kg) often determines the number of fractions (see, e.g. Fowler35 or
Barendsen36), i.e. for a total dose of Dtot the number of fractions Nfx=Dtot/2 Gy. Hypofractionated RT, however, is transforming the 2 Gy/day approach and prescribing a higher dose
per fraction (e.g. 12 Gy/fraction) for many treatments.
The α/β ratio is a retrospectively derived quantity based on the LQ model.34 According to the
model, the number of surviving cells N from an initial cell population of N0, after irradiation to
dose D is
N N0 = exp ( −α D − β D 2 )
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Biologic Equivalent Dose (BED)35 considers the effects of fractionation and radiation sensitivity
according to the LQ model. It is computed based on the number of fractions (Nfx), dose per
fraction (Dfx), and the α/β ratio according to

D 

BED = N fx D fx  1 + fx  .
 α β
For lung cancer RT, the number of fractions can be as few as 1 in hypo-fractionation37 in
stereotactic body radiation therapy (SBRT) of early stage lung cancer, while 30-35 fractions is
the standard of care in conventional-fractionation for locally advanced, stage III and greater
disease.38
The appropriate prescription dose level in order to achieve local control in non-small cell lung
cancer (NSCLC) is debatable. The uncertainty in the appropriate value arises due to many
factors including competing morbidity and the effects of chemotherapy combined with RT.
However, for traditional fractionation, physical doses of at least 60 Gy and not more than 84 Gy
are appropriate according to the results of (Radiation Therapy Oncology Group) RTOG-931138,39
based on 3DCRT planning and delivery. Bradley et al.38 established a possible upper limit on
treatment dose based on two dose-related deaths of 40 patients treated to a physical dose of
90.3 Gy in 42 fractions. For a given treatment protocol, the total treatment dose is often a
compromise between a dose sufficient to eradicate the tumor and the ability of collateral dose
to spare normal tissues. A realistic value for physical dose and fractionation routine for locally
advanced disease is 70 Gy delivered in 33 fractions38 which is the prescription used in this work.
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In SBRT of lung cancer, physical doses up to 24 Gy in a single fraction have been reported40,
however a more common regimen is 40-70 Gy in 3-4 fractions as prescribed in RTOG- 0236,
RTOG-0915, and the Japan Clinical Oncology Group trial 0403. The physical dose of 50 Gy
delivered in four fractions, assuming α/β = 10 Gy, results in a BED>100 Gy but some authors
have questioned the validity of the linear-quadratic model for single fraction doses >5 Gy.41 For
SBRT patients in this work, a physical prescription dose of 48 Gy is used.
One method to evaluate physical dose is through the dose-volume histogram (DVH). The DVH
is a 2D graph of (relative) volume parameterized at dose levels. The DVH was introduced in a
letter by Shipley et al.42 in order to graphically display a proportion of posterior rectal wall at
variable dose levels. The DVH has since become an important utility for assessing dose and the
quality of RT plans. The DVH currently influences decision making in plan approval, in
optimization, and in retrospective evaluation. By
relating tumor control probability (TCP) and
normal tissue complication probability43 (NTCP) to
non-uniform dose to partial volumes of a region
of interest (ROI) through the DVH, a reasonable
estimate of safe and effective treatment is
possible.44

Figure 4 shows 3D- anatomy and dose, which can Figure 4. Patient anatomy (top left) and a
dose-distribution (top right) are
be combined to form a DVH. The DVH shown in combined to form a 2D plot of relative
volume at dose, the dose-volume
Figure 4 includes the target (the PTV) and organs histogram (DVH).
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at risk (OARs) typically considered in lung cancer RT including the spinal cord, esophagus, heart,
and both lungs (where ipsi- and contra- lateral positions are defined with respect to the tumor).
A more recently introduced method to evaluate physical dose is the generalized equivalent
uniform dose (gEUD)45 which is mathematically equivalent to a generalized mean (or power
mean) of dose with an organ-specific exponent a. Considering a structure composed of n
voxels, where fractional dose to the ith voxel is D fx ,i , the gEUD of the structure is computed
according to
1
gEUD = N fx 
n

∑(D )
fx , i

i∈n

an

1/ an





.Based on decades of published complication rates for patients

who received RT, the QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic)
reports46 summarize normal tissue reactions to partial-volume irradiation. These summary
reports build on the work of Emami et al.47, who estimated NTCP based on reported patient
outcomes and dose-volume parameters including dose-at-volume (for volume level X, dose at
volume is DX) and volume-at-dose (volume at dose level X is VX). Simple evaluation metrics
which describe 3D-dose on 3D-anatomy can be used to predict NTCP based on observed
outcomes.
This work proposes a method of dose evaluation on lung cancer patient anatomy which uses
mass rather than volume in evaluation. According to the LQ model, when cell density is
proportional to physical density, dose-to-mass should be a more appropriate measure of
radiation response in tissue. Dose-to-mass is discussed in Chapter 6.
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2.3.1 Organs at Risk
Following the recommendations from the QUANTEC reports, dose-volume levels which indicate
non-zero complication probabilities are described for the spinal cord48, esophagus49, heart50,
and lungs51 in the next several sections. Organs are traditionally classified as serial or parallel
organs (see, e.g. Chao et al.52). In serial organs, damage to any part of the structure will result
in a loss of functionality of the entire structure. For parallel organs, a percentage of the
structure must be damaged in order to lose functionality.
Spinal Cord
Spinal cord is considered a serial organ; the maximum dose to any region of the spinal cord has
the potential to cause myelopathy and at high enough doses, paralysis. Based on data from
conventional fractionation to the cervical spine, complication probability is 0.03% at BED =
45 Gy, or a physical dose of around 50 Gy48 delivered in 2-Gy fractions. Assessing complication
probability to spinal cord in hypo-fractionated therapy of cervical spine is inconclusive,
according to the QUANTEC report.48 However, 4 fractions resulting in a physical dose between
13 and 17 Gy (Dfx<4.3 Gy) has complication probability 0.3%±0.3%, based on outcomes from
consistent treatments at Medical College of Virginia,53 Massachusetts General Hospital,54 and
University of Virginia.55 In these studies, 339 patients were treated to a 2-Gy equivalent BED
between 57 and 61 Gy at per fraction doses between 3 and 5 Gy and one patient suffered from
grade III myelopathy. In evaluations of spinal cord dose in subsequent chapters, maximum
dose (Dmax) to spinal cord is reported.
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Esophagus
The esophagus shows parallel traits at low doses and serial traits at high doses. The most
commonly observed effect of irradiation in the esophagus is acute esophagitis; however grade
III-V esophageal toxicity is also a concern at high physical doses.49 There is recent evidence that
esophagus NTCP is related to mean structure dose exceeding 28 Gy.56 Krafft et al.57 indicate a
correlation between complication and regional mean dose.57 The studies of Singh et al.58 and
Qaio et al.59 show maximum doses above 60 Gy predict high grade (≥III) esophageal toxicity in
3DCRT. Belderbos et al.60 indicate that dose >35 Gy is a predictor of Grade 2 acute esophagitis
from a study with 156 patients, Wei et al.61 indicate volume at 20 Gy (V20) is a predictor of
Grade 3 acute esophagitis at volumes exceeding 35% of esophagus based on outcomes from a
215 patient study. Based on these studies, in this dissertation esophagus volume (and mass) is
evaluated at 20 Gy and 25 Gy. It is also of interest to note that esophagus motion has been
measured between 5-9 mm during respiration, with magnitudes of motion dependent on the
anatomic region.62
Heart
Heart irradiation has the potential to cause acute pericardial effusion and numerous late effects
including congestive heart failure, ischemia, and coronary heart disease.50 However, these
effects are more commonly observed following left breast and lymphoma RT than following
lung RT due to lung cancer morbidity, lung-cancer patient demographics, and other factors.
Pericardial effusion, based on the studies of Wei et al.61, occurs at pericardium doses >30 Gy.
The report of Gagliardi et al.50 shows that heart V25<10% results in <1% probability of cardiac
morbidity. The heart is a (relatively) large and massive organ with many complex regions;
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however cardiac doses above 30 Gy correlate with both acute (e.g. effusion) and late effects
(e.g. cardiac-related morbidity). Heart volume and mass is evaluated in subsequent sections at
20 Gy and 30 Gy.
Lungs
Lung damage due to RT, and the associated symptoms, has proven difficult to describe and
quantify. Marks et al.51 specifically mention confounding disease, the physician’s preference in
prescribing steroids (which is defined as either Grade II or III pneumonitis depending on the
protocol), and improved lung function due to tumor regression as confounding factors in
recognizing lung damage due to RT. Due to lung-cancer patient mortality, late effects are not
quantified. Other confounding issues arise from uncertainty in dose-volume estimates due to
challenges in dose estimation in heterogeneous lung tissue and volume variation during
respiration.63 When a (single) planning image is used for dose-evaluation, the phase chosen for
lung definition will influence the dose and volumes used to estimate DVH. Despite all of these
factors, there is clear evidence that both mean lung dose (MLD) >10 Gy and lung volume >10%
at 20 Gy (lung V20>10%) result in non-zero incidence of pneumonitis.51 In this dissertation,
dose to lung is typically evaluated using the V20.

2.4 GEOMETRIC UNCERTAINTY
Fractionated RT requires repeated alignment of the patient in the treatment room with respect
to the LINAC. Inaccuracies and imprecision in setting up the patient in the coordinates of the
LINAC results in what is termed setup error. Setup error is not considered in this work due to
several factors, including inter-institution variability in techniques used to perform the patient
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realignment. However, in order to implement the methods described herein clinically,
accounting for setup error is necessary. This section briefly describes geometric uncertainty in
the context of lung cancer RT.
Set-up error is a combination of random fraction-to-fraction positioning deviations and a
systematic offset between the mean position of the treated patient and the patient geometry
in planning images. The random and systematic components64 each have a different effect in
the delivered dose distribution, random errors blur the dose distribution, systematic offsets
shift the mean location.65 In order to ensure geometric uncertainty does not compromise dose
delivery to the target, setup error is accounted for via the setup margin (SM), a spatial margin
designed to encompass possible positions of the actual target and define the PTV.15 The
appropriate size of this margin depends on the magnitudes of both random deviations and
systematic uncertainties. Margin formulas for SM often use a summation or quadrature
summation of random and systematic components and are often tumor-site specific.64 One
source of systematic error is finite patient representations in simulation images due to
discretization of anatomy into finite voxels, these voxels are typically 1-3 mm. Target
delineation is also a source of systematic error in geometric uncertainty66 and is a limiting factor
in the elimination of geometric uncertainty.64 Systematic error can be accounted for through
inclusion of an internal margin (IM) in the SM, which is designed to account for delineation
uncertainty and anticipated internal-motion not captured in simulation images.15
Random errors result in dose blurring and can be estimated through convolution.67 An onboard imaging device can be used to image the patient in treatment position immediately prior
to treatment and reduce random error. This approach is termed image guided RT (IGRT).
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Patient alignment and repositioning in IGRT can be performed using bony anatomy or using
structures of interest including implanted markers, nearby organs, or the tumor itself.24,68–71
Use of IGRT combined with immobilization devices suggests an institution-specific estimate of
random error may be more appropriate than using population models.64 Some examples of
implementations include the study of Bissonette et al.71, who utilized the VacLok
immobilization cushion (Civco Medical Solutions, Kalona, IA) and indicated cone-beam CT
(CBCT) based IGRT resulted in random and systematic error of 0.4 mm and 1.7 mm,
respectively. A recent study by Grills et al.68 used at least three CBCT scans; two scans to
realign and verify realignment, and one scan following treatment, to estimate appropriate
setup margins. The lung cancer patients were positioned in either a stereotactic body frame or
an alpha-cradle72 and a 4-parameter model73 indicated margins between 2.2-2.4 mm mediallateral, 3.2-5.3 mm anterior-posterior, and 3.9-4.3 mm superior-inferior (with variability based
on the immobilization device) were suitable to account for geometric uncertainty due to
random and systematic errors. The measured random deviations were less than 1.2 mm preand post- treatment using a stereotactic frame, and less than 1.6 mm pre- and post- treatment
using the alpha-cradle in all directions.
Purdie et al.70 also used repeat CBCT and demonstrated that geometric uncertainty was
bounded by a Euclidean-norm distance of 5 mm when multiple CBCT images were acquired
within 34 minutes of one another. Beyond 34 minutes, however 6/10 patients showed 3Dnorms between tumor points of interest >5 mm. Purdie et al.70 used a “full-body vacuum
pillow” inside of a stereotactic body frame (Elekta Oncology Systems, Stockholm, Sweden),
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initially aligning the patient according to tattoos. Their results show alignment to bony
anatomy is not an acceptable approach for IGRT of lung cancer.
In this work, for both locally advanced and early-stage lung cancer patients, the moving target is
defined as a 3-5 mm of the expansion of the GTV, i.e. the combined microscopic extension of
disease and the IM is 3-5 mm, so that CTV=GTV+IM. Due to inter-institution variability in
patient immobilization devices, use of on-board imaging for IGRT, and plan design for locally
advanced, conventionally fractionated RT; set-up error is not considered in this dissertation, i.e.
SM = 0 and PTV=ITV+SM=ITV. Using the convention of Stroom et al.74, the target surrogate is
termed the representative target volume (RTV), this is either the CTV or the ITV.
Ideally, all institutions will use immobilization devices, minimize inherent spatial uncertainty,
and accurately estimate geometric uncertainty in order to design a SM and ultimately an
appropriate RTV. Alternatively, through probabilistic sampling of the actual moving target
according to an assumed motion distribution, a PTV-like solution can be designed during plan
optimzation.75,76 Both methods lead to design of an appropriate target surrogate for doseevaluation based on institution-specific implementation, and one must be used in order to
implement the methods described herein clinically.

2.5 RADIOTHERAPY PLAN OPTIMIZATION
With structures defined on the planning image, a set of treatment beams (or continuous arcs)
are designed and simulated on the planning image during the treatment planning process. The
beam configuration and patient anatomy are input parameters for RT plan optimization. In
ideal IMRT optimization, each beamlet, for all beams, is optimized for the patient-specific
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anatomy to maximize dose to the target and minimize dose to healthy tissue. In reality, RTPoptimization is most often performed utilizing protocol-defined objectives for targets and OARs
based on historical or hypothesized outcome data. The individual objectives are combined,
often in a sum of squares formulation, to form a scalar-valued objective function (see, e.g. Wu
and Mohan77). When the individual objectives of RT are conflicting, i.e. when two objectives
trade-off, human interaction is necessary in order to make decisions based on the importance
of each objective. The importance (of each objective) is expressed by weighting factors
determined by the decision maker (i.e. dosimetrist, physicist, or physician). The weighting
factors are assigned arbitrary values in order to achieve a desired result, and weight adjustment
redefines the importance of objectives in an optimization problem. Considering this ill-defined
specification, a general solution is not realizable.
In general, a compromise must be made in multi-objective optimization problems. The RT

r
multi-objective optimization can be classified by a decision vector of beamlet weightings b∈R n ,
r
a set of n numeric objectives, fn , with each objective mapped to an outcome Fn b . The
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r
objective function value should reflect the utility of the combination of outcomes Fn b . The
goal of an optimization algorithm is to find the jth decision vector such that the combined utility
of n outcomes is preferred to the combined utility of n outcomes resulting from some other

r
decision vector b j ≠k , or

{ ( )} { ( )} , where the f symbol means preference.
r
Fn b j

r
f Fn b j ≠ k
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r
This does not imply that each of the n outcomes resulting from b k are preferred to those which
r
result from b j ≠ k , but if the objective (or utility) function obeys stochastic dominance, at least

one of the n outcomes resulting from the kth decision vector will be strictly preferred to those
r
resulting from b j ≠ k .

The objective function in RT optimization considered in this work is a scalar, weighted sum of
least-squares penalty functions. The process of scalarization maps the multi-objective decision
problem to a single value. For N objectives, the objective function is

{ ( )} =O ( b) = ∑ w f ( b)

r
Oˆ Fn b

r

r

2.1

n n

n∈N

When trivial weightings are considered (e.g. wn' = 1 ,wn≠ n' = 0 ), a set of decision vectors can be
found which optimize individual objectives. When weightings are non-trivial ( wn ≠ 0 ∀n ) the
value of the scalar objective function does not necessarily relate to clinical value, i.e. a lower
objective value does not imply a better plan. However, numerical optimization minimizes the
uur
uur
uur uur
objective function under the assumption that O bj < O bk implies bj f bk .

( ) ( )

In IMRT optimization for lung cancer, the primary objective (often treated as a constraint) is to
irradiate the tumor to a tumoricidal dose; other objectives aim to spare healthy tissue including
lung, heart, esophagus, and spinal cord. Consider a region of interest (ROI) labeled by the index
n and represented by a collection of i voxels (in the planning image). If each of these ROI voxels

has dose d ( i ) and a prescription or tolerance dose DnRx then the objective for this ROI is written

f n ( d ( i ∈ n ) , DnRx ) = f n = ∑ ci ,n ( d ( i ) − DnRx )
i∈n

2

2.2
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The ci,n include Heaviside functions to penalize only voxels with dose above prescription levels
(or below prescription in the case of the target) and also include proportionality constants.
The optimization implementation considered in this work is based on the Pinnacle3 TM TPS
(Phillips Medical Systems, Fitchburg WI). The optimizer utilizes the ORBIT objective functions
described in Löf.78 The vector of beamlet weightings which minimizes the objective function is
searched via a quasi-Newton method similar to the Broyden-Fletcher-Goldfarb-Shanno (BFGS)
method79 and includes an iterative update of the inverse Hessian,80 this method is described in
more detail in Chapter 5. Once a solution with trade-off consistency between objectives is
found, weight variation and re-optimization is performed to satisfy the planner, physicist, and
physician to meet the overall goal of treatment. This 2-step process (a numerical optimization
and planner adjustment) continues until a solution is deemed acceptable. This process is
named the planning-loop, displayed in Figure 5.
In the numerical optimization stage, for many treatment planning systems, dose is calculated
on the planning image, the geometric relationship between target and OAR voxels determines
beamlet preferences, and the objective function is minimized. In the planner (or human) step,
weight variation allows adjustment of the optimized plan and, in some cases, additional
objectives are added. With new weights and possibly new objectives, a numerical re-

Figure 5. The planning loop requires
numerical optimization in order to
meet the physician’s intent and may
require several re-optimizations
before accepted by the physician.
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optimization is performed; this planning loop continues until a plan is deemed acceptable. This
time-consuming process results in arbitrary variations in plan quality depending on institutionspecific variables.
Use of fixed OAR objectives (e.g. Lung V20<30% or Esophagus Dmax<60 Gy) results in no penalty
for treating normal tissue up to the anticipated tolerance levels (e.g. there is no penalty for
treating lung V20 to 29.9% or esophagus maximum dose to 59.9 Gy). By utilizing population
data to estimate NTCP and guide optimization, the therapeutic ratio is not ensured to be
maximized for individual patients. This is a departure from the basic goal of radiotherapy, and
is investigated in Chapter 7.
Chapter 7 discusses methods to improve on plans which utilize fixed optimization objectives by
minimization in order to approximate Pareto efficiency. Named for renowned economist
Vilfredo Pareto, Pareto efficiency81,82 means individual objectives cannot be further improved
without a corresponding degradation to one or more other objectives. This approach is
explored using multi-criteria optimization (MCO).83 By pre-computing plans which minimize
OAR objectives based on variable objective weights, MCO allows real-time planning and
decision making without numerical re-optimization in the planning loop.
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2.6 PATIENT COHORT
In this dissertation, a total of fifteen lung cancer patients are included in related publications
and manuscripts. The group includes
ten locally advanced (LA), non-small
cell lung cancer (NSCLC) patients and
five early stage, SBRT patients. All
patients were part of internal review
board-approved studies of lung
cancer RT at Virginia Commonwealth
University (HM-10395, HM-12533).
The LA patients (named P1-P10)
include moderate CTV motion, with
3D-norms ranging from 0.29 – 0.95

Patient

Tumor Centroid
Motion (cm)

ITV (cm3)

Ratio
(GTV/ITV)

(IMRT)

AP

LAT

SI

P1

0.15

0.07

0.24

221.5

0.83

P2

0.21

0.13

0.22

294.8

0.89

P3

0.21

0.28

0.17

401.8

0.84

P4

0.08

0.24

0.31

60.2

0.78

P5

0.16

0.19

0.43

174.6

0.70

P6

0.08

0.07

0.57

174.4

0.81

P7

0.30

0.41

0.41

232.6

0.70

P8

0.32

0.25

0.56

105.1

0.80

P9

0.44

0.15

0.61

173.1

0.79

P10

0.36

0.16

0.86

442.4

0.82

N1*

0.07

0.11

0.41

56.5

0.89

(SBRT)

N2

0.30

0.14

0.48

18.2

0.70

cm. Treatment plans did not include

N3

0.12

0.10

0.03

35.2

0.97

lymph nodes. The SBRT patients (N1-

N4

0.23

0.17

1.17

12.5

0.67

N5

0.15

0.19

1.52

83.8

0.62

N5) include cases with 3D- motion
ranging from 0.18 cm to 1.4 cm

Table 1. Patient Details. *This is a gated
internal target volume (ITV) including only the
30% -70% phase-based GTVs.

including 1 patient (N1) which was
treated using RT-gating. A few patient details are detailed in Table 1. The clinically delivered
plans were evaluated for the early stage patients considered.
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3 Specific Aims

The aims of this dissertation are detailed in this chapter. The goal of these aims is to implement
and develop techniques which, when clinically implemented and applied to patient treatment,
have the potential to improve the therapeutic ratio of radiation therapy for time-dependent
anatomy. The aims specifically address elements of RT for lung cancer treatment including
dose estimation, plan and structure evaluation, and plan optimization.

3.1 AIM 1: MULTIPLE ANATOMY OPTIMIZATION (MAO)
The first aim of this study is to show that RT for time-dependent anatomy can be improved
through inclusion of all phase images from a 4DCT simulation, as opposed to using a single
planning image in the beam optimization. Specifically, Chapter 4 compares dose estimated on
entire 4DCT data-sets with dose estimated on individual planning images. Chapter 5 compares
plan optimization based on a single planning image with multiple anatomy optimization (MAO),
a method which utilizes the entire set of 4D-images in plan design.
Dose estimation is a fundamental requirement of modern RT planning. Differences between
planning image dose and accumulated dose delivered to time-dependent anatomy (based on
4DCT image-sets) are reported for the patient data-sets and motivate implementation of MAO.
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The robustness of target dose due to interplay effects between patient breathing and inevitable
phase-weight variations due to finite delivery time is also considered.
Unlike gating, breath-hold, and target tracking methods, which also have the potential to
increase the therapeutic ratio compared to ITV planning, MAO is designed to be delivered
under free-breathing conditions. Hence, MAO can be clinically implemented without additional
complications inherent in solutions which require monitoring or control of patient breathing.
MAO has the potential to generate a plan which is superior to single-image (3D) clinical plans in
terms of dose accuracy, precision (or robustness), and can be delivered with current,
conventional RT hardware. MAO and ITV plans are compared in Chapter 5 for ten locally
advanced lung cancer patients.

3.2 AIM 2: DOSE TO MASS IN EVALUATION AND OPTIMIZATION
The second aim of this dissertation is to utilize mass-based metrics in radiation therapy plan
evaluation and plan design, as opposed to using volume-based metrics. Structure mass is
considered in the context of delineation consistency, dose-evaluation, and RT plan optimization
in Chapter 6.
While structure volumes can physically vary in different respiratory phases, structure mass is
constant. If structures delineated on 4DCT phase images are accurate representations of
physical anatomy, then each structure mass should be constant as a function of respiratory
phase. Inter-phase mass conservation of structures is evaluated in Chapter 6 based on
physician-delineated and deformably-registered structures. Mass-variation over the course of
treatment is also considered for one patient in Chapter 6.
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Volume and density variations during respiration introduce ambiguity in dose evaluation for
lung cancer anatomy. Evaluation of dose-to-mass, as opposed to dose-to-volume, will reduce
this ambiguity and may be more closely related to the physical effects of radiation in tissues.
Dose-to-structure volume and the DVH are compared to dose-to-structure mass and the dose
mass histogram (DMH) in Chapter 6. DMH plots (relative) structure mass as a function of dose.
DMH is a more appropriate evaluation of dose on mobile, heterogeneous structures.
Treatment plans are optimized based on DMH levels in Chapter 6. Using single-image, ITVplans, optimized dose distributions are compared based on DVH- and DMH- objectives for eight
locally advanced patients. Mass-based optimization (DMH-optimization) is essentially a
functional optimization which assumes voxel importance is determined from the planningimage density. The validity of mass as a surrogate for voxel importance is also discussed.

3.3 AIM 3: TOWARD PARETO-EFFICIENT RADIOTHERAPY PLANNING
Aim 3 of this dissertation is to improve plan design and design-efficiency in RT plan
optimization. This aim is addressed using multi-criteria optimization (MCO) and a precomputed set of basis plans. Decision making is clarified by permitting rapid identification of
conflicting objectives. Patient- and objective- specific variations are incorporated in plan design
without the numerical re-optimization stage of the planning-loop by interpolating the MCO
basis-set. Different MCO-bases, optimized based on different OAR-objectives, are also
compared. Because MCO enables plan browsing in real time, the effects of delivering the plan
to time-dependent anatomy can be analyzed during plan-selection without numerical re-
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optimization. An application of MCO which allows for a clear decision environment for
radiation therapy of locally advanced lung cancer is developed in Chapter 7.
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4 Dose Estimation in Time-Dependent Anatomy

Chapter 3 list of abbreviations:
3DD – 3D-dose
4DD – 4D-dose or accumulated dose
DIR – deformable image registration
DVF – deformation vector field
ETM – energy transfer method
wp – anatomic phase weighting

Dpa – dose to phase p due to aperture a
Dpb - dose to phase p due to beam b
MU – monitor unit
MUb – monitor unit per beam
DR – dose rate
Np– number of phases

The first aim of this study is to show that dose estimation and plan optimization for RT in timedependent anatomy can be improved through inclusion of all of the respiratory phase images
acquired during 4DCT simulation. This chapter focuses on dose-estimation.
In current clinical practice, a single planning image is often used for dose computation in lung
cancer radiation therapy despite widespread availability of 4DCT images. The total
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(accumulated) dose delivered to moving anatomy may deviate from this single image estimate
which allows for the possibility of inaccuracies in plan evaluation and optimization when using a
single image for dose estimation. Following a brief introduction to dose computation and dose
accumulation, differences between single image dose and accumulated dose are reported in
this chapter.
Dose computed on a single image is termed 3D-dose (3DD). Clinical use of 3DD assumes the
simulated dose is approximately independent of 4D-anatomic phase (i.e. the patient anatomy
may change in time but the dose cloud is static) and delineated structures are independent of
phase (i.e. a single contour is sufficient to represent a moving and deforming structure).
Accumulated dose, or 4D-dose (4DD), computes 3DD on several anatomic images followed by
accumulation. Accumulation is a dose summation after transformation to a common reference
phase. The images and transformations are assumed to be true representations of the patient
anatomy and motion. This assumption ignores uncertainty in the 4DD resulting from errors in
the spatial transformations and from errors introduced by the method of dose accumulation,
which is also discussed in this chapter.
The methods and results of submitted and published manuscripts which describe 3DD and 4DD
differences are detailed in this chapter. Appendix A compares 3DD and 4DD for relevant
structures in lung cancer anatomy for ten locally advanced patients. Appendix B focuses on the
moving lung cancer target and shows that for a given patient, plan, and evaluation metric (e.g.
DVH values or gEUD), 3DD can deviate from 4DD in the target. These studies imply evaluation
of 4DD is necessary in assessment of dose to moving anatomy.
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Finally, this chapter considers the effects of finite delivery time and patient specific breathing
on 4DD. Potential deviations between the realized anatomy during each fraction and the
anatomy recorded in 4DCT are reported, together with target dose variability resulting from
these anatomic variations. In appendices A and C, 4DD variations are reported due to finite
delivery time and patient-specific breathing for locally advanced patients (Appendix A) and for
early stage SBRT patients (Appendix C).

4.1 COMPARING SINGLE IMAGE, 3D-DOSE AND ACCUMULATED, 4D-DOSE
Evaluation of dose to a moving, 4D tumor (or target) can be estimated by assessing dose to a
larger, static structure which encompasses all possible tumor locations. This is a common
method used in radiation therapy to account for set-up error. Treating the PTV to uniform
prescription dose, assuming approximate conservation of anatomic mass along radiation pathlengths (or buildup) on different days of treatment, assures the target is also treated to a
uniform dose. The tumor location varies during each fraction according to random and
systematic geometric deviations from the planned tumor location, but always exists within the
PTV. In this case, the PTV is the representative target volume (RTV) of the actual, moving
target. Treating the entire PTV to a uniform dose, however, necessitates treating normal
tissues to prescription dose. Furthermore, if prescription dose is not uniform in the PTV and/or
mass and energy are not conserved in different realized anatomies, there is no assurance that
the target will absorb the prescription dose without knowledge of the probability distribution of
the target within the PTV. In this case, an estimate of accumulated dose, or 4DD, may be
necessary.
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4.1.1 Accounting for Geometric Uncertainty in Accumulated Dose
In order to evaluate 4DD on a moving lung cancer target while also accounting for setup
uncertainty, the moving lung cancer target should be expanded by a setup margin (SM). This
margin may be consistent with the SM used in ITV-PTV expansions, assuming the random and
systematic components of setup error for the moving target and the ITV are equal. For
example, if a 5 mm SM is applied to the ITV to account for random and systematic deviations in
setting up the patient, then a 5 mm margin should also be applied to the moving target in 4DD
evaluation in order to create an appropriate RTV. Dosimetric margins designed to specifically
account for 3DD and 4DD differences (see, e.g. Hugo et al.84), however, do not need to be
included in the RTV.
Admiraal et al.85 compared 3DD and 4DD for ITV plans designed with zero PTV margin, i.e.
PTV=ITV, RTV=CTV. For the ten SBRT patients considered, minimum dose to the moving target
was consistent with the minimum PTV-3DD. Admiraal et al.85 claimed the use of identical
margins on the ITV and CTV in 3D- and 4D- dose estimation was a “worse-case scenario;”
however, this scenario accounted for setup error in the actual, moving lung cancer target
consistently with setup error in the ITV. Inclusion of systematic geometric uncertainty due to
deformable image registration (DIR), discussed briefly in the next section, implies the RTV may
require a safety margin different from the ITV-PTV margin.
Many published studies compare planned PTV-3DD (3D-dose to the PTV) to CTV-4DD (where
the CTV is the moving target) without consideration of geometric uncertainty on the CTV.86–93
For example, Guckenberger et al.90 used a 0.5 cm ITV-PTV margin in SBRT treatment for early
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stage lung cancer and reported no significant differences between the PTV-3DD and GTV-4DD
for 7 patients. Rosu et al.91 evaluated CTV-4DD in 3DCRT using a 1-cm ITV-PTV margin and
show point doses can vary by >10% between 3DD and 4DD in the CTV, but differences in
evaluation metrics such as gEUD may not be significant.
In estimating point doses in lung cancer anatomy, many studies suggest the differences in 3DD
and 4DD may be significant to clinical outcomes.93–96 In 7/15 patients presented by Starkschall
et al.93, dose to 99% of the CTV (CTV-D99) in 3D- and 4D- estimates differed by >3% of

prescription. Two ITV-PTV margins were designed on different patients; the ITV was expanded
by 0.5 cm if IGRT was used for patient positioning and by 1.0 cm if IGRT was not used. The
patients planned with each margin method were not identified and the ITV-PTV margin was not
correlated to 3DD-4DD differences as part of the published study. In physical measurement
studies, which potentially include setup error, Vinogradskiy et al.94 reported 4DD passing rates
of measured dose using 5%, 3 mm-gamma criteria which were 8%-16% lower than the
corresponding 3DD (static) passing rate. Berbeco et al.95 conclude “there is the possibility of
underdosing the tumor by several percent” based on film measurements of IMRT fields
delivered on a mobile phantom.
For the locally advanced patients considered, simulation studies are performed without
consideration of setup error in PTV definition (SM=0, PTV=ITV). Therefore, consistent with the
study of Admiraal et al.85, estimates of 4DD to the moving lung cancer target do not consider
setup error. The reported CTV-4DD use SM=0 cm, consistent with the SM used to define the
PTVs in the simulation studies. In analysis of SBRT patient images, the clinically delivered dose
distribution is evaluated. The target surrogate (or RTV) for these five patients is a 0.3-0.5 cm
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expansion of the GTV (RTV=GTV+0.3 cm or RTV=GTV+0.5 cm) consistent with the ITV-PTV
expansion used for each patient.

4.1.2 Deformable Image Registration and Dose Accumulation
The 4DD estimates in this dissertation and in related publications are weighted sums of
individual phase-doses computed on ten 4DCT breathing phase images. Prior to summation,
the phase-image doses are transformed to a common reference phase (designated by ref). The
transformations are calculated according to deformable vector fields (DVFs) defined at voxel
indices in the ref image to corresponding points in each of the other 9 phase images. DVFs are
calculated using deformable image registration (DIR). Figure 6 is a graphical representation of
DIR for accumulation of dose at a single point (labeled by A); this common anatomic point is
mapped from spatial positions in several images. The DVF is a collection of these vectors which
map anatomic voxel positions in one image to their positions in another image.
The DIR algorithm used in this work is a variant of the Demons algorithm introduced by
Thirion.97 The algorithm is implemented in the Insight Tool Kit98 which has been integrated in a
research version of the Pinnacle3 TPS (version 9.100). The implementation of the Demons
algorithm is described in Vercauteren99 and Dru and Vercauteren.100 In summary, the method
minimizes differences between image intensity in the log domain and includes Gaussian
regularization to generate smooth DVF vector fields.
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Figure 6. Deformable image registration (DIR) creates deformation vector fields (DVFs). A
single vector is shown as the line between images, the vector maps a common anatomic
point or dose point (point A) from different images.
For dose calculated on 4DCT-phase p labeled by Dp with a weight w p (which is normalized so
that

∑

p

r
w p = 1 ), and a DVF vector which maps a point at position r defined in the designated

r r r
r
ref image to a point r ' = r + vref → p ( r ) in phase-image p. The accumulated dose is estimated:
r
r r
r
4DDref ( r ) = ∑ w pDp ( r +ν ref → p (r ) )

4.1

p

r r
r
This approach interpolates phase doses ( Dp ) at vector positions ( r + vref → p ( r ) ) and is used in all
reported 4DD estimates in this dissertation and related manuscripts. For purposes of
comparison, this value of 4DD is assumed to be the ground truth value of dose to moving and
deforming anatomy. Interpolation of dose as presented, however, can introduce errors in the
accumulated dose due to inconsistent summation of the ratio of energy deposited in voxel
mass when using interpolation. Siebers and Zhong101 presented a Monte Carlo-based dose
calculation algorithm, the energy transfer method (ETM), in order to more accurately consider
energy deposition in mass for accumulation. Another Monte-Carlo-based method of estimating
4DD was presented by Heath et al.102 in which a voxel-warping method was used to calculate
volume overlap between deformed reference voxels. Dose was accumulated via scoring in
tetrahedral voxels. Heath et al.92 compared a voxel-warping approach to ETM and
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demonstrated equivalence when the DVF is exactly known. However, when the DVF fails to
conserve mass between the reference and phase image, the 4DD resulting from each method
will deviate. Yan et al.103 show, for mass conserving image pairs, that a similar method can be
used to identify errors in the corresponding DVF.
Estimating DVF errors and uncertainty is outside the scope of this dissertation, but sufficiently
accurate DVFs so as to not introduce clinically significant dose errors is a precondition of clinical
implementation for many of the techniques described herein. Analogous to the inclusion of
systematic delineation error in the RTV, uncertainty in target definition due to DIR errors must
also be included in the definition of the target when evaluating 4DD. If this systematic
uncertainty is not included in target definition, the 4DD estimate of dose may not be a reliable
surrogate of actual dose received by the target. The utility of DIR for clinical implementation of
the methods presented herein will be determined by the algorithm’s ability to delineate timedependent targets and normal structures accurately and efficiently as compared to physician
delineation. As discussed in Chapter 6, consideration of structure mass is one method to
compare DIR- and physician- defined structures.
In evaluation of 4DD in this work and in related publications, the uncertainty in target
definition, defined by either an expert physician or by the Demons DIR algorithm, is accounted
for by a 0.5 cm expansion of the GTV. In this work, for locally advanced patients,
RTV = CTV = GTV + 0.5 cm. This 0.5 cm margin is designed to include microscopic extension of
the GTV, internal margin (IM), and delineation uncertainty due to either physician contouring or
due to DVF errors. This 0.5 cm margin may be a reasonable estimate if microscopic extension
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is, e.g. 0.4 cm, delineation uncertainty is 0.2 cm, and IM is 0.2 cm (

0.42 + 0.22 + 0.22 = 0.5 cm).

However, uncertainty in physician delineated structures and structures defined according to
DIR may not be equivalent.

4.2 COMPARISON OF SINGLE IMAGE, 3D-DOSE AND ACCUMULATED DOSE
In the following section, differences between 3DD and 4DD for the patient cohort are reported.
The 3DD is estimated on different planning images including the aCT-image, the inhale phase
image (00%), and a mid-ventilation phase images (30%) for the LA patients. 3DD and 4DD are
compared to the clinically delivered, SBRT plan for the early-stage patients. The 4DD is
calculated according to eq. 4.1 and evaluated on either the inhale or exhale 4DCT phase. Mean
differences and standard deviations about the mean are tested for significance using the
students t-test with probability of rejecting the null hypothesis at a 5% confidence interval.

4.2.1 Results: Locally Advanced Patients
Three dimensional, ITV-plans are optimized based on the aCT-image, the inhale phase image
(00%), and mid-ventilation phase images (30%) to create three plans for each of the ten LA
patients. Dose voxels are 0.3x0.3x0.3 cm3 and cover the entirety of the lungs. Following plan
optimization, 3DD is computed on each of the other 9 phase images and dose is accumulated to
the inhale phase image to estimate 4DD. The 4DD is evaluated on physician-defined structures
on the inhale phase. 3DD and 4DD differences are summarized, based on the results of
Appendix A.
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Mean dose differences between 3DD and 4DD (i.e. <3DD> - <4DD>) for lung, esophagus, and
heart are less than 1 Gy for 116 of 120 estimates (10 patients x 3 plans x 4 OARs) and relative
OAR volume differences at fixed 3DD and 4DD, and maximum dose (Dmax) to the spinal cord
differ by less than 3% in 147/150 estimates. The range of volume differences in ipsilateral lung
V20 is -3.2% to 3.5%, in contralateral lung V20 is -2.1% to 3.5%, in esophagus V25 is -0.2% to
1.3%, and in heart V30 is -3.2% to 1.2%. These findings suggest that dose-volume estimates to
time-dependent OARs can be approximated to within ±3% from single image, 3DD estimates
independently of planning image. Starkschall et al.93 found similar results (i.e. small 3DD-4DD
differences) for OARs in a 15 patient study, with the exception of spinal cord Dmax in 2/15 cases.
Comparing 3DD and 4DD for the lung cancer target (the CTV), 3DD-4DD>0 in 28/30 estimates.
The range of mean dose differences between 3DD and 4DD in the CTV is -0.1 to 1.8 Gy (p=10-7)
with 3DD-4DD >1.7 Gy in 2 of 30 estimates. Target mean dose differences between 3DD and
4DD are independent of the ITV-planning image, with a mean difference of 0.5 Gy for plans on
both 0% phase (± 0.4 Gy, p=0.002) and 30% phase (± 0.4 Gy, p=0.007), and 0.7 Gy ± 0.4 Gy
(p=0.001) when planned on the aCT. Figure 7 shows estimated dose differences between 3DD
and 4DD for the ten locally advanced patients for the CTV-target and OARs. It can be visually
verified from the figure that OAR 3DD-4DD are small compared to the CTV 3DD-4DD, which also
shows a consistent trend of 3DD > 4DD.
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Figure 7. Dose
differences between 3Dand 4D- dose for ten
locally advanced
patients. The 3D-dose is
calculated on three
different planning
images, the 4D-dose is
computed according to
equation 4.1 and
accumulated to the
inhale phase image.

For dose-volume comparisons, including dose to 95% of the CTV (CTV-D95) and CTV-volume at
70 Gy (CTV-V70), 3DD systematically overestimates the 4DD in the cases considered. The
differences exceed 2.1 Gy (or 3% of prescription) for at least one plan for 4/10 patients.
Average differences in CTV-V70 = 3.4% ± 4.9% (p=10-4) and are independent of the planning
image (p > 0.2 in all comparisons of the difference distributions). Correlations between the
difference in 3DD and 4DD and 3D-motion of the CTV are not evident (r2 = 0.002), nor is CTV to
ITV ratio an indicator 3DD-4DD differences (r2 = 0.124). These differences indicate that the
CTV-3DD is not an appropriate surrogate of CTV-4DD.
The purpose of planning dose to the PTV is to ensure the moving target receives the
prescription dose. In 27/30 plans considered, PTV-3DD95 > CTV-4DD95. The CTV-4DD95 is less
than PTV-3DD95 by 0.51 Gy in the aCT plan of P1, by 1.08 Gy on the aCT plan of P4, and by 0.54
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on the 30% plan for P7. The range of differences between PTV-3DD95 and CTV-4DD95 is -5.39 Gy
to 1.08 Gy, with magnitude of differences >3% of prescription in 19/30 plans. The difference
distributions of PTV-3DD95 and CTV-4DD95 are significantly different from zero, with average,
standard deviation, and probability of rejecting the null hypothesis of -3.05±1.82 Gy, p=5x10-4
when planning on the 30% phase, -1.47±1.87 Gy, p=0.03 when planning on the aCT image,
and -2.23±1.60 Gy, p=0.002 when planning on the inhale phase image. Figure 8 shows the PTV3DD95 for each plan, compared the CTV-4DD95.

Figure 8. Dose to 95% of PTV
based on the planning image 3Ddose, and accumulated dose
(4DD) to the moving CTV based on
ITV-plans optimized on the 30%
phase image, on the average CT
(aCT) image, and on the 00%
phase image.

Appendix B discusses 3D- and 4D- dose differences for five of the LA patients planned with the
ITV-method on aCT and 30%-phase images including comparison of biologic metrics such as
gEUD45 evaluated on the moving target (the CTV) and the PTV. Differences between CTV- 3DD

and 4DD for gEUD(a=-5) (corresponding to a radiosensitive target) range from -6.5 Gy to 3.8 Gy.
For a=-20, representing an aggressive tumor, 3D- and 4D- differences in CTV range from -3.9 Gy
to 9.6 Gy. Appendix B also shows that planning on the aCT decreases 3DD-4DD gEUD
differences compared to plans designed on the mid-ventilation image in 12 of 15 CTV-gEUD
estimates.

43

4.2.2 Results: SBRT Patients
Clinically planned and delivered SBRT dose distributions are compared to accumulated, 4DD for
five early stage patients in Appendix C. In all cases considered, the clinically planned target
differed from the ITV defined as the union of phase-based GTVs, which invalidates the PTV
surrogate for target coverage. In two cases, a MIP image was used to define the target; in
another case a single phase-image was used to define the target. Figure 9 shows the clinically
planned PTV, defined as a uniform expansion of a target defined in a MIP image, and the PTV
defined as a union of phase-based GTVs with a 0.5 cm expansion. Target evaluation in this
dissertation is always carried out on the PTV defined as a 0.3-0.5 cm expansion of the ITV
(defined as a union of phase-based GTVs); where the SM expansion is selected in order to
closely match the clinically planned PTV.

Figure 9. A coronal slice of
patient N1 showing contour
differences between the
planning target volumes (PTV)
defined in three different
ways. The planning image
contour is defined on a MIP
image (blue); the PTV defined
as an expansion of the ITV is
shown in black for physician
and DIR-based GTV contours.
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The target RTV is defined as the exhale-phase GTV expanded by 3-5 mm and is designated the
CTV. Figure 10 shows the 3DD PTV-D95, 3DD CTV-D95, and 4DD CTV-D95. In all five patient cases
considered, the 3DD CTV-D95 is within 1 Gy of the 4DD CTV-D95 and the PTV-3DD95 > CTV-4DD95.
For OARs, the differences in dose and volume at dose are shown in Figure 10. Similar to the
locally advanced cases, differences between OAR structure volumes evaluated at 3DD and 4DD
is less than 3% in all estimates. The only difference of note is the spinal cord Dmax for N2, for
which the 4DDmax is greater than the 3DDmax by 1.8 Gy; however both doses are less than 5 Gy
which are not significant cord complications.

Figure 10. Dose to 95% of the PTV and CTV, based on 3D- and 4D- estimates for the early
stage SBRT patients. Neither the 3D- estimate of CTV-D95 nor the PTV-D95 are reliable
surrogates for dose to the moving CTV.
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Table 2 Planned, single image 3D-dose (3DD) compared to accumulated, 4D-dose (4DD) for
organs at risk for five early stage SBRT lung cancer plans.
Patient:

N1

N2

N3

N4

N5

3DD

4DD

3DD

4DD

3DD

4DD

3DD

4DD

3DD

4DD

spinal cord (max. Gy)

7.38

7.38

3.2

5.0

6.3

6.7

6.8

6.8

10.5

10.2

Ips. lung (V10)

0.23

0.24

0.26

0.27

0.23

0.23

0.18

0.18

0.26

0.26

con. Lung (v5)

0.02

0.02

0.01

0.01

0.06

0.06

0.01

0.01

0.19

0.2

heart (V5)

0.25

0.23

0.34

0.34

0

0

0.12

0.11

0.53

0.5

Esophagus (V5)

0.18

0.18

0.17

0.19

0.18

0.21

0.02

0.01

0.37

0.39

The CTV-4DD95 is consistently greater than the planning dose to the PTV in the cases
considered, but is less than the CTV-3DD95 by in 4/5 cases (maximum of 0.7 Gy difference, or
<1.5% of prescription).

4.2.3 Summary: 3D- and 4D- Dose
Consistent with ICRU-62,15 coverage of a designated target surrogate, e.g. the PTV, should
ensure coverage to the actual target. It is shown in Appendix A and B that the relationship
between dose to the moving lung cancer target and dose to the target surrogate (the PTV) is
not obvious, and is patient and plan-dependent. For different plans and planning images, the
dose to the moving target can be greater than, less than, or equal to the PTV dose. According
to the results of this dissertation, under-dosing 95% volume of the moving lung cancer tumor is
not likely, but is possible. Increasing D95 of the moving target by values >2.5% of the 3DD PTVD95 surrogate, however, is likely to occur. This was observed in 19/30 LA plans and 3/5 SBRT
plans evaluated.
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The observed under-dosing of the moving target in the LA plans, compared to the PTV, appears
to violate the premise of ITV planning; that a uniform dose to the ITV will also ensure a uniform
dose to the moving target. However, the dosimetric tolerance in the (larger) target surrogate
allows for the possibility of under-dosing the CTV. Reducing dose in the PTV through
prescribing to 95% of the PTV volume, rather than prescribing to a minimum dose, enables
reduction in surrounding OAR dose and reduces the volume of normal tissue at prescription.
However, the volume of the PTV is larger than the volume of the moving CTV, so that 5%
tolerance in the PTV could result in a relatively larger cold-spot in the actual moving target,
depending on the time the target resides in
each region of the PTV.
Figure 11 shows a motion-probability
density function (PDF) for the breathing
pattern of patient P1. The marker moves a

Figure 11. A probability density function of
a patient breathing pattern. An ITVmuch time in the spatial region near 1.4 cm optimized dose distribution assumes this
PDF is uniform across all spatial positions.
(which corresponds with end-of exhale,
total of 1.8 cm, but spends about twice as

50% phase) than the region near 0.4 cm (near the end-of-inhale, 00% phase). If the ITV plan
under-doses a spatial region of high probability (e.g. near 1.4 cm), CTV coverage may be
compromised. Because an ITV-plan assumes a uniform distribution of the target within the ITV,
it cannot take advantage of a region of low/high probability and may be susceptible to
3DD/4DD dose differences. However, minimum dose to a moving target can be estimated by
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single image, 3D calculations if two conditions are met: (1) approximate conservation of mass
between the planning image density and patient density on the day of treatment; and (2) the
entire ITV region is treated to the minimum dose.
The hypothesis of ITV planning, that a minimum dose to the ITV will ensure minimum dose to
the PTV, is confirmed in the SBRT cases examined. However, the LA, ITV-plans show underdosing the moving CTV is possible, but not likely, when the PTV is not treated to a minimum
dose. If a PTV cold-spot coincides with a region of high probability for the CTV, the CTV can be
under-dosed. Far more likely, according to the results of Appendices A, B, and C, is delivering a
higher dose to the CTV than indicated by the PTV-dose. The deviations in the delivered target
dose will propagate into uncertainty among lung cancer outcome studies which aim to tie a
dose-level to local control or survival. In OARs, however, for both LA and early stage patients,
3DD-4DD differences are small. OAR volumes at fixed 3DD and 4DD differ by less than 3.5% in
all cases considered.
Dose estimated according to equation 4.1 assumes the anatomic weightings per phase are
independent of finite delivery time and that the distribution of 4DCT phases realized during
treatment is identical to what is sampled at the time of simulation. This may be a reasonable
estimate for fractionated therapy with a consistent breathing pattern, where patient breathing
is sufficiently sampled to reproduce anatomy which matches the distribution recorded during
4DCT simulation. However, unless the beam-on time is correlated to the breathing pattern, the
equi-weighted phases will never be realized in each individual fraction. Methods to estimate
the effects of finite delivery time on accumulated dose are investigated in the following
sections.
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4.3 SAMPLING 4D-ANATOMY BASED ON FINITE DELIVERY TIME AND
PATIENT-SPECIFIC BREATHING
In order to estimate the accumulated dose (4DD) in equation 4.1, an estimate of the probability
of treating each phase image ( w p ) is required. Equation 4.1 assumes the phase (or anatomic)
weights are independent of finite delivery time. By estimating the dose distribution and
anatomic weightings for each aperture (or collection of beamlets), the effects of finite-delivery
time on dose can be estimated prospectively. This effect is commonly called the interplay
effect, i.e. the effect of interplay between anatomic motion and non-uniform dose delivery.
Physical measurements of dose to a moving dosimeter (dose detector) allows for estimation of
the interplay effect (see e.g. Jiang et al.104 or Berbeco et al.95). For a fixed aperture sampling
rate, previous studies have used MLC-logged output and exit-fluence measurement to estimate
dose to time dependent anatomy retrospectively105–107 and prospectively.107,108 Based on
measurement and simulation, the effects of MLC interplay have been shown to have a
negligible effect on the total dose due to fractionated sampling.104,109 However, the magnitude
of this effect is dependent on several factors including the dose distribution, the dose-rate, the
fractionation schedule, and delivery techniques (e.g. dynamic MLC motion, step-and-shoot MLC
delivery, etc).110,111
In order to estimate 4DD and variability in 4DD due to the effects of fractionated delivery,
patient breathing, and delivery conditions (including dose-rate and optimized monitor units),
plausible sampling of the patient anatomy is investigated in this section. Dose to anatomic
phase p due to aperture a is designated Dpa and is weighted by a sampled probability of w pa .
4DD can be estimated as:
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r
r
r
4DDref ( r ) = ∑∑ w paDpa ( r + ν ref → p (r ) )
a

4.2

p

In appendices A and C, 4DD is estimated including the effects of finite beam-on time and nonuniform delivery on a per-beam basis, not on a per-aperture basis. A per-aperture sampling of
anatomic phase weights and a per-aperture dose calculation, as in equation 4.2, in addition to
the effect of finite delivery time and non-uniform delivery, will estimate the interplay effect
between MLC motion and anatomic motion. However, interplay between MLC and anatomic
motion is beyond the scope of the current work. Such an estimate must also consider the MLC
motion sequence (or the order or apertures) which delivers each optimized beam fluence.111
Estimating 4DD on a per-beam basis assumes the collections of apertures which compose each
beam are realized for the entirety of each beam-on time. The 4DD, in this section, is estimated
as a sum of deformed doses per-beam b, per phase p ( Dpb ), with phase-weightings w pb according
to
r
r
r
4DDref ( r ) = ∑∑ w pbDpb ( r +ν ref → p (r ) )
b

4.3

p

The difference between equation 4.1 (used to estimate 4DD in the previous section) and
equation 4.3 is the latter considers beam-on time and per-beam weightings of each beam dose,
rather than per-phase weightings of the combined dose from all beams on each phase. The
two 4DD estimates will diverge when beams deliver dose to the ITV non-uniformly and perbeam phase weights vary, inter-phase. As an example, consider superior-inferior tumor motion
defined in two phase images, p1 (tumor in a superior location) and p2 (tumor in an inferior
position) with weights w1 and w2. Assume beam 1 (b1) delivers dose only to the superior
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region of the ITV, b2 only two the inferior region, dose to the tumor due to each beam in each
phase is:

Dpb11 = 1 , Dpb12 = 0
Dpb21 = 0 , Dpb22 = 1
According to equation 4.1, 4DD is independent of beam-on time and dose to each phase is
estimated as
Dp1 =

∑

Dpb1 = 1

∑

Dpb2 = 1

b = b1,b2

Dp2 =

b = b1,b2

Then 4DD =

∑

w pDp = w p1 + w p2 = 1 ∀w p , independent of per-fraction weight variations.

p=p1,p2

However, according to equation 4.3, 4DD =

∑ ∑

w pbDpb = w pb11 + w pb22 = [ 0,1] , i.e. the dose

b = b1,b 2 p = p1, p2

can vary from 0 to 1 depending on the sampled phase-weights per beam, per fraction.
For eight patients (4 LA, 4 SBRT), 4DD is estimated according to equation 4.3. Before estimating
4DD, however, an estimate of weight variations per fraction, per beam, is necessary.

4.3.1 Methods to Estimate Variability in Anatomic-Phase Weights
The variation in anatomic weights during each beam of each fraction can be estimated from the
total beam-on-time as the product monitor units per beam (MUb) and the dose rate (DR), and a
reproducible patient breathing period (T) divided by the number of fractions. For ten phases
per breathing period (Np=10), the expectation value of the number of anatomies seen by each
beam during each fraction is
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nana =

MUb × Np
N fx ×DR × T

.

4.4

By randomly sampling the beam-on starting phase for each fraction, the realized weights during
each fraction will fall between a minimum ( w pmin ) and maximum ( wpmax ) of

 n
w pmin = floor  ana
 Np





nana ;

w pmax = w pmin + 1 nana .

Using these min- and max- values to estimate per-fraction variability allows for a simple
assessment of anatomic weightings, assuming a reproducible breathing pattern. In reality,
breathing patterns are not perfectly reproducible.
By sampling actual patient breathing patterns for durations determined from beam-on times
estimated from controllable, machine-specific parameters, a more realistic value of phase
weights can be estimated for each patient, for each fraction. An interface to the Pinnacle3 TPS
was constructed as part of this dissertation which utilizes patient-specific breathing patterns, as
captured by the RPM infrared camera, to determine patient-specific, per-beam phase-weights
for each fraction.
The RPM infrared camera samples breathing amplitudes at 33 Hz with each point labeled with a
phase (between 0 to π) determined from peak inhale and exhale positions. The beam-on data
defines the equi-weighted, 4DCT phase images. Variations of phase-weights, based on
sampling portions of the breathing pattern normalized according to the beam-on data, are used
to estimate per-beam, per-phase weight variations and ultimately variations in 4DD. Figure 12
shows the RPM-interface and the weights from sampling the entire beam-on data set (left, the
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weights are defined as equal for the beam-on set) and a portion of the breathing data (right)
based on a random starting phase and beam-on time determined from MUb, number of
fractions, and dose-rate.

Figure 12. A breathing-data interface to the Pinnacle3 TPS is shown. The beam-on data is
used to establish the equal phase weightings sampled in 4DCT (left). By sampling a portion of
the breathing pattern the phase-weights are reassigned (right).
The method of sampling the patient-specific breathing patterns in this dissertation assumes
that the assigned phases are independent of the sampled amplitude, i.e. that the RPM-assigned
phases are labeled correctly with respect to reconstructed phase images. In fact, the
reconstructed 4DCT phase images may be more closely related to the amplitude of the
breathing trace at the time the images are captured. For example, in the right-panel of Figure
12, the minimum amplitude at (time =) 120 seconds is approximately -0.6 cm in amplitude,
whereas the surrounding exhale peaks display -0.8 cm amplitude. This work assumes all of
these minima positions represent the maximum exhale phase-image (50%). An alternative
method assumes the 4DCT phase is a function of amplitude, so that the exhale-peak at -0.6 cm
may, in-fact, identify weightings for a different phase (e.g. 30%).
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For the 8 selected patients, 4DD is calculated according to equation 4.3. Per-beam phaseweightings are estimated for LA patients for 30 fractions at 2 dose-rates: 600 and 1000 MU/min
and for four fractions and 3 dose-rates for SBRT patients: 1000, 1400, and 2400 MU/min. For
the LA patients, the MUs from the 30%-ITV plan are varied to achieve a minimum of
CTV-4DD95≈70 Gy. For the SBRT patients, the clinically planning MUs are used to estimate
phase-weight variations.

4.3.2 Accumulated Dose Estimation with Varying Phase-Weights
Figure 13 shows the average anatomic weights which may be realized over 30 fractions as a
function of beam monitor units, according to equation 4.4. The error-bars show two standard
deviations about the mean (which converge to the 4DCT sampled equal weights of 0.1 in all
cases); the standard deviations show the range of weights which will be realized during each
fraction. When beam-on time per fraction is an integral number of breathing periods the
standard deviation goes to zero. For the four LA patients, the median MUb=3846 MUs, the
mean is 5467 MUs, and the range is 1,555 to 16,034 MUs.

In

Figure 13. Average inter-fraction
phase-weights, and two standard
deviations sampled over 30 fractions
based on random starting phase. The
standard deviation goes to zero when
the beam-on time is an integral
number of breathing periods for each
fraction.
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the four hypo-fractionated SBRT plans, delivering treatment in four fractions at 1,000 MU/min
is a typical approach, however new technology delivers up to 2,400 MU/min.112 For the four
SBRT patients considered in this study, clinically optimized monitor units per beam per range
from 436 up to 1508. Figure 14 shows anatomic weight variations per beam per fraction, based
on delivering to ten anatomies (Np=10) over four fractions (Nfx=4) at variable dose rates and
breathing periods according to equation 4.4. In the patient cases considered, weight variations
from 10%-20% will be observed during each fraction for all patients, even if the patient
breathing pattern is perfectly reproduced throughout treatment.
For both LA and SBRT patients, sampling patient-specific breathing patterns shows similar
variability revealed in Figures 13 and 14 with common per-fraction weight variations between
0.09 and 0.11 for LA patients and >20% variations about the mean weights (0.08 to 0.12) in
hypo-fractionated, SBRT treatment. However, the effect of fractionation results in average
phase-weights which approach 0.1 as sampled in 4DCT.
Two methods are used to estimate the variability in dose to the target (4DD95), defined as the
standard deviation in 4DD95 for each of the eight patients. In the first method, termed the 3sample approach, three samples of 4DD95 are averaged and used to compute the standard
deviation. The three samples are (1) nominal weightings ( wp = 0.1) on all phases, (2) wp = 0.11
on the five phases surrounding inhale (i.e phases 80%, 90%, 00%, 10%, and 20%) and 0.09 on
the phases surrounding exhale, and (3) wp = 0.09 on the phases surrounding inhale while the
phases surrounding exhale have wp = 0.11. This method of estimating the effects of interplay
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shifts the weights between different portions of the respiratory cycle where dose differences, in
all likelihood, are at a maximum.
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Figure 14. Anatomic phase-weightings and inter-fraction variations based on delivering
radiation to 10 different anatomies in four fractions.
In a second method to estimate the standard deviation in 4DD95, the patient breathing patterns
are sampled ten times to estimate inter-fraction phase weights. The ten weight samples are
used to compute ten samples of target 4DD95 and are averaged. The variability in 4DD95 is
reported using the standard deviation of the ten samples for the eight patients.
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4.3.3 Results: Effects of Weight Variations on Accumulated Dose
The three sample approach to estimate variability in accumulated dose results in equal or larger
variations than sampling patient specific breathing patterns for the four LA patients. The
standard deviations about the mean CTV-4DD95 (<CTV-4DD95>), based on the 3-sample
approach for the four patients are 0.01 Gy, 0.01 Gy, 0.2 Gy, and 0.6 Gy. Sampling patientspecific breathing patterns for 30 fractions at a dose rate of 600 MU/min and 1400 MU/min, for
ten samples, results in standard deviations which are less than or approximately equal (to
within 0.01 Gy) to the 3-sample approach. The mean dose and standard deviation about the
mean are reported in Table 3 for the LA and SBRT patients based on sampling patient-specific
breathing patterns. In all cases, the standard deviation in 4DD95 is less than 0.5% of the equiweighted estimate based on equation 4.1.
Despite the sampled weight distributions varying by >50% of the nominal values (i.e. from 0.05
to 0.15) in sampling patient breathing patterns dose rates ≥1400 MU/min, the 4DD95 varies by
less than 0.32 Gy in the LA plans and by less than 0.26 Gy for the SBRT patients. The standard
deviation in 4DD95 increases by a factor of at least 2 for delivery at 2400 MU/min compared to
delivery at 1400 MU/min. However, even at high dose-rate, the variability in 4DD95 is
negligible.
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Table 3. Average and standard deviation (σ) of
accumulated dose to 95% of the target (<4DD95>)
based on ten simulated deliveries. The variations
in total dose are negligible in all cases.
<4DD95> ± σ (Gy)

Nfx
Dose Rate (MU/min)

1000

1400

2400

N2

4

48.43±0.01 48.45±0.03 48.40±0.08

N3

4

47.73±0.01 47.73±0.02 47.76±0.11

N4

4

47.58±0.04 47.57±0.04 47.66±0.26

N5

4

46.10±0.02 46.09±0.02 46.01±0.07

Dose Rate (MU/min)

600

1400

P3

30

70.15±0.01 70.15±0.01

P5

30

71.65±0.32 71.71±0.32

P6

30

72.11±0.02 72.08±0.02

P10

30

68.66±0.01 68.66±0.02

4.3.4 Summary: Effects of Finite Delivery Time and Patient Breathing
on Accumulated Dose
Weight variations due to finite delivery time, non-uniform delivery, and interplay with patient
breathing have a negligible effect on target 4DD95. Standard deviations in mean CTV-4DD95
based on sampling ten deliveries are less than 0.32 Gy in all cases considered even when
delivered at dose rates up to 1400 MU/min for LA patients and up to 2400 MU/min for hypofractionated, SBRT patients. Simulating as few as three scenarios, considering 10% weight
variations between different portions of the breathing cycle, results in larger standard
deviations in mean CTV-4DD95 than sampling patient-specific breathing for the cases
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considered. This implies that a simple evaluation of a few extreme scenarios may bound
estimates of 4DD variability due to finite delivery time.
Further studies are needed to estimate 4DD variability due to interplay effects. Several effects
were not considered in this preliminary study including the effects of mis-labeled breathing
phase, biologic effects of inter-phase dose variation, and per-aperture, MLC interplay.
Incorporating these effects into 4DD estimation is a future goal. A per-aperture sampling and
4DD estimation methods are analogous to the per-beam approach, but requires dose
distributions computed for each aperture. Once the per beam phase sampling is complete, the
per-aperture weightings are a subset of these weightings which depend on the MLC leaf
sequence. Consideration of the leaf sequence and appropriate temporal resolutions will allow
an estimate of MLC interplay effects. The breathing interface to the treatment planning system
creates possibilities for these and other studies.

4.4 CONCLUSIONS: DOSE ESTIMATION IN TIME-DEPENDENT ANATOMY
This chapter focused on improving single planning image dose estimates (3DD) using all 4DCT
phase images and estimating accumulated dose (or 4DD). Using a single image to estimate
dose, when 4D-data is readily available, may be justified if differences in 3DD and 4DD are
insignificant to clinical outcomes. However, this chapter shows target 4DD can be less than,
greater than, or equal to 3DD for several different 3D-RTVs (e.g. the stationary target or the
PTV) and several different dose-evaluation metrics (e.g. dose at fixed volume, volume at fixed
dose, and gEUD). In fact, target dose deviated from PTV dose by >3% in 19/30 cases considered
for locally advanced patients and in 3/5 SBRT cases considered. This implies that dose

59
accumulation is a necessary component of RT to time-dependent anatomy and can improve
knowledge of dose delivered to time-dependent anatomy.
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5 Multiple Anatomy Optimization of Accumulated
Dose

MAO – Multiple Anatomy Optimization
PTP – Probabilistic Treatment Planning
EV – Expectation Value
PDF – Probability Density Function
MIGA – Multiple Instance Geometric Approximation
RC – Robust Counterpart

The first aim of this study is to show that RT for time-dependent anatomy can be improved
through inclusion of all 4DCT phase images for dose-estimation and plan optimization. This
chapter focuses on plan optimization which incorporates all 4DCT phase images, as opposed to
plans optimized on a single planning image. Based on the results of the previous chapter,
under-dosing a moving lung cancer target is possible if the entire PTV is not treated to a
minimum dose. This implies, in order to ensure the moving target is covered; regions of normal
tissue must be treated to a tumoricidal dose. By optimizing the accumulated dose (or 4DD)
based on a known motion pattern, it is possible to incorporate patient-specific motion in plan
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design and potentially increase the therapeutic ratio. Radiotherapy plan optimization of the
accumulated dose distribution is introduced in Appendix A as multiple anatomy optimization
(MAO) and is discussed in this chapter. MAO is a method of probabilistic treatment planning
(PTP) which has been researched extensively in RT, but has not been clinically implemented.

5.1 INTRODUCTION
Probabilistic treatment planning (PTP) integrates a probability density function (PDF) of
multiple anatomic instances into an optimized dose distribution. Statistical characteristics of
the dose distribution evaluated on planning structures can be inferred from a known PDF of the
occurrence frequency of variant anatomies, including an estimate of the dose expectation-value
(dose-EV). Li and Xing113 introduced a method to optimize dose-EV using organ specific,
Gaussian PDFs. Birkner et al.114 proposed a similar method to account for rigid motion which
optimized the dose-EV based on measured random and systematic set-up error. Birkner et

al.114 proposed an adaptive routine relying on information gathered throughout treatment, as
opposed to use of a single planning image. McShan et al.115 introduced a method termed a
multiple instance geometry approximation (MIGA). MIGA calculated dose on multiple anatomic
instances and computes an expected dose, this is consistent with the MAO approach described
herein.
After the introduction of 4DCT for lung cancer simulation, methods of optimizing the
accumulated dose using 4DCT data were described by Trofimov et al.31 In their work, a dose-EV
approach is introduced based on two methods of dose estimation, (1) a weighted sum of dose
kernels computed on 4DCT images (similar to MIGA) and (2) a convolution approach, where the
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motion PDF is convolved with a planning image, 3D-dose.109,116 The two methods are
equivalent if the motion is rigid for all anatomy. Plans generated via the motion kernel method
were compared to margin-based plans, gating plans, and idealized tracking plans for one lung
and one liver case. The comparison showed that motion-kernel methods can produce plans
comparable to idealized gating and tracking in terms of target coverage and OAR sparing.
Zhang et al.117 compared target tracking and a dose-EV approach (named 4D-inverse planning)
using a convolution dose calculation. Their work also demonstrated that 4D-optimization can
achieve similar target coverage and OAR sparing to target tracking without necessitating
delivery synchronization with breathing for four patients. Söhn et al.118 compared lung cancer
plans optimized based on the ITV method, idealized-tracking, and a weighted sum of dose
kernels for one patient and also show potential to spare OARs using PTP. While the potential
advantages of incorporating 4D- information (and estimating the dose-EV) in RT optimization
have been shown by these studies, there is concern about the validity of these, and other 4Dplanning approaches due to variability and uncertainty in the motion PDFs.
For a known PDF, Unkelbach and Oelkfe introduced dose-EV optimization for assumed Gaussian
distributions119 and for estimated data using Bayesian inference.120 By simultaneously
optimizing dose-EV and minimizing dose variance, their method achieved robustness against
uncertainty in the PDF. Heath et al.121 implemented these methods for lung cancer RTP and
included uncertainty in patient breathing. They compared optimized solutions to worst-case
optimization (see e.g. Fredrikkson et al.122) and a margin-based approach. Heath et al.121
demonstrated that target dose can be compromised in the presence of uncertainty if the dose-

63
EV is optimized without consideration of the dose variance. A similar result was shown by
Sheng et al.123 in a simulation study.
Chan et al.124 and Bortfeld et al.125 optimized dose-EV and included uncertainty in patient
breathing using a robust counterpart (RC) approach126 in which the objective function is
redefined in terms of robust parameters. Nohadani et al.127 investigated stochastic
optimization and applied the method to the lung cancer RT optimization problem including
uncertainty in the patient breathing pattern. Mulvey et al.128 was one of the first to consider
stochastic optimization for problems with uncertain parameters, a method in which several
solutions are generated with different sensitivities to uncertain parameters. For a given
parameter variation, solutions below a threshold of sensitivity were called robust. The
threshold should depend on the level of risk, and the level of risk in the RT optimization
problem depends on the intent of treatment, uncertainty in the TCP and/or NTCP, clinical
significance based on calibration tolerances, and several other factors.
The collection of reviewed literature which presents and compares methods of MAO for lung
cancer RT optimziation31,117,118,121,125,129 includes a total of 12 lung cancer patients. Among this
patient cohort, 3D-motion ranges from 0.8 cm to 2.9 cm, including 9/12 patients with 3Dmotion >1.1 cm and 5/12 with 3D-motion >1.6 cm. In fact, only Heath et al.121 considered
patients with tumor motion <0.9 cm (2 of 5 total patients considered). Despite moderate CTV
motion, Heath et al.121 indicated a potential to spare ipsilateral lung mean dose (from 3.8 Gy to
2.7 Gy and from 5.4 Gy to 5.2 Gy) and reduce ipsilateral lung V20 (from 23% to 20% and 7% to
4%) for these patients. It is intuitive that the MAO approach will benefit patients which exhibit
large tumor excursions (e.g. >1cm) because the proportion of healthy tissue within an ITV is
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directly proportional tumor excursion. However a recent study of 250 lung cancer patients
shows evidence that approximately 90% of all lung tumors move <1 cm.130 This suggests the
patient population presented in studies of 4D-optimization is not representative of the lung
cancer patient population and that the benefits of an MAO approach may not yet known for
>90% of all lung cancer patients.
This work implements MAO in in a research version of the Pinnacle3 commercial TPS. The
proposed method uses a single, 10-phase 4DCT image set for planning and computes dose on
all phase images, analogous to the MIGA method. The accumulated dose (or 4DD) is optimized
for the ten locally advanced (LA) lung cancer patients. MAO plans are compared to ITV plans
for these ten LA patients all presenting <1 cm motion (detailed in Table 1). Target dose
robustness based on the MAO dose distribution due to finite delivery time and sampling
patient-specific breathing patterns is also examined.

5.2 METHOD OF MULTIPLE ANATOMY OPTIMIZATION (MAO)
The general objective function in eq. 2.1 is combined with individual objectives specified in eq.
2.2 to write the MAO objective function as

r
O d 4D =

( ) ∑ w ∑ c (d
n

n∈NROIS

i ,n

i∈n

4D
i

− DnRX ) .
2

5.1

The sums are carried out over i 4DD values ( di4D ) which define dose to the nth structure; each
structure has a prescription DnRX ∀i ∈ n . Consistent with the ORBIT implementation, the ci,n
include a proportionality constant and a Heaviside function defined such that
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 0if x ≤ 0
Π ( x) = 
1 if x > 0
For maximum and minimum dose objectives, the constant for voxel i of relative volume ∆vi
within the nth ROI is

ci ,n = Δvi

Π ( mdi4D ± DnRx )

(D )

Rx 2
n

.

The relative volume of each voxel, ∆vi is less than 1 when part of the ith voxel is outside the ROI,
and is equal to 1 in all other cases. The argument of the Heaviside function flips signs of the
dose value and dose prescription depending on whether the objective is a minimum or
maximum dose objective.
For dose volume objectives, there is a 2nd term in the ci,n coefficient which includes volume of
the ROI at or above a specified accumulated dose level. The relative volume at prescription
dose is

(

r 4D

V d

∑ Π ( d − D ) ∆v
)=
∑ ∆v
4D
i

Rx
n

i

i∈n

i

i∈n

and the coefficient for minimum and maximum DVH objectives is

c i ,n =

Π ( m d i4 D ± DnRx ) Π ( mV (d i4 D ) ± VnRx )

(D )

Rx 2
n

where VnRx is the volume prescription level. If the ROI volume at prescription dose is acceptable,
no voxels are penalized. If the volume at prescription dose is not met, only voxels with dose
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below dose-prescription are penalized for targets, voxels with dose above dose prescription are
penalized for OARs.
Consistent with the BFGS method (Radiotherapy Plan Optimization, page 19), the gradient of
r
the objective function with the respect to the vector of beamlet weights, b , is calculated and
used to estimate the inverse Hessian. The gradient of the objective function defined in eq. 5.1,

r
for a collection of p phase images and a vector of accumulated dose d 4D (=4DD) is
r
∂ O d acc
r
∂ 
r = r  ∑ wn ∑ ci ,n d i4D b − DnRx
∂b
∂b  n∈NROIS i∈n

( )

( ()

)

2

r 4D

4D
Rx ∂d
 = ∑ 2wn ∑ ci ,n ( d i − Dn ) r
∂b
i∈n
 n∈NROIS

r
Focusing on the last term on the right hand side, d 4D is computed as a weighted sum of perbeam phase doses Dpb each weighted by wpb :
r
r
r
r
r
d 4D = 4DDref ( r ) = ∑∑ w pbDpb ( r + ν ref ← p (r ) ) with r parameterized at each of i spatial positions.
b

p

The jth beamlet deposits dose to the ith voxel of phase p according to the according to the dose
deposition coefficients K pij , however the i voxels are rearranged according to the DVF, v ref →p ( ri )
at the indexed positions ri. The 4DD at voxel i in the reference image due to beamlet j is

di4D = ∑∑ w pbK pi ' j bj with i’ determined from ri ' = ri + vref → p ( ri ) . The rearranged dose deposition
b

p

coefficients to phase p, K pi ' j can be written as a matrix K% p , then the 4DD vector is written
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r
r r
d 4D = ∑ K% p w p o b with ◦ the element by element, Hadamard multiplication between a vector of

(

)

p

r
phase weights wp with elements wpj , each representing the probability of encountering the pth
phase anatomy for the jth beamlet. Then

r
∂  % r r 
r  ∑ K p w p o b  = ∑ Kˆp ( Id ) jxj w p = ∑ Kˆpwˆ p ≈ ∑ w pK% p = K%
∂b  p
p
p
 p

(

)

5.1

Where the weight matrix, ŵ p , has the anatomic weights for each beamlet along its diagonal.
The right hand side assumes the anatomic weights are constant for all beamlets (i.e.
independent of beam-on time) and is reduced for clarity, so that the weighted sum of deformed
dose deposition coefficients is approximated by K% . The deformation and interpolation (to
perform accumulation) of the dose-deposition kernels, rather than the dose itself, was first
discussed in Trofimov et al.31 The gradient with respect to the jth beamlet is
g bj =

∑

n∈NROIS

2wn ∑ ci ,n ( d i4D − DnRx ) K% ij =
i∈n

∑

n∈NROIS

2w n ∑ ci ,n ∆ i K%
i∈n

ij

Where the superscript b is used to indicate beamlet space, and ∆i is the difference between the
ith voxel dose and the prescription dose. The K% transforms the gradient of the objective
function from dose-space to beamlet space. The gradient is estimated in dose space with each
element defined according to
gid =

∑ 2w ∑ c ( d
n

n∈ROIs

i ,n

i∈n

4D
i

− DnRx )

5.2

r
where g d denotes the gradient defined in dose space. In the BFGS-implementation, the Hessian
is initialized with an identity matrix and updated at each iteration. Following the work of Löf et
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al.80, the Hessian is initialized to the identity matrix and a line search algorithm131 is used
determine the step size λ, the optimization algorithm is:
1. Compute the gradient according to 4.2, define an update
r
ˆ rd
u d = − Hg

(

r
ˆ rd
With a corresponding beamlet update of u b = − Hg

)

T

K

r r
r
2. Line search for the step size λ, based on d ' = d − λu
a. If d ( i ) < 0 set d ( i ) = 0

r
r
b. Compute the new gradient, g ' according to 4.2, based on d '
c. Test Wolfe conditions (see, e.g. Nocedal and Wright79, Chapter 3) for constants
c1 , c2 , 1 > c2 ≥ c1 > 0
.

r
r Tr
O d ' ≤ O ( d ) + c1 λ ( g d ) u d , the Armijo condition.

( )

rd '

(g )

T

r T r
r
u d ' ≥ c2 ( g d ) u d , the curvature condition.

i. If met, accept, go to (3)
ii. If not met, try new λ (up to 20 times)
3. Accept solution and end optimization, or continue to 4.
r r
r r
4. Define δ = d ' − d , γ = g ' − g and update Ĥ
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δδ T  γ T Hˆγ  δ γ T Hˆ + Hˆγ δ T
ˆ
ˆ
H = H + T  1+ T  −
δ γ
δ γ 
δ Tγ
5. return to (1)

The MAO algorithm computes the accumulated dose at each step size (step 2), according to
equation 4.1, so that the 4DD and the 4DD-gradient must meet the Wolfe conditions. The
initial approximation of the Hessian in MAO is determined by continuing a single image, ITVbased optimization. The current implementation of MAO does not directly access the dose
deposition coefficients and therefore does not use the deformed dose-deposition coefficients

r
described in equation 5.1 which results in an inaccurate beamlet update, u b , (in step 1). This
often results in several line searches per iteration, and often exhausts 20 attempts (as in 2.c.ii
above) in which case the search direction is changed. By integrating the deformed dosedeposition coefficients in the numeric optimizer of the Pinnacle3 TPS, the efficiency of the
method will be improved.
Implementation of MAO, as described herein and in Appendix A, has reference-phase
dependence. In computation of the gradient and the objective function, the reference phase
determines which voxels are included (i.e. which violate prescription) and which voxels are
assigned to each structure. For example, the Heaviside function is zero-valued in the reference
phase but the corresponding position in other phases has ci,n ≠0. In order to ensure all target
voxels are included in the gradient and objective function calculation, the obejctives on
structures which overlap the PTV are defined as non-zero for all dose distributions. If an
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objective reaches zero-value, the volume level at prescription, VnRx , is reduced in 5% increments
until a non-zero objective value is found. In heart, for example, the dose-volume prescription
at 30 Gy is reduced to 0% if necessary. This ensures all voxels of the PTV are included in each
optimization step, even if these voxels enter the objective function as OARs.

5.3 MULTIPLE ANATOMY OPTIMIZATION (MAO) IMPLEMENTATION
The three-phase phantom shown in Figure 15 is used to demonstrate possible advantages in
MAO-planning compared to the ITV method. A region of the image which includes a target (a 2
cm water sphere) moves rigidly and is defined in left, middle, and right phases. There is a
phase-dependent relationship between the target (green) and the OAR (red) in the phantom.

Figure 15. A 3-phase phantom which includes a moving target (green) and a fixed OAR (red).
All plans are optimized to deliver 70 Gy to the target. The OAR is also a water equivalent
sphere and is stationary in all phases; plans include a max-dose objective of 45 Gy on the OAR
(similar to a spinal cord objective). The surrounding 103 cm3 cube has CT#=300, similar to lung,
and the optimized plan includes a non-zero dose-volume objective at 20 Gy (V20<0.15).
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The ITV-plan is designed to deliver 70 Gy to the union of phase-defined targets, while the MAO
solution is designed to treat the moving target to 70 Gy. Figure 16 shows the ITV solution (top
left) and the MAO solution (bottom left)
assuming equal phase weightings. The MAO
solution uses phase-specific dosimetry so that
the accumulated dose (bottom right) achieves
the OAR objective (OAR Dmax<45 Gy) and avoids
treating the target in the reference phase.

Figure 16. Optimized dose distributions using the ITV method (top left) and MAO (bottom
left). MAO avoids treating the OAR in all phases, but the accumulated dose (right images)
meets prescription.

The MAO solution reduces the volume at prescription dose but also increases maximum dose in
the surrounding cube. This is an example of a potential advantage of MAO compared to ITV
planning. If there is a time-dependent relationship between an OAR and a moving target, MAO
will incorporate this information in plan design and preferentially treat regions which avoid the
OAR.
Another possible advantage of MAO is the ability to incorporate the target PDF in the optimized
solution. The ITV method assumes the target is uniformly distributed within the ITV, i.e. all
regions of the ITV are equally weighted. If the CTV is non-uniformly distributed in the ITV, MAO
can preferentially treat the target in spatial locations of high probability and avoid treating
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regions of low CTV-probability. In order to show this effect, the phantom phase weights are
shifted from equal weightings, i.e. wp = (0.33, 0.33, 0.33), to unequal weights wp = (0.2, 0.1,
0.7). The ITV solution is unchanged, whereas the MAO solution preferentially treats the target
in the region where it spends the most time. Shown in Figure 17, the accumulated dose (right)
meets prescription and reduces V20 on the surrounding cube from 26% to 22%. The MAO dose
distribution follows the PDF distribution, preferentially treating in the right phase with higher
CTV-probability.

Figure 17. An example of an MAO dose distribution (left) and accumulated on the reference
phase (right). The target spends 70% of the time in the right phase and 20% of its time in the
left phase, and MAO shifts the dose towards the right phase.
5.3.1 Results: Comparison of MAO and ITV Plans
In Appendix A, MAO plans are generated and compared to ITV plans for the ten LA patients.
ITV plans are designed on the inhale phase (00%-ITV plan), the mid-ventilation phase (30%-ITV
plan), and the aCT (aCT-ITV plan) as described in chapter 4. Plans are compared at optimizedMU values and, by adjusting MUs in the 30%-ITV plan, at fixed CTV-4DD95. Increasing MUs in an
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ITV-plan can ensure accumulated dose meets prescription and clarifies potential advantages of
MAO plans in terms of OAR sparing.
At optimized monitor units, MAO increases 4DD-V70 by an average of 3.5% (±4.3%, p=0.01)
compared to ITV plans. Increased D95 with MAO planning is not significant in the patient
population, on average 0.35 Gy ± 1.27 Gy (p=0.8), but is increased by at least 1 Gy in 8 of 30
comparisons (10 patients, 3 ITV plans each). At fixed CTV-4DD95, the MAO plan is superior to
the 30%-ITV plan in 5/10 cases in terms of OAR sparing by at least 3% volume at fixed dose.
For P3, with 3D motion just 0.39 cm, there were clear advantages in MAO planning. At
optimized monitor units, MAO meets the CTV-4DD95 prescription, whereas the 30%-ITV plan
treats CTV-4DD95=71.5 Gy. By reducing target D95 to 70 Gy, ipsilateral mean lung dose is
reduced by 2.2 Gy, a reduction in V20 of 7%, even though 3D motion for this case is just
0.39 cm. At fixed CTV-4DD95 for P3, ipsilateral lung V20 is reduced from 48% to 41%, esophagus
V25 from 12% to 7%, heart from 28% to 25%. DVH curves for the MAO- and ITV- plans are
shown in Figure 18.

Figure 18. Dose volume histogram
(DVH) for P3 based on the 30%-ITV
plan and an MAO plan. At fixed
dose to 95% target volume (CTVD95), MAO spares all OARs at
objective dose levels.
In two other cases, ipsilateral lung
volume at 20 Gy (V20) is reduced by >4% volume. For the other two patients which show >3%
OAR volume sparing in MAO compared to ITV, esophagus V25 is reduced by >3%. Using the
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Pearson correlation coefficient, the potential for OAR sparing using MAO compared to the ITV
method is not correlated to 3D-motion (r2 = 0.08, p = 0.8). The lateral motion showed a weak
correlation (r2 = 0.42, p = 0.2), the largest CTV motion is measured in the lateral direction for P3
(0.28 cm) and P7 (0.41 cm) and MAO reduces a combined total of all OAR volumes at
prescription levels by 16.3% and 5.9% for these cases.
There is less than 3% improvement in combined OAR volume sparing in 5/10 cases considered.
However, MAO is always superior to the ITV method in terms of OAR sparing at fixed CTV4DD95, even if this sparing is small (e.g. <3% volume). For P1 and P2, this may attributed to 3DCTV motion which is on the order of the voxel size (~0.3 cm). P7 is a unique case, different from
others because the patient presents an extended lesion with central and peripheral
components extending from the inferior airway to the diaphragm; MAO showed little benefit in
treating these lesions. Patients P8 and P9 present 3D-motion of 0.7 cm and 0.8 cm,
respectively, and while MAO reduces ipsilateral lung V20 by 2% in each case compared to the
30%-ITV plan, MAO does not reduce dose in other OARs. For each of these patients, both
presenting central lesions, there is little benefit to an MAO approach.
Figure 19 shows MAO plans optimized on the inhale, 00%-phase (top left) and an MAO plan
optimized on the 30%-phase (bottom left) for P10. The reference phase dependence of the
MAO solution is clear in this case in both the optimized solution (left) and the accumulated
dose (right).
In MAO as implemented in this dissertation, dose-voxels enter the objective function as
components of either the CTV, of an OAR, or of both. The optimizer aims to reduce dose in
voxels which are included as OARs, and increase dose in voxels included as target. This leads to
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hotspots in the reference-phase CTV and cold-spots outside of the reference phase CTV. This
reference-phase dependence biases solutions and may not lead to globally optimal solutions.
Methods to generate a solution independent of reference phase structures are focus of future
studies. Considering dose updates on each phase and combining these updates is one
approach to generate a solution independent of reference-phase structure definitions.

Figure 19. The MAO solutions are shown on the left as optimized with a 00%-phase assigned
as the reference (top) and a 30%-phase reference (bottom). The solutions are clearly
different, as are the accumulated dose distributions (right).
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5.3.2 Results: Effects of Interplay on MAO Dose Distributions
The sensitivity of target dose with respect to finite delivery time and patient-specific breathing
is estimated using the same methods described in Chapter 4. Two analyses are carried out, the
first method uses the 3-sample approach of CTV-4DD95 values (equal weights for all phases, and
10% weight variations distributed over inhale and exhale); in the second analysis, 10 simulated
deliveries are carried out based on sampling patient-specific breathing patterns for 30 fractions.
Two dose rates are considered, 600 MU/min and 2400 MU/min, which span a range of clinically
relevant dose-rates (600 MU/min) and a high dose rate (2400 MU/min) which could potentially
be used clinically. For four MAO-optimized plans which show potential to spare OARS
compared to ITV plans, the standard deviation in CTV-4DD95 based on the two analyses are
reported.
The variance in CTV-4DD95 using the 3-sample approach is 1.4 Gy for P3, more than double the
ITV-plan CTV-4DD95 standard deviation of 0.6 Gy using the same approach, the 3-sample
method. This is the only case, however, with standard deviation about the mean >0.2 Gy.
Similar to the ITV plans, simulating 10 deliveries by sampling the patient specific breathing
patterns reduced the standard deviations in accumulated dose compared to the 3-sample
approach. This implies the MAO dose distributions, in many cases, are not susceptible to target
dose deviations due to PDF variations.

77

5.4 SUMMARY
For half of the patients considered, MAO shows the ability to spare individual OARs by at least
3% volume compared to ITV plans, whereas for five other patients, little to no benefit was
evident. Identifying a population of patients which will benefit from MAO planning is an
important element of clinical implementation. Clinical protocols require categorization of
patients based on identifiable features, e.g. many clinics use respiratory gating when lung
tumor motion is >1 cm. Methods need to be developed which can identify patients which will
benefit from MAO and Appendix A shows this is not a trivial identification, 3D-motion did not
correlate with MAO’s potential to spare OARs in the cases considered. For patients exhibiting
large motion (>1 cm), other studies have shown MAO offers benefits in terms of OAR sparing.
Based on the results of this work, it is clear MAO may benefit patients which display moderate
CTV motion as well.
Phantom studies show MAO can incorporate the target PDF and time-dependent relationships
between target and risk structures in plan design. Identifying the target PDF – and its departure
from a uniform distribution – may be an indicator of potential improvements. Variations in
relative overlap of targets (including uncertainty) and OARs as a function of phase may also
correlate to potential improvements using MAO, compared to the ITV method.
Concerns about PDF reproducibility over the course of treatment may not be warranted for all
MAO plans. Simulated delivery of MAO plans indicated that variations in CTV-4DD95 exceeding
1 Gy are possible due to finite delivery time and patient-specific breathing. However, in ¾
cases, the standard deviation of CTV-4DD95 based on 10 simulated deliveries is less than 0.10 Gy
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delivered at 600 MU/min and less than 0.13 Gy delivered at 2400 MU/min. Fractionated
sampling of patient-specific breathing patterns resulted in a smaller standard deviation in CTV4DD95 than using a simplified, 3-sample approach. For the one case that did show a large
variation in CTV-4DD95, robust optimization may be a viable solution. Several methods of
robust optimization have been implemented for lung cancer RTP121,124,125,129,132 and is an active
area of interest.
The previous chapter showed dose estimation which includes all phases of 4DCT can deviate
from single image estimates. This chapter shows optimized dose distributions which include
4DCT data are superior to optimized dose-distributions which use a single planning-image.
MAO plans can ensure target coverage is achieved without necessitating a homogeneous dose
distribution to the entire ITV. Moreover, MAO plans have the potential to spare OARs and
increase the therapeutic ratio, consistent with the overall goal of this dissertation.
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6 Dose to Mass in Lung Cancer Radiation Therapy

DMH – Dose Mass Histogram
VROI – volume of a region of interest
MROI – mass of region of interest
D95V – dose to 95% structure volume
D95M– dose to 95% structure mass

The second aim of this dissertation is to utilize structure mass in lung cancer RT treatment
planning, as opposed to using structure volume. In this chapter, structure mass is used to
estimate delineation consistency, dose-evaluation, and is used in RT plan optimization.
According to the linear quadratic (LQ) model, assuming cell density is proportional to physical
density, dose-to-mass is a more appropriate measure of radiation response in tissue.
Moreover, there is ambiguity in defining volume and dose-to-structure volume during
respiration due to several factors including physical volume variations and delineation
inconsistencies. Physically, mass is conserved during respiration and motivates the dose-masshistogram (DMH) for IMRT evaluation. Analogous to the DVH, the DMH transforms 3Danatomy and dose into a simple 2D-graph; the cumulative DMH plots relative structure mass as
a function of dose level. In section 6.1, differences in DVH and DMH are presented based on
planned, 3D-dose distributions and based on accumulated, 4DD for SBRT patients.
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Consistent and efficient structure definition in time-dependent anatomy is a hurdle which must
be overcome in order to implement 4D-RTP methods such as MAO. Delineating relevant
structures on (e.g. ten) phase images in a 4DCT image set is too time-consuming for clinical
implementation. Deformable image registration (DIR) offers an automated method to handle
structure definition on multiple phase images but DIR validation remains a challenge. In section
6.2, structure mass as a function of respiratory phase is examined. Inconsistencies in structure
mass will arise due to delineation inconsistencies and/or images which do not represent
physical anatomy.
Finally, section 6.3 considers optimization of dose-to-structure mass. Each voxel of each
structure is assigned an importance weighting designated by the voxel density. The method
preferentially treats massive regions of the PTV while avoiding massive regions of normal
tissue, showing the potential to increase the therapeutic ratio for lung cancer patients. The
introduced model of functional optimization can also be used to design RT plans based on an
arbitrary importance weighting distribution.
These sections utilize mass, as opposed to volume, in order to present more consistent doseevaluation metrics, more consistent structure delineation, and a potentially better method of
optimizing dose distributions in heterogeneous anatomy.

6.1 DOSE-TO-MASS AND THE DOSE MASS HISTOGRAM
In 2005, Nioutsikou et al.63 described the opacity in defining lung volume and dose to lung
volume during respiration. Through phantom experiments, they indicated dose to volume is
not a relevant quantity for evaluation of lung dose. Nioutsikou et al.63 contended that they
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agree with Butler et al.133, that dose-to-mass and the DMH are more appropriate quantities in
evaluation of lung cancer RT than dose-to-volume and the DVH. Butler et al.133 used dose-tomass evaluation in a study on gated lung cancer RT because the entire lung was not consistently
imaged in the included datasets. Mavroidis et al.134 described the magnitude of uncertainty in
estimating the DVH of lung based on Gaussian dose distributions due to volume variations. The
authors assess the difference between DVH and DMH using two phantoms, one homogeneous
and one heterogeneous, and show up to 40% differences between DMH and DVH in the
heterogeneous phantom. In a second analysis, a patient case was examined using a pair of
opposed-tangential fields; the resulting differences in DMH and DVH were approximately 5%
across the entire dose range.
During respiration the volume of lung varies and serves as an example of a limitation of the
DVH. Dose-to-mass is a more precise evaluation metric if structure mass, as represented by
4DCT, is constant during the breathing cycle. However, differences between DVH and DMH are
not solely due to volume variations. The distribution of density differences between the
irradiated set of voxels and the average density of all voxels which compose a structure will
create DVH and DMH deviations, even in constant volumes. An ROI volume is the sum of each
of the voxel volumes which compose the structure, or VROI =

∑v

i

and the mass of an ROI is

i∈ROI

defined as the sum the individual voxel masses, M ROI =

∑ ρv
i

i

.

i∈ROI

For anatomy with homogeneous density, any irradiated subset of structure voxels will contain
equal proportions of mass and volume and results in equal DVH and DMH at all dose levels.
Partially irradiated heterogeneous structures will show DVH and DMH differences that are
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patient and radiation-path specific which do not depend on volume differences. No
generalization can be made about DVH and DMH differences, as the irradiated volume may be
more dense than the structure-mean (and DMH>DVH) or less dense than the structure-mean
(with DMH<DVH).
Assuming an ROI is composed of voxels of fixed volume, v, the cumulative DVH is

DVH ( D ) =

 v 
ND
 Π ( D − Di ) =
N ROI
i∈ROI  ROI 

∑ V

where the RHS is simply the ratio of the number of voxels at dose D (ND) and the total number
of voxels in the ROI (NROI). The DMH value at dose D, for the same ROI, can be expressed

∑
 mi 
( i|di >D )
DMH( D ) = ∑ 
 Π ( D − Di ) =
i∈ROI  MROI 

ρi

∑ρ

.

6.1

i

i∈ROI

The cumulative DMH is the ratio of the sum of voxel densities at dose D and the sum of all voxel
densities in the ROI. The differences in DVH and DMH reveal physical characteristics (i.e. the
density) of the irradiated region of a structure.
Dose at volume (e.g. D95), volume at dose (e.g. V20), mean dose, and the generalized mean
(e.g. gEUD) are common quantities used to evaluate RT plans. These metrics assume all voxels
within an ROI have equal importance. If a structure has heterogeneous density and the number
of cells in each voxel is directly proportional to density, then according to the LQ model of
radiation damage, all voxels should not have equal importance in evaluation of RT. Figure 20 is
a graphical way to show the difference between volume- and mass- based evaluation. The
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volume-based quantities treat all voxels within an ROI equally (top), whereas mass-based
quantities define voxel importance according to density (bottom).
In section 6.1.1, summarizing results of Appendix D, DVH and DMH values are compared for 8
of the locally advanced patients. Dose calculation is performed within the Pinnacle3 TPS and
mass sampling is performed with dose and image voxels
of 0.3x0.3x0.3 cm3 (the images are re-sampled at the
dose distribution). Two DVH plans are designed for
comparison, one on the inhale phase image (inhaleplan) to simulate idealized breath-hold treatment and
one on the aCT image (to simulate free-breathing
treatment). The inhale-plan density results in welldefined (visible) image contrast; the aCT blurs the

structure densities according to 10 phases of the

Figure 20. The DVH is analogous to
respiratory cycle and obscures structure boundaries in the top image, with each voxel
weighted by either a 1 or 0. The
DMH uses density to weight voxel
many cases.
importance.
The DVH-optimized plans used for evaluation include
objectives for 70 Gy to 95% of the PTV-volume (D95>70 Gy) and PTV maximum dose less than
80 Gy (Dmax<80 Gy) while minimizing lung V20, esophagus V25, heart V30, and spinal cord
Dmax<40 Gy. In the inhale plan, the PTV is defined as the inhale-phase GTV surrounded by a
1 cm margin. In the aCT plan, the PTV is a 1 cm expansion about the ITV – the union of the GTV
in ten, 4DCT-phase images. DVH and DMH are compared at all dose levels in the following
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section for eight locally advanced patients based on DVH-optimized dose distributions. If the
differences are insignificant, dose-to-mass evaluation does not offer new information, as
compared to dose-to-volume evaluation.

6.1.1 Results: DVH-DMH Differences
Observed differences in relative volume and relative mass depend on the ROI. For the spinal
cord and heart, differences in DVH and DMH (DVH-DMH) are <3% at all dose levels for all
patients (8) and DVH-plans (16) considered. For the esophagus, 1 of 8 patients show relative
mass/volume differences exceeding 3% at doses above 2 Gy. In each lung, differences in
relative mass and volume are patient and plan dependent, exceeding 3% in 3 of 8 inhale-based
plans and in 6 of 8 aCT- plans at dose levels ranging from 10-20 Gy. The targets, including GTV
and PTV on inhale-plans and ITV and PTV on aCT-plans, also show differences exceeding 3% for
all patients near the prescription dose. The PTV dose at 95% volume (D95V), when compared to
PTV dose at 95% mass (D95M), differ by up to 15.7 Gy (for P3), implying dose cold spots occur in
massive regions of the PTV for this patient. For 5 of 8 patients considered, PTV differences in
D95V and D95M are less than 1 Gy in both inhale and aCT plans. For the other three patients,
these differences exceed 2 Gy in at least one of the two plans. For the GTV (in inhale plans) and
ITV (in aCT plans), the results are similar to PTV, with differences occurring near the
prescription dose. An example of a DVH and DMH plot is shown in Figure 21.
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Figure 21. Dose-volume histogram (DVH, solid) and dose-mass histogram (DMH, dashed) for
a plan designed on the inhale 4DCT phase (using single image, 3D-dose). Differences in the
PTV and ipsilateral lung imply that a relatively dense region of each structure is receiving a
large proportion of dose (i.e. DVH<DMH).
6.1.2 Summary: DVH and DMH differences
DVH and DMH differences in the each lung often exceed 3% at fixed dose and exceed 2 Gy at
fixed volume or mass solely due to tissue heterogeneities. The study of Mavroidis et al.134 show
similar results for a breast cancer patient. Appendix D shows DVH and DMH in both lung and
lung-cancer targets can vary by >10%, and the sign of this difference is patient and radiationpath dependent. However, dose-to-mass evaluation is approximately equivalent to dose-tovolume evaluation (to within 3%) for esophagus, heart, and spinal cord, likely because these
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structures are approximately homogeneous. In lung and PTV, however, it is possible that the
use of DVH indices result in uncertainty in estimating radiation damage due to corresponding
uncertainty in the in initial cell population, based on the LQ-model of cell-kill. The population of
cells in these structures may not be trivially related to volume.

6.2 MASS-CONSISTENCY IN 4DCT STRUCTURES
Mass is approximately conserved during respiration, assuming the mass of air exchanged and
blood-flow variation as a function of 4DCT-breathing phase is negligible. Structures defined on
different phases of a 4DCT dataset should also conserve mass if the images and delineated
structures are an accurate representation of physical anatomy. In appendix D, mass and massconservation in delineated structures as defined in different breathing phases of 4DCT are
reported. Defining structures in all phases of 4DCT is a time-consuming task in RT, but can be
done relatively quickly using DIR and contour propagation between different phases of a 4DCT
image-set.
In this section, multi-phase structure mass estimation is used to estimate intra-observer
delineation consistency for two “observers” - an expert physician and the Demons DIR
algorithm available in the research version of the Pinnacle3 TPS.99,100 However, delineation
consistency is one of several factors which will contribute to mass variation in 4DCT. Motion
artifacts due to intra-phase residual motion7 can artificially change mass; sorting errors (i.e.
projections sorted into the wrong respiratory phase)10 generate mixed-phase images which will
reproduce some regions and remove others. Li et al.135 contend that mass deviations due to
blood and air exchange create uncertainties in structures defined by DIR algorithms which
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specifically penalize mass deviations, including the Demons algorithm (see, e.g.136,137). Yin et
al.138 introduced a DIR algorithm designed to conserve mass between individual voxels, claiming
mass deviations are small enough to be ignored. The Demons registration algorithm, as
proposed by Thirion101, includes an optical-flow step which minimizes intensity differences
between points in different images, implying that an ideal Demons-based registration will
conserve integral intensity (or in the case of CT images, mass). However, the Demons algorithm
used in this work includes regularization terms which allow for some differences in point-topoint intensity conservation without penalty, so the algorithm is not strictly mass-conserving.
The basic assumption of Appendix D, and the following summary, is that mass deviations due to
phase-dependent variations in air and blood are negligible. These mass variations can be
estimated. The minimum of eight lung masses considered in appendix D is 426 grams (g). The
maximum inter-phase volume variation is 480 cm3 and assuming this volume is composed of
air, a mass deviation of approximately 5 g is plausible in a worse-case scenario (i.e. small lung
with large volume changes). A recent study of pulmonary blood flow and pulmonary blood
volume139 shows the difference in stroke volume between the sum of pulmonary arteries and
the sum of pulmonary veins was 8 ± 8 ml for a cohort of 10 healthy patients. This small blood
variation implies blood mass is approximately independent of systole/diastole stages of the
cardiac cycle. Estimated instantaneous volume of blood in pulmonary veins and pulmonary
arteries showed maximum differences of approximately 50 ml; however, the temporal
resolution of 4DCT phase-images is approximately 0.5 seconds - about ½ a heartbeat. The
instantaneous differences will not be observed in 4DCT phase images due to the finite temporal
resolution of each phase image, and are irrelevant to structure-mass variation reported in this

88
dissertation. The stroke volume difference (8 ± 8 ml) introduces a potential mass variation of
8 g on average, assuming the 4DCT phases exactly coincide with systole and diastole. Thus, the
total mass-variation due to air and blood variations could result in approximately 3% mass
discrepancy, i.e. (5g + 8g)/426g, in actual lung anatomy. Based on this information, this
dissertation assumes observed inter-phase mass deviations >3% are due to intra-observer
delineation inconsistences between structures on different phases of 4DCT.
For 8 locally advanced lung cancer patients, mass of GTV and ipsilateral lung are reported in
each of 10, 4DCT phase images. Observed, inter-phase mass differences are assumed to be due
to delineation inconsistencies and are cast into a 1-dimensional (1D) spatial difference to
describe contouring, or delineation error. Using the volume of the physician-defined 00%
phase structure (V00%) and defining a sphere of equivalent volume, the radius of the sphere is
1

 3
 3
r0 =  V00%  . Assuming volumes contoured in other phases (Vph) are sampled from similar
 4π


density arrays of mean density ρ , the difference in total mass (∆M) between V00% and Vph are
used to estimate a corresponding volume discrepancy, ∆V = ∆M ρ . The phase volume is
assumed to have deformed to a spheroid, so that the spatial discrepancy occurs over a fraction
f of the original surface (Vph = f Vph + (1-f) V00%) and ∆V = f(V00%-Vph); the local spatial
discrepancies grows with decreasing f. For example, a 10% volume change due to deformation
over 1/4 of the original volume (f=1/4) results in a 1D-spatial difference, called ∆r, of 16% (or
0.5 cm for r0 = 3 cm). ∆r based on an observed mass difference (∆M) is
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∆M 

3 (1 − f )V00% −
ρ

∆r = r0 −
 4π

(1 − f )



1

3

Mass and volume of ipsilateral lung and GTV are summarized based on physician delineated
contours (5 lungs, 8 GTVs) and deformed contours (8 lungs, 8 GTVs), based on the results of
Appendix D. A corresponding spatial discrepancy is estimated for the structures with the
fractional volume of deformation arbitrarily chosen as f=1/4 in all evaluations.
In section 6.2.3, mass and volume are compared over the course of radiation therapy for one
locally advanced patient. Tumor regression is an often-observed consequence of radiation
therapy23,140,141 and increase in lung density (due to, e.g. fibrosis) is a known side-effect of RT in
lung.142 Analyzing the mass of a regressing GTV and changing lung may shed light on the interscan consistency of contours and/or mass dynamics between a regressing GTV and lung.

6.2.1 Results: Lung Mass in 4DCT Contours
Physician-defined contours of ipsilateral lung indicate a coefficient of variation for lung volume
for each patient ranging between 3.0% and 7.5% of the mean volume, however maximum interphase mass variations are greater than 5.2% for all five patients considered based on these
volumes (range 5.2%-12.4% of the inhale phase mass). For the same 5 patients, deformed
contours of lung result in maximum inter-phase mass differences range from 2.2% - 7.0% of the
inhale-phase mass. Figure 22 shows boxes representing the relative mass about the mean at
25th and 75th percentiles, together with the median relative mass, and data which lie beyond
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the 99th percentile assuming normally distributed data. P3 and P6 show the largest differences
for physician contours, with maximum ∆M = 36.7 g resulting in ∆r = 0.47 cm for P6.

Figure 22. Boxes show the 25th and
75th percentile relative mass about the
mean. The whiskers show the extent
of data about the median within the
99th% confidence interval, assuming a
normal distribution. Outliers (beyond
the 99th%) are shown as red crosses.

Deformed contours result in maximum ∆M = 28.8 g with a corresponding ∆r = 0.36 cm for P6.
The P6-4DCT dataset has recognizable 4DCT sorting artifacts (including a ‘floating diaphragm’)
visually evident in many of the phase images. Compromised lung function and alectasis are
evident in the images for P3; deformed contours indicate small volume changes (less than 18
cm3 of air intake, a 1.5% volume change) and mass conservation to within 11.2 g (2.4% of the
mass at inhale). The physician contours, in this challenging case, indicate >6% volume variation
and mass changing by >10% (>50 g) between different phases in the lung. Using the calculated
average density of 0.38 g/cm3, the 1D spatial discrepancy is ∆r = 0.38 cm when ∆Μ = 55 g.
For patients P1, P5, and P8, average relative mass and volume of lung is shown in Figure 23.
This figure shows inter-patient variability in lung volume as a function of respiratory phase is
often >10%. Using DIR to define structures has the potential to conserve mass to within 3% in
these cases.

91

Figure 23. Relative lung mass and volume as a function of respiratory phase, normalized to
the 00% (inhale) phase. Error bars show the standard deviation about the average relative
mass and volume for three patients, P1, P5, and P8.

6.2.2 Results: GTV Mass in 4DCT Contours
Gross tumor volume and mass for physician-contoured and deformed structures are shown in
Figure 24 as a function of respiratory phase for the eight patients. In 4/8 cases, physician
defined mass varies by >4.5 g across respiratory phases and by >13 g in 2/8 cases. Deformed
contours vary by >4.6 g in 5/8 cases and >12g in 1/8 cases. Mass of the GTVs is approximately
constant, especially for tumors with smaller volume. However, larger GTVs resulted in larger
mass deviations in both sets of contours for the patients considered. The coefficient of
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variation of physician contours varies from 1.6%-4.6% of the mean; similarly for 7/8 sets of
deformed contours the coefficient of variation varies from 1.0%-3.5%. However, for P9 the
coefficient of variation of GTV mass is 8.6%. This is the largest deviation in deformed contours,
and can be considered a failure of the DIR algorithm (∆M = 12.4 g, ∆r = 0.33 cm). Inspection of
the inhale-phase image, where the GTV contours are initially defined, reveals sorting artifacts
near the superior and inferior border of the tumor. This implies that DIR is not reliable if image
artifacts are present, which is not surprising. However, this also implies that evaluation of
deformed structure mass may enable detection of 4DCT artifacts.
The physician contoured GTV mass and volume for P10 shows phase dependence similar to the
lung, the GTV mass and volume are at maximum near inhale and minimum near exhale
(maximum ∆M = 15.6 g, ∆r = 0.16 cm). In general, in the GTVs considered, a large volume
variation resulted in a large mass variation. The Spearman correlation coefficient between
maximum volume and mass differences between the phase images is 0.93 for the physician
contoured GTVs, and 0.98 for the deformed GTVs. Similar correlation is revealed when
considering the standard deviation in GTV mass as a function of phase. Specifically, the
correlation between the standard deviation in volume and the standard deviation in mass
is >0.93 in all cases considered. This implies that GTV motion is approximately rigid in the cases
considered.
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Figure 24. Gross tumor volumes (GTV) masses and volume as a function of respiratory phase
for eight locally advanced lung cancer patients for physician defined contours and deformable
registered contours based on the demons algorithm.
6.2.3 Mass Variation during Radiotherapy
For one patient who received serial 4DCT simulation scans, structure volume and mass is
reported at different stages of RT in this section. Two 4DCT image sets for P10 were acquired
approximately 6 weeks apart amid fractionated RT. The physician defined lung and tumor
contours on the inhale phase indicate a 65.8 g reduction in tumor mass at 6 weeks, a 35%
reduction of initial mass. The volume is similarly reduced by 66.8 cm3. The ipsilateral lung,
according to the physician drawn-contours shows an increase in mass and volume of 120.9 g
and 652 cm3, respectively. Inspection of physician contours in each scan, e.g. in Figure 25,
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shows regions of the physician defined, regressed GTV contour exclude regions of anatomy
which were included in the initial, planning contours. This delineation inconsistency dominates
analysis related to lung and GTV mass dynamics for this case. Deformation of the planning
contours to the 6-week scan results in a GTV with volume and mass 113.8 cm3 and 84.0 g, 27 g
less than the physician contour. Based on this case, more consistent structure definition is
required in order to use mass of lung and GTV to estimate regression and lung fibrosis due to
radiation damage.

Figure 25. Coronal images of P10 at simulation and 6 weeks after simulation (during
fractionated treatment). The gross tumor volume (GTV) varies significantly inter-scan and
inter-observer.
6.2.4 Summary: Mass-Consistency in 4DCT Structures
The current standard for simulation of lung cancer patients is 4DCT; under the assumption that
4D information will improve the quality of plans and the associated risk/benefit analysis. A
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prerequisite to improving the quality of plans, however, is accurate and consistent structure
definition in 4D-images. Reduction of inter- and intra- observer contouring variability remains a
significant challenge (see, e.g. Louie et al.66). There is no ground-truth value of a delineated
internal structure, so that inter- and intra- observer delineation studies can only measure
precision of contours.
In addition to inherent variability in delineated structures, the process of manually delineating
structures on slices of CT images is also time-consuming. For a ten-phase 4DCT dataset,
contouring ten-sets of structures is not clinically plausible. This is an unacceptable burden on
expert physicians, and limits the utility of 4DCT data. Deformable image registration (DIR), on
the other hand, can create contours on multiple 4D-images through contour propagation
relatively quickly. However, DIR-based structure definition suffers from the same limitations as
physician contours; there is no way to measure the accuracy of these contours. Using the fact
that structure mass defined in different phases should be constant, delineation consistency can
be estimated.
Monitoring structure mass in different phases of 4DCT has the potential to lead to more
consistent structure definition. In this work, consistent GTV mass (to within 7 g) is observed
using Demons-DIR contours for 7/8 patients. In 1 image set, however, DIR failed to preserve
mass across respiratory phases. Further inspection of this image, and in particular the image
used to define the initial contour, revealed image-artifacts. For this case, mass-based
evaluation of structures identified registration problems that required attention. Structure
mass is more consistent across respiratory phases in DIR-based contours than physiciandelineated structures for lung and GTV.
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Mass variation due to RT is an active area of interest. Using mass analysis, it may be possible to
estimate mass-dynamics between the GTV and surrounding lung and relate these dynamics to
RT outcomes. However, consistent structure delineation is a necessary condition in order to
perform such an evaluation.

6.3 OPTIMIZING DOSE TO MASS
Integral dose is defined as the integral of dose ( D ) to mass, I = ∫

mass

D dm .143 Integration of

dose over volume reveals a fundamental difference in evaluation of dose-to-volume and doseto-mass. Integration of dose over a volume composed of n elements, each with dose Dn =En/mn
is
mn

∫ D dV = ∑ D

n

n

ρn

=∑
n

En

ρn

,

or the sum of energy absorbed per unit density in each voxel. The Integral dose of n-elements
is the energy absorbed within the mass,
En

∫ D dm = ∑ m
n

n

mn = ∑ En = E abs .
n

Consider, for example, a heterogeneous structure composed of 2 voxels with densities of

ρ1=1.0 g/cm3 and ρ2= ρ1/10 =0.1 g/cm3 and equal volumes, v = 1 cm3. A beam is designed to
deliver uniform dose of 50.0 Gy to each voxel (estimated using a dose calculation algorithm
which corrects for heterogeneities). All of these quantities are reasonable estimates in, e.g.
two (large) voxels of an SBRT lung cancer patient PTV – one which is GTV, one which is a
mixture of GTV, lung tissues, and air. The energy absorbed in voxel 1 is E1=0.05 J (Joules),
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energy absorbed in voxel 2 is E2=0.005 J. The integral dose is the total energy absorbed,
0.055 J. The dose integrated over volume of the structure is 0.10 J / (g/cm3). In this case, the
dose integrated over volume is not representative of a physical quantity. However, if the voxels
had equal densities, integral dose to volume is directly proportional to integral dose to mass.
Limitations of external beam radiation therapy through rotational photon delivery have been
described based on the concept of integral dose conservation within spherical shells of
homogeneous tissues.144,145 Specifically, all beam arrangements and fluence patterns which
deliver equal dose to an isocenter point will also deliver equal integral dose to concentric
spherical shells about the isocenter point. However, integral dose is not conserved between
different beam/delivery conditions in heterogeneous structures, i.e. the limitations only apply
to homogeneous structures. Specifically, delivering a larger proportion of fluence through
lower density normal tissue will reduce the integral dose in such a spherical shell. This implies
that inclusion of voxel mass in plan optimization has the potential to reduce radiation path
lengths (and radiation dose) in normal tissues. Consistent with the overall goal of this thesis,
optimizing dose to mass has the potential to increase the therapeutic ratio for lung cancer RT.
Optimizing dose-to mass through evaluating dose-mass histogram (DMH) levels is a simple
method of voxel importance weighting for RT optimization which only relies on information
acquired in 4DCT simulation. However, density may not be well-correlated to functionality in
organs in such as lung. Several studies have investigated the relationship between density and
lung functionality, but this area must be further explored in order to minimize dose to
functional lung using only 4DCT.146–149 Castillo et al.146 have considered methods to produce
ventilation images from 4DCT data sets but their results indicate that neither the Jacobian
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determinant of the DVF nor the fractional air content of each voxel correlates well with
perfusion imaging, with dice similarity coefficients less than 0.4 in six of seven cases.
In parallel organs such as lung, the number of surviving functional sub units (FSUs), as a
proportion of the total number of FSUs, determines the complication probability.150 Assuming
FSU density is directly proportional to physical density; the biologic effect of treating less mass
is directly proportional to complication or control probability, implying that the DMH is an
appropriate choice for RT evaluation. However, as previously mentioned, the FSU and physical
density are not trivially related in lung. Another surrogate will be required for functional
optimization of lung tissue and an analogous evaluation metric can be constructed and
optimized. Analogous to the CT-reconstruction of physical densities, the quantity which labels
voxel importance will replace ρ in the definition of DMH (equation 6.1) if a functional image is
available. Previous studies have incorporated lung perfusion imaging in lung-cancer RT plan
optimization151–156 in order to reduce dose to functional lung. Perfusion imaging can replace, or
be combined with, mass weighting to optimize dose to functional tissue.
Section 6.3.1 summarizes results from appendix D, where plan-optimization based on DMH
levels is carried out and compared to DVH-based optimization. A total of four plans per patient
are compared, two DVH-optimized plans described in section 6.1 (an inhale-plan and an aCTplan) and two DMH-optimized plans. In the inhale plan, the PTV is defined as the GTV
surrounded by a 1 cm margin. In the aCT plan, the PTV is a 1 cm expansion about the internal
target volume (ITV) – the union of the GTV in all phase images defined in the aCT image. All of
these plans use single images for dose-estimation (i.e. 3D-dose) and plan optimization (single
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planning image), combining mass-based optimization with 4D-dose optimization is a focus of
future studies.
The DVH plan objectives include 70 Gy to 95% of PTV while minimizing lung V20, esophagus
V25, heart V30, and spinal cord maximum dose limited to 40 Gy. The DMH-objective levels are
translated trivially from these DVH values. Objectives are defined at relative mass levels; 70 Gy
to 95% of the PTV mass (M70) and minimization of M20 for lung, M25 for esophagus, M30 for
heart. Plans are compared at objective dose levels.

6.3.1 Results: Optimized Dose-to-Mass
A total of sixteen DMH-optimized lung cancer plans are created, two plans for 8 locally
advanced patients. The target-prescription in each of the plans is to treat 95% of the PTV
volume or mass to 70 Gy and this objective consistently trades-off with the ipsilateral lung, V20
objective. This tradeoff, combined with large differences between DVH and DMH levels for
these structures, is the primary force producing differences between DVH- and DMH- optimized
plans. In 13/16 DVH-optimized plans, cold-spot distributions in dense PTV sub-volumes result
in V70 > M70. DMH-plans, for these cases, increase PTV-mass coverage towards prescription
with a corresponding increase lung-mass at dose.
Optimization of DMH levels for P1 increases PTV-D95M from 49.7 Gy to 58.4 Gy compared to
the DVH-plan. This 8.7 Gy increase in mass-coverage is achieved by increasing PTV-D95V by just
3.2 Gy (from 65.4 Gy in the DVH-plan to 68.6 Gy in the DMH-plan). A comparison of DVH- and
DMH- optimized inhale-plans is shown in Figure 26 for P1.
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Figure 26. DVH- and DMHoptimized dose distributions for
P1. Ipsilateral lung DMH < DVH
and optimized DMH levels
resulting in target (the PTV)
dose increased to meet
prescription.

A different trend was observed for P3, PTV-D95V is reduced by 12.6 Gy in the DMH-based inhale
plan and by 8.5 Gy in the DMH-based aCT plan, resulting in reduced lung mass and volume at
dose (by 9-14% of DVH-optimized values). However, PTV-D95M is reduced by just 2.5 Gy in the
inhale plan (69.4 Gy to 66.9 Gy) and by 1.8 Gy (68.8 Gy to 67 Gy) in the aCT-plan. In other
words, the DMH plan for P3 reduces dose to low-density regions of the PTV in order to spare
lung, while maintaining an approximately constant dose to the massive regions of the PTV.
Consistent with 13/16 DVH-plans, PTV-V70 > PTV-M70 and the DMH-plan boosts PTV-M70 to
prescription for P3. By increasing dose to massive regions of the PTV, the DMH plan for P3
reduces lung-mass at 20 Gy by >5%.
Figure 27 shows DVH and DMH curves resulting from optimizing dose-to-volume and dose-tomass. In this case, the DMH-optimized plan boosts a dense region of the PTV up to prescription
in order to spare lung. However, the PTV volume is not covered which is a concern when
considering geometric uncertainty. The purpose of treating the PTV is to ensure all plausible
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spatial location of the actual target are treated to a prescription does but the DMH-optimized
dose distribution does not cover the PTV.
For P4, the DVH- and DMH- optimized plans are nearly identical. Comparing the two plans, lung
V20 and M20 vary by 0.5% volume in the inhale plans, and by less than 1% in the aCT plans and
PTV dose (both D95V and D95M) varies by <1.3 Gy in all plans. The inhale DMH-plans are also
approximately identical to DVH-plans for P5, while the aCT plan shows potential to reduce
ipsilateral lung (ilung) V20 and M20 by >3% volume while maintaining constant target dose.
The DMH plan also spares ilung in the aCT (4.6% volume decrease in V20, 5.1% mass decrease
in lung M20) and boosts PTV-D95M compared to the DVH plan, but the inhale plan shows very
small differences. Both the inhale- and aCT- DMH plans show potential to spare lung volume
and mass at 20 Gy by >2.9% relative volume or mass at comparable target dose.
While lung volume and mass levels varied between plans optimized using either DVH or DMH,
this was not the case for heart, esophagus, and spinal cord dose. For all eight patients and all
16 plans compared, esophagus V25 and M25 and heart V30 and M30 differ by <0.6% volume or
mass between DVH and DMH plans. Spinal cord volume at 40 Gy varies by up to 0.6% volume
between DMH and DVH plans for P10, but for the other 7 patients, this volume is equal among
DVH and DMH plans.
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Figure 27. An optimized
DMH-plan which
maintains dose to the
PTV-mass while reducing
dose to the PTV-volume
compared to a DVH-plan.
The DMH-optimized plan
spares lung volume and
lung mass by >5% at 20
Gy.

6.3.2 Summary: Optimizing Dose-to-Mass
Mass as a surrogate for voxel importance in DMH-based optimization for RT of lung cancer
shows potential to spare lung and increase the therapeutic ratio. The DMH weights voxels
according to their density, implying the DMH-optimized solution will preferentially treat
relatively dense target regions and avoid relatively dense regions of normal tissue. Using mas
as a surrogate for cell-importance makes sense, intuitively, in the lung cancer target. The LQmodel of radiation damage relies on the initial number of cells. In lung, however, low density
parenchyma may be important in oxygen exchange. Optimizing DMH uses density for voxel
importance, but this quantity can be replaced by some other indicator of functionality (e.g.
perfusion) if one is available.
Further investigation of DMH-based optimization must incorporate spatial uncertainty. In one
case considered, DMH-optimization achieved the dose-to-target mass objective, PTV-
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M70>95%. However, in order to simultaneously reduce dose to lung, the resulting plan
reduced PTV-D95V by 12.6 Gy. This solution invalidates the PTV, i.e. the solution is no longer
robust against setup uncertainty. Combining functional information and geometric uncertainty
is a focus of future studies, including methods to over-write voxel importance based on spatial
locations. By considering the probability distribution of target mass, an appropriate dose-tomass optimization may be possible using MAO.

6.4 CONCLUSIONS
Evaluation of structure mass has utility in delineation, in dose evaluation, and in plan
optimization. By incorporating mass in RT for lung cancer and for time-dependent anatomy in
general, potential improvements in the therapeutic ratio may be possible. Relying on the
premise that mass is constant during respiration, evaluation of structure mass defined on
different respiratory-phases is an estimate of intra-observer delineation consistency and is able
to detect 4DCT artifacts. In dose evaluation using the DMH, density of the irradiated tissue is
explicitly included in evaluation, so that dose evaluation is more closely associated with
prospective models of cell damage. Optimizing RT plans using mass (and the DMH) has the
potential to reduce radiation path lengths through normal tissue in order to increase dose in
massive regions of the target. Optimizing dose-to-mass must be further investigated in order to
properly account for geometric uncertainty.
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7 Multi-Criteria Optimization for Lung Cancer

DVO – dose volume objective
MCO – multi-criteria optimization
FO – fixed objective
aCT – average CT image
MODA – multi-objective decision analysis
NTCP – normal tissue complication probability
OAR – organ at risk
PCA – principal component analysis
ROCO – reduced order constrained optimization
sim-min – simultaneous minimization
ilung – ipsilateral lung
clung – contralateral lung
COPD – chronic obstructive pulmonary disease

As presented in Section 2.5, radiotherapy (RT) optimization is a multi-objective decision which
necessitates assigning importance weightings to competing objectives in order to numerically
achieve an optimal solution. Modification of objective weights can lead to different optimal
solutions from the numeric optimization. However, the plan which truly optimizes the
therapeutic ratio for each patient does not necessarily correspond with the numerically optimal
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solution for a predetermined set of weights. Ideally, the numerically optimal plan for a given
set of objectives and objective weights will be a member of a class of solutions which are
relevant for clinical delivery for a given patient. Throughout the history of RT, it has been the
role of the planning team to identify a clinically acceptable and ideally optimal treatment plan.
To navigate the multi-parameter numerical solution space, a clear and efficient method to
present the patient-specific decision space is introduced in this chapter.
A numerical optimization, as described in section 2.5, relies on a set of input objectives and
objective weightings in order to determine an optimal solution. Use of dose-volume objectives
(DVOs) based on outcome data in a numerical optimization implies a treatment dose just below
the DVO-level is equivalent to a treatment of zero dose. For example, minimizing lung volume
at 20 Gy (V20) implies 100% of lung treated to 19.99 Gy is equivalent to 100% of lung at 0.00 Gy
within the numerical optimization. This is one weakness of population-based, fixed DVOs. On
the other hand, achieving fixed DVOs in lung cancer RT is often impossible for a given clinical
objective which is truly the intent of treatment; including treatment of the target (e.g. the
prescription to the target must be met in order to realize any benefit). The set of achievable
DVOs depend on patient-specific geometry and may conflict with treatment intent.
In this ill-defined scenario, where population-based objectives are applied to patient-specific
treatment, iterative human interaction and re-optimization guide decision making and
ultimately determine the treatment plan. During the planning loop, the presented decisions
often involve two or more conflicting objectives and, despite a lack of information about tradeoffs for the patient-specific geometry and dose distribution, decisions are made which may
influence the efficacy of treatment. This decision process leads to inherent variability in plan
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quality (in terms of the therapeutic ratio) due to inter-patient variability and inter-institution
variability among decision-makers. One approach to aid in the decision-making process is
multi-criteria optimization (MCO), which is investigated in this chapter. MCO computes a
collection of basis-plans which can reveal relevant objective-tradeoffs for patient-specific
anatomy. If two more objectives tradeoff, a decision must be made regarding preference, this
is a decision opportunity.
An advantage of utilizing population-based DVOs is consistency in delivered plans despite interpatient heterogeneity, i.e. for a given protocol, everyone receives (approximately) consistent
treatment. This approach often leads to unnecessary irradiation of healthy tissue but may
assist in retrospective outcome analysis due to consistency in the dose-volume data. While this
is of interest in determining the effects of RT and associated complications, the aim of this
study is to increase the therapeutic ratio through minimizing dose to normal tissues. One
method to accomplish this aim is to achieve Pareto efficiency between objectives, for every
objective for every patient, which is an ethical approach to RT. Pareto efficiency means that an
objective cannot be improved without sacrificing another objective, i.e. all objectives are
minimized with respect to one-another. Conventional, fixed-objective (FO) optimization does
not guarantee DVOs are Pareto-efficient if the DVOs are zero-valued. This chapter, consistent
with aim 3 of this dissertation, describes the design of an MCO plan constructor which
generates a basis-set of plans which approximate Pareto-efficiency. Patient-specific tradeoffs
are identified through analysis of the basis set in Section 7.2 and often reduce patient-specific
planning to a few decision opportunities.
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The purpose of the basis-set is twofold, (1) to reveal the relevant region of the Pareto-efficient
front for each patient and (2) to identify the OARs which present decision opportunities
through identifying conflicting objectives. However, the MCO basis set of plans as described in
section 7.2 are not guaranteed to be Pareto-efficient and may not reveal all relevant decision
opportunities. Section 7.3 compares tradeoffs revealed in different MCO-basis sets generated
using different DVOs. In section 7.3, MCO-basis plans and the decision opportunities based on
different DVOs are compared.
Real-time planning through interpolation of the MCO basis set is described in section 7.4. The
MCO plans are optimized on a single planning image (average-CT, aCT) for density estimation
with static structures defined on the 30% phase image. However, variations in OAR dosimetry
due to delivery of the MCO plan to time-dependent anatomy may compromise potential
dosimetric benefits. Dosimetric variability due to delivery of different MCO plans to 4Danatomy is estimated on a per-plan basis in section 7.4. While the MAO approach (described in
Chapter 5) considers 4D- information in plan design a-priori, MCO enables plan variation in real
time and therefore can consider 4D-information a-posteriori without necessitating numerical
re-optimization.
The MCO model developed in this work is implemented for four LA lung cancer patients under
the premise that a simple model of the patient-specific decision space is superior to a complex
one. MCO has the potential to transform modern radiation therapy treatment planning from a
complex combination of conflicting decisions to a very efficient and conceptually clear decision
space (or set of decision opportunities) which can be navigated in real time.
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7.1 PARETO EFFICIENCY AND MULTI-CRITERIA OPTIMIZATION
Several authors have investigated Pareto-efficiency for RT objectives and MCO for RT planning.
MCO has been introduced clinically through the RayStationTM (RaySearch Labratories,
Stockholm, Sweden) treatment planning system, but methods of construction of an MCO basisset are not yet clear. There is not a universally accepted method of generating an MCO-basis
set.

7.1.1 Background
Multi-objective decision analysis (MODA) and Pareto-efficient optimization of radiotherapy
plans has been discussed by several authors.157–162 Considering the RT problem in the context
of MODA, Yu157 designed a ranking system for plans according to objective weightings defined
by the decision-maker (designated as the physician in the rest of this document). The method
computed a family of solutions with rankings determined by interpretation of the physician’s
intent and, essentially, automated the planning loop. Cotrutz et al.158 solved for a family of RT
solutions based on objective weight variation, allowing the physician to select a plan which
meets the treatment objective.
The method of generating the MCO basis set presented herein, similar to Yu157, uses concepts
from MODA regarding utility and preference. However, the goal of this work is not to make
decisions (or automate decision making), but to present a clear and efficient decision space to
the physician. This is more consistent with the goal of Cotrutz et al.158 but they considered
tradeoffs between the target-dose and the sum of normal tissue complication probabilities
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(NTCPs) for all organs at risk (OARs). In the method presented in section 7.2, target-dose and
target-dose homogeneity is a constraint for all patients so the relevant decision space is only
with respect to OAR dosimetry.
The decision opportunities revealed by an MCO-basis set may depend on the method of
generating the basis set. Craft et al.159 investigated the variation in basis plans optimized with
maximum- and mean- dose objectives under the hypothesis that, if the solution space is similar
for these different objectives, then “they should be similar for other cases as well.” Their
findings reveal an important characteristic of Pareto efficient solutions and independence with
respect to the objectives used to estimate them; using their words, “any two functions which
are positively correlated are the same in terms of the generation of the Pareto surface.”163
Romeijn et al.83 presented a general method for MCO and rigorously prove the independence
of the revealed Pareto-efficient front with respect to convex objective functions combined with
linear operators. In section 7.3, several MCO bases are generated using different objectives in
order to estimate proximity to the Pareto-efficient front and the consistency in revealed
decisions.
Several other studies have investigated MCO for RT planning and included plan interpolation for
real-time planning.164–168 Craft and Bortfeld165 estimated the number of basis plans required to
perform real-time planning with interpolation without significantly departing from the Pareto
frontier; they found that N+1 plans, where N is the number of objectives, is typically sufficient.
Monz et al.164 investigated interactive updates of basis plans in order to remain near the Pareto
front and ensured interpolated plans do not deviate from Pareto efficiency. Ensuring Pareto
efficiency of solutions is important; it ensures the solutions minimize objectives. However, the
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hypothesis of this dissertation is that a clear and concise presentation of patient-specific
decision-opportunities is more important, and will have more impact on conventional RT
planning, than ensuring Pareto-efficiency for all objectives for all plans.
In order to create a more concise and clear decision space, Spalke et al.169 reduced the MCO
basis set of plans via principal component analysis (PCA) and via the isomap method for the set
of optimized fluence vectors. Stabenau et al.170 also reduced the number of basis plans
generated via Reduced Order Constrained Optimization (ROCO) using PCA of the fluence
vectors. Both of these studies considered variation in the beamlet space in order to determine
an efficient representation of the patient-specific decision-space. Variability in vectors of
beamlet fluence is of interest for computational efficiency, but the OAR-dosimetry in terms of
the evaluation metrics used to determine plan quality, i.e. the DVH, is the quantity of interest in
the relevant decision space. The basis plans described herein are designed in order to reveal
tradeoffs in OAR-dosimetry, which is evaluated with the DVH, while approximately minimizing
objectives.

7.2 MULTI-CRITERIA OPTIMIZATION FOR RADIATION THERAPY OF LUNG
CANCER
Multi-criteria optimization (MCO) is used to form a model of the patient-specific decision-space
for four locally advanced lung cancer patients. The method is implemented in the Pinnacle3 TPS
using the ORBIT optimization engine.78 The MCO basis set of plans is constructed based on
weight variation of a set of DVOs. The basis set forms a model of the relevant patient-specific
decision space for each patient.
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7.2.1 Estimating the Patient-Specific MCO Basis Set
The goal of radiation therapy is to maximize the therapeutic ratio, i.e. maximize the tumor
control probability (TCP) and minimize the normal-tissue complication probability (NTCP) for all
normal tissues. The utility of each radiotherapy plan (U), labeled by the vector of the beamlet

r
weightings b , can be expressed
r
r
r
U b = w1 TCP b + w 2 NTCP b

( )

( )

( )

7.1

The first term in the sum, the TCP, is conceptually simple. The TCP is determined according to
treating the target to a prescription dose; it is the intent of treatment and in this work is
considered a constraint. In order to estimate the second term, the NTCP term, each OAR must
be compared to other OARs in terms of importance and the impact of each of the possible OAR
complications must be weighed against patient-specific quality of life, for each patient. The
weights of the TCP and NTCP terms, w1 and w2, specify the importance of TCP with respect to
NTCP, i.e. how important is tumor control as compared to complications on quality of life.
The estimated NTCP for each irradiated OAR can be used to estimate and assign a weight (or
ranking) to each OAR (wOAR-i) with respect to other OARs.
r
NTCP b =

( ) ∑w

OAR-i

NTCP ( OARi )

7.2

i∈NOARs

r
An individual plan, with beamlet vector b can be expressed through a value hierarchy, or utility
assessment, of the TCP and the NTCP of each OAR, as illustrated in Figure 28.
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Figure 28. A value hierarchy to represent utility of a radiotherapy plan designated by a
r
beamlet of vector weights b in terms of tumor control probability (TCP) and normal tissue
complication probability (NTCP). The NTCP term can be difficult to estimate when multiple
OARs are considered.
The beamlet vector, as indicated in Figure 28, has utility determined by importance weightings
and values of TCP and NTCP. The objective function which is minimized during numerical

r
optimization should be a numeric representation of the utility function for each b . Expressed
as a weighted sum of N objectives consistent with equation 2.1, the objective function is:
r
r
O b = ∑ wn fn b

()

n∈N

()

7.3

According to equation 7.1 and 7.2, the weight factors in the objective function for the OARs are
wn = w 2 × wOAR-n for each OAR, i.e. the importance weighting for each OAR must consider the
benefit of TCP versus NTCP and the importance of each OAR to overall NTCP. The decision

r
variable is the vector of beamlet weightings, b , and the objectives are one-sided, least-squares
r
r
ˆ ≥ 0 , where K̂ is the matrix of dose deposition coefficients)
penalty functions in dose ( d = Kb

with tolerance (or prescription) DnRx .

113
r
r
2
ˆ − D Rx .
fn b = ∑ ci ,n Kb
n

( )

i∈n

(

)

All N of the objectives contribute to the objective function and influence the “optimal” solution.
According to the results of Craft and Bortfeld,165 an N objective MODA problem can typically be
described by N+1 MCO-basis functions. The Pareto front for the objective function in equation
7.3 is N-dimensional with N degrees of freedom.
Consideration of an N-dimensional Pareto front (where N is the total number of objectives) is
not a desirable approach for implementation of MCO for RT planning. The goal of this work is
to create an efficient and conceptually clear decision environment, and the N-dimensional
Pareto front fails in both efficiency (it is not efficient to consider every variable in the RT
problem when designing an MCO database) and in conceptual clarity (very few people can
envision an N-dimensional surface). Rather than consider the Pareto-front of the objective
function described in equation 7.3, consider a decision space where a preference for the ith and
jth vector of beamlet weightings is written.

r
The utility of the ith beamlet vector, bi (which labels the optimized plan), only needs to be

considered in the context of other acceptable plans; this does not necessarily include the entire
N-dimensional Pareto-front. This more compact representation of the decision space should be
expressed in the numerical optimization of the objective function when generating the MCO
basis set. The set of N objectives are divided into three subsets: (1) Nhc hard constraints each
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with weight wn-hc, which, if not met render a plan invalid, (2) Nsc soft-constraints (or goals,
described in detail later) each with weight wn-sc, and (3) No objectives with weights wn-o. The
objective function is now
r
r
O b = ∑ wn-o fn-o b

()

n∈N0

()

such that
r
r 

min  ∑ wn-hc fn-hc b + ∑ wn-sc fn-sc b 
nsc ∈Nsc
 n-hc∈NHc


()

()

For the locally advanced lung cancer patients considered in this study, the set of (three) hard
constraints are (1) the prescription dose to the target, PTV-D95>70 Gy, (2) maximum dose to the
target, PTV- Dmax<80 Gy, and (3) spinal cord Dmax<45 Gy. It is interesting to note that the
formulation is actually independent of the magnitude of the prescription dose constraint, an
arbitrary prescription dose can be achieved through scaling plan monitor units (MUs) and dose
to OARs can be expressed as a fraction of the prescription; this is shown in section 7.4. If any of
the three hard constraints are violated for any given plan, the solution is invalid and is not
considered in the MCO-basis set. These hard-constraints define the solution space (or the
relevant region of the Pareto-efficient front) for each patient and can be considered on a
patient-specific basis. The utility of the hard constraints is constant (C) across all plans and
combine to form a constant prospect,171 so that a preference relation between plans depends
only on the remaining soft-constraints and objectives. The weight factors which balance TCP
and NTCP no longer need to be considered. The constraint on the target dose, PTV-D95>70 Gy
determines the TCP, so that the preference relation between plans only depends on NTCP:
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In order to further reduce the complexity of this decision, the set of soft constraints (or goals)
are also defined as part of the constant prospect (C). The soft constraints avoid hotspots in
normal tissues. In order to express this desirable feature of lung cancer RT plans in the
objective function, for each OAR and for the entire body minus the PTV, objectives are included
which minimize Dmax>35 Gy. If an OAR overlaps the PTV, the objective is varied to minimize
Dmax>63 Gy (90% of prescription). Soft constraints on Dmax are included for both the entire body
minus PTV and each OAR, which overlap, in order to place additional emphasis on reducing
hotspots in OARs. Another desirable feature of lung cancer RT plans is increasing the minimum
PTV dose towards prescription, i.e. minimize PTV-Dmin<70 Gy, and while many plans attempt to
prescribe to Dmin (or D99), this prescription is often only achievable after altering the PTV regions
which overlap OARs. In this work, all regions of the PTV are simultaneously considered PTV and
OAR in terms of optimization. Assuming the set of soft constraints compose an approximately
constant prospect across different plans, the decision space now depends on four objectives
(N0 = 4). Preference between plans now depends on NTCP of each lung, esophagus, and heart,
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For these four OARs, potential trade-offs (or decisions) are identified based on analysis of basis
plans resulting from weight variation on these objectives. Five basis plans are designed for
each patient and approximate Pareto efficiency between DVOs for the ipsilateral lung (ilung),
the contralateral lung (clung), the esophagus, and the heart.
Five plans are computed per patient and together form the MCO-basis set, they are computed
by (1) simultaneously minimizing all four DVOs (called sim-min plan) and (2-5), for each DVO,
one weight is varied by a factor of 10-3. The resulting five plans are labeled by (1) sim-min and
(2-5) the OAR plans (ilung-plan, clung-plan, esophagus-plan, and heart-plan). These five plans
create the patient-specific basis set where, for each OAR plan one OAR is sacrificed in order to
reveal a potential improvement in the DVH of some other OAR. If there is no improvement for
a given OAR plan with respect to the sim-min plan, then the corresponding OAR does not tradeoff and is not a decision variable in the problem.
Generating the five-plan basis set is accomplished with a 3-step sequential optimization. Step
1, the initialization step, is optimized for 20 iterations with wn-hc=100, wn-sc=1, and wn-o=0. The
purpose of the initialization step is to bias the solution to meet the set of (hard and soft)
constraints. Step 2, the weight-variation step, the DVO weights are increased from zero to
either 1.0 or 0.001, depending on the plan (e.g. in the sim-min plan, wn-o=1 for all DVOs, in the
ilung plan, wilung=0.001, etc.). The weight variation step is performed five times, once for each
basis set, and is optimized using a large number of iterations (e.g. 100). This step establishes
trade-offs between the DVOs. In step 3, the re-normalization step, the weights of both the
DVOs and the soft constraints are reduced by 2-3 orders of magnitude and the plan is reoptimized (20 iterations) to ensure the hard constraints are met. Step 2 and 3 are repeated for
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each DVO in order to form each basis plan, which is stored as a vector of beamlet weights. The
flow chart is shown in Figure 29.

Figure 29. Flow-chart for generation of the
MCO basis set. The initialized solution is
input for each DVO basis plan, which are
determined by weight variation (to reveal
trade-offs) and renormalization (to ensure
the plan meets the hard-constraints).

Steps 2 and 3, the weight variation and renormalization steps, are used to uncover tradeoffs
between OARs given the constraints of the problem. The sequential optimization, as
introduced, may not be necessary to unveil potential tradeoffs. Another plausible approach is
to use an interior point method (see e.g.Nocedal and Wright,79 Chapter 14) which will render all
solutions which violate the hard constraints unfeasible. However, this approach limits the
search space and may conceal potential tradeoffs. By allowing the hard constraints to vary
during the weight variation step, the feasible search space is expanded to solutions which do
not meet the hard constraints of the problem. When the plan is renormalized, the solution will
either converge to an approximate equivalent solution to the sim-min plan (and a tradeoff is
not identified) or it will converge to a new solution which reveals a potential trade-off.
The sim-min plan is the reference point for identifying decision opportunities, if a basis plan
reduces an OAR DVH-levels compared to the sim-min plan, then a tradeoff is present.
Evaluation of the set of basis plans, for each patient, reveals which organs trade-off and clarifies
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which decisions opportunities are available to the physician. Automated determination of
trade-offs can be employed to further reduce the problem to as few as two plans (assuming at
least one trade-off is identified), but may not be necessary (i.e. analysis of four plans is
sufficiently clear to be useful clinically).
The four locally advanced patients included in this chapter, P6-P8 and P10, each present a
unique tumor location. P6 presents a right, central upper lobe cancer with hilar involvement.
P7 presents a left-lower lobe tumor with central and peripheral components; the tumor
extends from the lower airway to the left diaphragm. P8 presents a right central tumor
abutting the heart and esophagus, and P10 presents a right, central- lower lobe cancer. Each
MCO data-base is optimized using the average- 4DCT density (aCT) and structures defined on
the 30%-phase image. The PTV is a union of the phase-defined CTVs without consideration of
setup error (i.e. PTV=ITV).
The basis plans and decision opportunities are presented for each patient. The basis plans are
also compared to a fixed objective (FO) optimization which achieves identical target coverage,
PTV-D95>70Gy, but uses fixed DVOs including ilung and cLung V20<30%, esophagus V55<30%,
and heart V40<50%.

7.2.2 Results: Identifying Patient-Specific Decision Variables
The five basis plans for both P6 and P7 show two decision opportunities based on trade-offs
between iLung and esophagus and iLung and heart. The sim-min and iLung plan DVHs for P6
are compared in Figure 30. Compared to the sim-min plan, this is the only basis-plan which
shows potential dosimetric improvement in any OAR. The decision opportunity for this patient
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is a single variable, increase the ilung-DVH in order to decrease heart and esophagus dose or
increase heart and esophagus dose to reduce dose to iLung. Esophagus V20 varies from 7% to
37% between MCO plans, however this increase in esophagus-volume corresponds with a
negligible (<1% volume) decrease in iLung-V20. A plot of the tradeoffs in mean-dose (<D>) for
iLung, compared to esophagus, heart, and
clung is shown in Figure 31, a small increase
in iLung mean dose (0.5 Gy) results in a
decrease of esophagus mean dose by nearly
5 Gy, whereas heart mean dose is reduced
by approximately 2 Gy when increasing ilung
mean dose by 3 Gy.
The FO plan for P6 results in zero-valued
objectives for cLung, esophagus, and heart.
Delivering the FO plan would irradiate 20% of
the esophagus to 40 Gy, compared to 4% in

Figure 30. Comparison of the plan which
simultaneously minimizes the four dosevolume objectives and the plan which
relaxes ipsilateral lung (iLung) reveals
tradeoffs between iLung and heart and
esophagus.

the sim-min plan and 1% in the ilung plan. By presenting the basis set to the physician, it is
evident that iLung-V20 cannot be reduced to less than 31% volume without degrading target
coverage, however esophagus and heart sparing is possible by increasing iLung V20 to above
31% volume. or P7, a similar decision is evident from the MCO basis set. The iLung trades-off
with heart and esophagus as shown in Figure 32. This patient presents an invasive tumor
plaguing a large volume of the lung, so that treating a larger region of ilung in order to spare
both heart and esophagus may be desirable. The remaining basis plans, together with the sim-
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min plan are plotted in Figure 33. Compared to the sim-min plan, the clung-, esophagus-, and,
and heart- plans do not show potential to spare OARs.

Figure 31. A tradeoff
in mean-dose
between ipsilateral
lung (iLung) and
esophagus (esop) and
ilung and heart is
clear, whereas
contralateral lung
does not trade off
with ilung.

Figure 32. The sim-min and
iLung basis plans are reveal
tradeoffs between ilung and
esophagus and heart.
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Patient 8 (P8) presents a right-central tumor and the PTV overlaps both heart and esophagus.
Similar to P6 and P7, one tradeoff is evident for this patient.
Increasing iLung-V20 from 24%
up to 30% corresponds to a
reduction in cLung from 23% to
17%. Variations in esophagus
and heart volumes at all dose
levels in basis plans for P8 are

Figure 33. Multi-criteria optimized (MCO) basis plan
DVHs are shown for patient 7. The OAR plans do not
<3%. By using the MCO plans,
show improvement in any OAR dose compared to the
cLung V20 can be adjusted, in real sim-min plan, and no tradeoff is evident for these
OARs.
time, from 29% (where a
V20<30% objective results in zero DVO penalty) down to 17% volume. The MCO plans based on
ilung and clung are shown in Figure 34 (dashed DVHs) and are compared to the FO-optimized
plan (solid DVH).
For the fourth patient considered, P10, decision opportunities are evident between iLung and
cLung and iLung and heart. An increase in iLung-V20 from 29% to 49% reduces V20 in cLung
from 15% to 9%. Heart V20 is reduced by 6% volume, from 19% to 13% for the same shift iLung
V20 (29% to 49%). Conversely, an increase of heart-V20 of 35% (from 19% to 54%) results in a
reduction of iLung-V20 of 3% (from 29% to 26%). The tradeoffs for Patient P10 are described in
more detail in the section 7.3.
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Figure 34. Patient 8 MCO basis plans for ipsilateral lung (iLung) and
contralateral lung (cLung), compared to a fixed-objective plan. The MCO plans
allow >5% in iLung and cLung V20.

7.2.3 Summary: Identifying Patient-Specific Decision Variables
Basis sets reveal at least one decision to be made by the physician regarding OAR sparing for
each patient. This decision in 2/4 cases involved trade-offs between two OARs, so that the
decision between plans depends on the physician’s weighting of 2 OARs. Rather than attempt
to automate the decision making, the physician is permitted to interactively view the tradeoffs
while balancing other variables, such as patient-specific quality of life, in order to determine the
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delivered plan. For example, a decision to increase dose to ilung in order to spare esophagus
was revealed for 3/4 patients. If the patient presents complications in breathing, e.g. due to
chronic obstructive pulmonary disease (COPD), perhaps lung dose should be minimized at the
cost of increased dose to the esophagus. In other cases the decision may be very obvious, e.g.
the 5 Gy decrease in esophagus mean dose at the cost of a 0.5 Gy increase in ilung mean dose
evident in P6. Compared to fixed-objective optimization, MCO methods have the potential to
spare regions of OARs at all dose levels.

7.3 OBJECTIVE DEPENDENCE IN MCO BASIS SOLUTIONS
The basis sets described in the previous section are not guaranteed to exist on the Pareto-front,
in fact is it is unlikely that they do. However, the plans may get “close-enough” to produce a
solutions which capture plan variation due to conflicting objectives relevant to possible decision
opportunities. Assuming all objectives with positive correlations will converge to the same
Pareto surface, this section compares MCO basis plans optimized using different DVOs for one
patient (P10). The goal of this section is to show the approach of MCO-basis estimation
presented in section 7.2 captures relevant plan variability, independent of the chosen
objectives. There will always be some level of objective dependence by setting a dose or dosevolume tolerance (or prescription) level >0 Gy or >0% volume; this is because all voxels which
meet this tolerance are ignored. This creates non-linear response in the objective function
about the prescription tolerance dose.
Consider a dose-volume objective for an ROI labeled by the index n, defined according to
equation 2.2,
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This non-linear response of the dose-volume objectives, due to the Heaviside operator, implies
that numerically optimized solutions using different dose-volume objectives may not converge
to an equivalent Pareto surface.
In order to estimate MCO-basis variation with respect to varying planning objectives, the five
MCO basis sets described previously are generated for four different sets of DVOs: (1) minimize
V10>20%, (2) minimize V5>10%, (3) minimize gEUD(a=2)>0 Gy, and (4) minimize Dmax>0 Gy (i.e.
minimize all dose in all voxels). The gEUD(a=2) approach is consistent with the
recommendation of Craft172 for MCO as implemented in the RayStationTM treatment planning
system. Both the gEUD(a=2)>0 Gy and Dmax>0 Gy objectives penalize all voxels in each OAR
with dose >0, but gEUD(a=2) penalizes higher dose levels quadratically. DVHs are compared for
the different sets of bases, and the approximate Pareto surface is displayed graphically for
objectives which trade-off.
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7.3.1 Results: MCO Basis Variation Based on Different Objectives
The collection of DVHs for all MCO basis sets, based on optimization with different dose-volume
objectives for each OAR, is shown in Figure 35. Also included with each basis set are the FOoptimized DVH curves. The basis sets optimized with different objectives are similar but not
identical for the patient considered. Using the gEUD(a=2) and Dmax objectives (which penalize
every voxel with non-zero dose) led to reduced DVHs compared to MCO-bases generated using
V5 and V10 objectives for heart and clung, but not for ilung. Minimum DVHs for ilung (by
trading off with heart in the heart-plan) were uncovered in the gEUD- and V10- MCO-bases but
minimum DVHs are not evident from the V5 and Dmax MCO-bases. The decision space, based on
OAR trade-offs, also varies based on the chosen DVOs.
Figure 36 compares the sim-min and ilung plans using V10 and gEUD objectives. The gEUDbases show the potential to increase ilung dose beyond what is evident in the V10 plans in
order to reduce (or approximately minimize) dose to esophagus and heart. On the other hand,
Dmax-bases failed to reveal decreases in ilung dose through increasing heart dose. One tradeoff
was clear in all MCO basis sets independent of chosen DVO, increasing dose in ilung decreases
dose to other OARs.
Mean dose (<D>) to ilung is plotted as a function of heart <D> for all MCO-plans in Figure 37.
The approximate Pareto-efficient front using just three MCO-bases are also plotted in Figure 37
using the heart, sim-min, and ilung plans. The four curves differ depending on the objectives
used. Plans optimized with Dmax did not achieve minimum ilung <D> compared to other MCObasis sets (minimum ilung <D> = 18.93 Gy compared to 17.86 Gy in the gEUD plans) but did
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achieve minimum heart <D> (reduced to 5.6 Gy in the Dmax plans compared to 11.47 Gy in the
V10 plans).

.

Figure 35. Dose-volume histogram (DVH) variation for each OAR based on different
MCO-basis sets (computed by minimizing different objectives) and a fixed-objective
optimized solution. MCO-bases were similar, but not identical for different objectives.

Figure 36. Multi-criteria basis sets using V10>20% and gEUD(a=2)>0 objectives. The gEUD
basis sets reveal potential to reduce esophagus and heart dose compared to the V10 basis set
at the cost of higher ipsilateral lung dose.
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The approximate Pareto-efficient front varies depending on which objectives are chosen, but
may also depend on the evaluated dose-volume metric. Mean structure dose was not
optimized in any of the plans but clearly shows tradeoffs in ilung and heart. Using dose-volume
based evaluation metrics, Figure 38 plots relative structure volume as a function of volume of
ilung at 20 Gy (top left), 10 Gy (top right), and 5 Gy (bottom right). Among the plans
considered, gEUD-based optimization (labeled with circles) reveals minimized ilung volume at
all three dose levels, with V10-objectives finding similar values for V20 (≈0.26) and V10 (≈0.52).
Conversely, only Dmax-based MCO plans reveal minima in heart and clung at all three dose
levels.

Figure 37. Mean dose <D> to ipsilateral lung (ilung) as a function of heart <D> for 20 plans,
five multi-criteria optimization (MCO) basis plans for four objectives. The approximate
Pareto-efficient front using three basis plans, each optimized using different objectives, are
shown with lines.
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Figure 38. Relative volume at three different dose levels for heart (red circle), esophagus
(green square), and contralateral lung (blue) as a function of ipsilateral lung volume at fixed
dose. The plans are each optimized with different objectives as part of an MCO basis set.
Utilizing a fixed prescription dose or volume level, e.g. minimizing V5 or V10 at a given OAR
volume, does not imply the resulting plan will minimize this dose metric. In fact, for every
structure, the MCO plans optimized based on V5<10% did not reveal minimum V5 levels. This
was also the case in all V10<20% plans at V10 levels. For example, optimizing V10<20% in clung
results in five MCO-basis plans with V10>26%, however every other set of basis plans (which
use lower-valued prescription) result in clung-V10<15% in at least one plan.
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7.3.2 Summary: Objective Dependence in MCO Basis Sets
The MCO basis set is designed to reveal relevant dosimetric variation for each patient while
maximizing the therapeutic ratio. This section shows that the dose-volume information
conveyed by an MCO-basis set depends on the dose-volume metrics used to optimize the plans.
Part of this variation is due to bias introduced by objectives with non-zero tolerance (or
prescription) dose. Dose volume objectives with non-zero tolerance levels should not be
expected to reach global minima for metrics such as mean dose. Through minimization of dose
to every voxel of every OAR, using e.g. a Dmax objective, minimum dose volumes in heart and
clung were revealed, but these objectives failed to achieve minima in ilung. Using gEUD(a=2)
objectives increases the importance of high voxel doses and did achieve minimum dose to
ilung, but did not reveal potential sparing in clung and heart.
The results of this section suggest an objective function comprised of different objectives (much
like what is used in conventional, FO-optimization) may be appropriate in construction of an
MCO basis set. Using an objective which penalizes all dose (e.g. minimization of Dmax>0 Gy)
may be appropriate in structures expected to receive low dose. For structures in close
proximity to, or overlapping the target, a non-zero dose-volume prescription tolerance or
gEUD(a=2) may be more appropriate. Further studies are needed which model objective
response as a function of dose-variation.
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7.4 PLAN ROBUSTNESS ON 4D-ANATOMY
Interpolation of MCO basis sets allows real-time planning and decision making through
estimating dose as a linear interpolation of basis-plan doses. However, the basis set doses are
computed on single planning-images and assume static structures as defined on the 30% phase
image. Variations in OAR dosimetry due to delivery of the MCO plan to time-dependent
anatomy may compromise potential dosimetric benefits or invalidate potential tradeoffs. This
section details dosimetric variations due to delivery of the MCO plan on 4DCT phase images and
moving, deforming structures for one patient.
The MCO basis-set of plans enables prospective analysis of the effects of delivering varying
plans to time-dependent anatomy. Dose variation as a function of respiratory phase can be
accomplished through dose calculation on each phase image, or using the static dose-cloud
approximation. The advantage of the latter approach is that it enables real-time evaluation of
plan robustness to 4D-anatomy, whereas dose computation on several phase images is more
difficult (or impossible) to achieve in real-time. The static dose-cloud approximation enables a
fast evaluation of plan (or dose) sensitivity with respect to variability in OAR-definition as a
function of respiratory phase. Dose computed on each 4DCT image and evaluated on
structures defined in each 4DCT phase reveals variations due to the combined effects of OARand density- variations with respect to respiratory phase.
The basis set of MCO plans for P6 are evaluated on 4DCT respiratory phases in order to
estimate plan robustness with respect to time-dependent anatomy. Because MCO allows plan
variation in real time, the effects of delivery to time-dependent anatomy can be considered in
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the plan selection stage (i.e. after the basis set is computed). Plans which result in minimal
variations in evaluation metrics such as mean-dose or volume-at-dose, as a function of
respiratory phase, are robust to uncertainty due to respiratory motion. By considering timedependent anatomic variations in the planning stage of radiotherapy, a confidence interval on
acceptable anatomy and/or plausible dosimetry, for a given treatment plan, can be established
before treatment begins.

7.4.1 Results: MCO plans on 4D-Anatomy
The MCO basis sets for P6 reveal potential tradeoffs between esophagus and ilung. Figure 39
shows the ilung plan evaluated on the structures defined in each 4DCT assuming dose is
independent of density variations (left) and computed on each phase image (right). The ilung
V20 varies from 47% in the inhale (00%) phase image up to 57% in the 60% phase. Computing
dose on each phase indicates ilung V20 varies from 44% in the 00% phase to 53% in the exhale
phase (50%). The MCO ilung plan, computed on aCT predicts ilung V20 is 54%, consistent with
the value computed on the exhale phase image.

Figure 39. The MCO ilung plan evaluated (left) and computed (right) on ten 4DCT phase
images. The inhale phase (thick, solid lines) and the exhale phase (thick, dashed lines)
approximately bound the DVH’s in all other 4DCT phases.
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Volume at 20 Gy (V20), whether evaluated using the static dose-cloud approximation or
computing dose on each phase image, is approximately constant for esophagus (<1.5% volume
variation), heart (<2.5% volume variation), and clung (<1.0% volume variation) in this basis set.
The CTV dose, irrespective of evaluation, is also approximately constant. This implies that
theses parameters are robust to 4D-anatomic motion.
The esophagus-plan decreases ilung V20 at the cost of increasing dose to the esophagus.
Evaluation of the MCO-plan on the ten phase 4DCT contours (assuming the static dose-cloud
approximation) shows ilung, heart, and esophagus volumes vary by 3-5% at all doses from 1030 Gy. This implies that the esophagus MCO plan is less robust to inter-phase variations than
the ilung plan. Figure 40 shows this plan evaluated on all of the phase-contours.

Figure 40. The esophagus MCO plan reduces ipsilateral lung (ilung) dose at the cost of
increased dose to esophagus. Evaluation of the plan on 4DCT contours shows dose to the
moving target is higher than the PTV dose.

133

This 4D evaluation of each plan can be accomplished in real time for any basis plan or linear
combination of basis plans using the plan interpolator, with the user interface shown in Figure
41. While the 4D-analysis presented in this section can be applied to any plan, MCO has the
advantage of enabling plan browsing in real-time without necessitating numerical reoptimization. By adjusting plan weights and interpolating, real-time plan browsing is possible
and using the static dose-cloud approximation, the effects of delivering the plan to 4D-anatomy
can be assessed.

Figure 41. The plan interpolator user
interface allows selection of basis plans and
allows weight variation on each.

7.4.2 Summary: Plan Robustness on 4D-Anatomy
By estimating dose on time-dependent structures as depicted in 4DCT, an estimate of planrobustness on 4D-anatomy for a given plan is possible. Based on the case presented, the staticdose cloud approximation is a reasonable assumption for this 4D-evaluation. MCO presents
decision opportunities based on OAR dosimetry. Combining MCO real-time planning with 4D-
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evaluation allows the physician to make decisions with knowledge of patient-specific decision
variables and the effects of delivering each plan to time-dependent anatomy.

7.5 CONCLUSIONS
By decomposing the lung cancer RT problem into hard constraints, soft constraints, and dosevolume objectives, decision opportunities can be clarified for each patient. The method
introduced herein constrains the dose to the target and to the spinal cord; however, in other
tumor sites other constraints are needed. By grouping together the maximum-dose objectives
as soft-constraints in the MCO method presented, the possible trade-offs which exist among
them are ignored. Without considering possible tradeoffs in maximum dose the entire relevant
region of the Pareto-efficient front may not be exposed to the physician.
By varying the set of objectives, varying dose-volume levels were exposed. The results of
section 7.3 imply that the use of different objectives for different OARs may be appropriate
based on factors including volumes and anticipated dose-volumes. For organs with low-dose,
an objective with a zero-valued dose-prescription uncovers minimal dose-volume levels
compared to other plans. This was not the case for ilung, which overlaps the target. For this
higher-dose structure, gEUD and V10 objectives were superior to other objectives considered in
terms of uncovering minima in OAR dose. Selection of the relevant portion of the Pareto
frontier, and only the relevant portion, will generate a simplified decision environment in which
MCO holds great potential. Further studies are needed to ensure the DVOs used to optimize
basis sets truly reveal the extent of decision space.
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The basis set, if it is truly on the Pareto-efficient front, should be independent of the dosevolume objectives chosen. This is a desirable feature of the MCO method but also represents
an acute deviation from current methods, where outcome studies consider reasonable safe
levels of radiation and prescriptions are set at non-zero dose and/or volume levels. This study
shows optimizing an objective with a non-zero dose or volume prescription does not imply that
the dose-volume level is minimized, using MCO reduced dose at prescription levels compared
to plans optimized at those levels.
Rather than consider accumulated dose (or 4DD) and uncertainties which influence 4DD (e.g.
phase-weight variations) in plan optimization, this study also shows variability in evaluation
metrics can be used to determine plan robustness. MCO offers advantages in this a-posteriori
analysis because the collection of MCO plans enables real-time plan design, so that if
unacceptable variations are observed in the planning stage, the plan can be redesigned without
necessitating numerical re-optimization.
Clinical implementation of MCO, and in particular MCO methods which minimize dose to OARs,
shows potential to increase the therapeutic ratio compared to conventional, fixed-objective
optimization. Unlike other methods which enable real-time planning, however, MCO also
uncovers decision variables for individual patients and enables an assessment of plausible plans
for each patient. The current clinical RT planning paradigm, i.e. the planning loop, explores
patient-specific tradeoffs in a trial and error process. MCO can clarify these tradeoffs while
simultaneously improving the therapeutic ratio.
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8 Conclusions

The objective of this work was to implement and develop techniques which, when
implemented, will improve the therapeutic ratio of radiation therapy in time-dependent (4D)
anatomy. Four-dimensional RT is an active area of research in radiation oncology because it
applies to nearly all treatments which utilize fractionated delivery. The methods herein focus
on lung cancer for several reasons including the availability of 4D-data. However, many of the
methods introduced and investigated also apply to all tumor sites which display timedependent features.

8.1 IMPROVING DOSE ESTIMATION AND PLAN OPTIMIZATION
Among the most fundamental preconditions of modern radiation therapy is a dose estimator.
In this work, a dose estimator utilizing Demons-based DIR and interpolation is compared to
single-image, 3D-dose estimation. The results suggest accumulated dose is comparable to 3Ddose in lung cancer organs at risk (OARs) including lungs, heart, and esophagus; however, high
dose regions within the PTV can cause large deviations in dose to the moving tumor. Hotspots
in the PTV may result in significant dose deviations (>3% of prescription) in the moving target.
Specific to respiratory motion, this study also developed a respiratory sampling system to
simulate fractionated delivery to 4D-anatomy. The effects of finite delivery time showed
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minimal effect on the accumulated dose. In the future, the effects of per-aperture interplay
with respiration-induced lung tumor motion can be modeled prospectively using the RPM
interface developed as part of this dissertation.
The results of this dissertation suggest large motion is not a pre-requisite to create large
deviations between planned dose to the target surrogate (i.e. the 3D-PTV) and delivered dose
to a 4D-target; however, these deviations rarely compromise the intent of treatment (i.e.
under-dosing moving targets in the PTV is possible, but not probable). Estimated differences
between 3DD and 4DD for OARs are generally less than ±3% independent of planning image
used to compute dose. This implies that 4D- imaging and planning may only be relevant in the
high-dose region, i.e. surrounding the PTV. Reducing the volume for which 4DD is necessary
presents advantages in terms of computational efficiency, and more importantly, in terms of
sparing healthy tissue from unnecessary radiation during image acquisition. The comparisons
of 3DD and 4DD suggest 4DCT for large regions of the thorax is not necessary. With an estimate
of the tumor location, e.g. on a 3DCT image or through automated detection through e.g.
positron emission tomography, only the tumor region needs to be imaged and considered in a
4D-model for lung cancer RT.
If the motion pattern of the tumor can be estimated, this dissertation shows MAO can directly
account for motion in plan design. By relaxing the uniformity (or minimum dose) objective on
the ITV and incorporating the tumor-PDF in plan design, the therapeutic ratio can be enhanced.
More importantly, MAO can be clinically implemented immediately without introducing new
hardware or relying on methods which may cause patient discomfort. Two scenarios which
show potential advantages in utilizing MAO, rather than ITV-planning, are (1) a time-dependent
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relationship between target and OAR can be exploited through preferentially treating in phases
which avoid the OAR, and (2) if a tumor PDF deviates from a uniform distribution, MAO
identifies regions of the PTV where the target dose can be adjusted to match the tumor-PDF.
Further studies of per-aperture interplay effects are needed in order to ensure treatment intent
is not compromised when delivering an MAO plan clinically. While the effects of finite delivery
time and interplay between patient-specific breathing and non-uniform delivery are not
alarming (<1.5 Gy variation in target D95 in all estimates), the effects of per-aperture interplay
must also be considered in a clinically realizable plan. This is a focus of future work in order to
ensure MAO can be safely implemented clinically.

8.2 STRUCTURE MASS IN RADIATION THERAPY
Another pre-requisite of RT is meaningful and precise evaluation metrics. Dose-volume metrics
may not be consistent with current prospective models of radiation damage (i.e. the LQ model)
in heterogeneous tissues. This is relevant in lung cancer, where volume-based metrics in
heterogeneous tissues in lung and PTV treat all voxels equally in plan optimization and outcome
analysis. In fact, a voxel of air within the lung or PTV surely does not include as many functional
cells as voxels of solid tumors or lung-tissues. An analogous comparison can be made in OARs
in the pelvis including rectum and bladder. By including non-functional matter in these organs,
rather than the organs walls, an inconsistency is created between the evaluation of dose and
radiation damage due to dose. Dose-to-mass is an intuitive measure, it is the total energy
absorbed in tissue.
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Using dose-to-mass to guide optimization is a method which assigns per-voxel weightings
according to voxel density measured in 4DCT simulation. The basic premise of DMH-based
optimization is functional density is proportional to physical density. This implies that the DMH,
which plots relative density at dose, is equal to a dose-to-functional-tissue histogram. This
assumption may be valid in the PTV, where tumor clonogen density is likely proportional to
physical density. In lung, however, low density parenchyma may be significant to oxygenexchange, whereas high density blood and blood vessels are not directly related to
functionality, i.e. dose to mass is not related to dose to functional tissue in lung. If a functional
signal can be acquired, for any ROI, it can be incorporated in a voxel-weighted optimization.
Because dose-to-mass penalizes treatment of massive regions of normal tissues, DMH
optimization has the potential to reduce integral dose to normal tissues.
Using dose-to-mass to evaluate dose distributions in tissue is a more precise evaluation than
dose-to-volume metrics on 4DCT image sets. While volume of lung and tumors physically
varies during respiration, mass is constant. Evaluation of delineated structure mass as defined
on 4DCT image sets allows for an estimate of delineation consistency. In many of the cases
considered, structures defined using DIR result in less inter-phase mass variation compared to
physician contours; however, DIR failed to conserve mass in GTV and lung to within 5% in the
presence of image artifacts.

8.3 RADIATION THERAPY DECISION MAKING
In general, a set of achievable objectives are defined by the constraints of the problem at hand.
In RT of lung cancer, this is the patient-specific anatomy and a constrained, prescription dose to
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the target. These two factors determine the relevant portion of the Pareto-efficient front,
where RT decision making can take place in order to design an optimal treatment plan. By
further reducing the set of objectives into a set of soft constraints, which are not intended to be
traded-off or compromised, this work shows that a tractable decision space can be revealed
based on as few as two plans, trading off as few as two OARs. Risk of complication and impact
on quality of life do not have a one-to-one correspondence for many individual patients. This
implies that risk of complication should be considered on a per-patient basis, including relevant
factors like age and prior health issues. Patient-specific OAR-weightings can be considered in
the context of a realizable decision space and MCO can uncover this decision space.

8.4 SUMMARY
The goal of this dissertation was to implement and develop techniques which, when
implemented, have the potential to improve RT for time-dependent anatomy and specifically to
improve the therapeutic ratio for time-dependent anatomy. This study shows implementation
of MCO for lung cancer planning will expose opportunities to increase the therapeutic ratio.
Estimating dose to time dependent anatomy, either through dose-accumulation or through
evaluation on multiple images, will allow for a more precise evaluation of dose during planning
and treatment. By explicitly considering anatomic motion in plan design, MAO can enhance the
therapeutic ratio for lung cancer patients by optimizing accumulated dose. Finally, using doseto-mass to evaluate radiation therapy will allow for more precise metrics which may be related
to outcomes and RT efficacy. Dose-to-mass is closely related to the currently used prospective

141
model of radiation damage, the LQ model, evaluation of dose-to-mass in lung cancer outcome
studies may allow for precise modeling of cell-kill in tumors.
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Multiple Anatomy Optimization of Accumulated Dose
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Purpose: To demonstrate the potential benefits of multiple anatomy optimization (MAO) compared to
internal target volume (ITV)-based IMRT optimization for lung cancer radiotherapy.
Methods: Four different IMRT plans are developed for ten lung cancer patients using two methods of
radiotherapy optimization, the ITV method and MAO. For the ITV method, three different plans are
created, corresponding with planning images at the end of inhale, mid-ventilation, and the average CT.
Differences between ITV-planned single image 3D-dose and the 10-phase accumulated 4D-dose are
examined. The MAO aims to optimize a single fluence to be delivered to all respiratory phases such that
the accumulated dose meets the plan objectives. MAO dose distributions are compared to ITV-based
cumulative dose distributions in the clinical target volume (CTV), lungs, esophagus, heart and spinal
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cord. Dosimetric comparisons and sensitivity to breathing interplay during fractionation for both ITVand MAO- solutions are examined.
Compared to accumulated 4D-dose, single image 3D-dose systematically overestimates both the dose to
95% of the CTV (ΔD95 = 1.29 Gy ± 1.8 Gy, p=10-4) and the target volume at the prescription dose
(ΔVRx=3.4% ± 4.9%, p = 10-4) in the ITV-plans considered. CTV-D95 is underestimated by greater than 1.75
Gy in 13 of 30 ITV-plans. For OARs, 3D-to-4D differences are less than 3.2% volume (at fixed dose) and
less than 1.5 Gy (at fixed volume) for all structures considered. The target dose underestimation can be
overcome by optimizing the 4D-dose in MAO, which simultaneously shows potential to spare OARs
compared with ITV plans. MAO reduces ipsilateral mean lung dose by 0.70 Gy ± 0.62 Gy (p=10-2,
maximum reduction of 2.12 Gy) compared to ITV plans at equal target coverage. All plans considered
are robust to breathing variations.
Conclusions: Dose-volume optimization on a stationary image does not ensure accumulated dose
coverage to the moving CTV. MAO can remove this dose discrepancy and improve plan quality.

1. Introduction
Approximations utilized in treatment planning of time-dependent anatomy limit the accuracy of
radiotherapy (RT) to the thorax and upper abdomen. The current standard for simulation of lung cancer
RT is four-dimensional computed tomography (4DCT),1,2 resulting in several patient images representing
the phases of respiration. Many current planning methods combine these 4D-images into a single image
(e.g. a stationary average3 or a maximum intensity projection (MIP)4–6) enabling three-dimensional (3D)
treatment planning while partially considering inherent motion. However, 3D-planning on 4D-anatomy
requires structures that may not physically exist (e.g. internal target volume or ITV) and dose may be
calculated on a synthetic image which is not representative of the true anatomy (e.g. MIP). The multiple
anatomy optimization (MAO) we utilize in this work includes the phase dependent information available
in 4DCT in the plan optimization process. In MAO, dose calculated on each anatomic phase is mapped
to a reference phase via deformable image registration (DIR) and summed to estimate the accumulated
dose (4D-dose) during plan optimization and delivery. In addition to comparing MAO- and ITV-based
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IMRT optimization for a 10 patient cohort, we also quantify differences between 3D- and 4D-dose for
several different methods of ITV planning, thereby demonstrating the need for MAO optimization.
Several other authors have investigated differences between 4D-dose and single image dose (3D-dose)
for ITV-based plans of lung targets and have shown that delivery of the ITV-based plans would result in
under-dosing of the target7–10 or clinical target volume (CTV). For example, Starkschall et al.7 found that
3D-dose overestimated target coverage (CTV-D99) in 10 of 15 patient cases considered. While these
differences motivate MAO, the need to demonstrate this fact for our patient cohort is necessary to
ensure that MAO can indeed compensate for deficiencies in ITV-planning.
ITV-plans assume that CTV-voxels can occupy any position throughout the ITV with equal probability,
whereas imaging and DIR may show that target and risk voxels are distributed non-uniformly. This
implies the ability to reduce healthy tissue dose through design of a non-uniform dose distribution in the
ITV. In fact, motion-inclusive RT planning, including gating11 and direct tumor tracking,12,13 do exactly
this, they create non-uniform dose distributions in the ITV in order to create a more conformal CTV
dose. Unfortunately, these methods rely on continuous and accurate target positioning and tracking,
require complicated deliveries, and may only offer advantages for tumors with large motion (> 1cm).
Like these methods, MAO produces a non-uniform ITV dose distribution which improves 4D-dose
conformality, but unlike them, MAO is delivered under free-breathing conditions, without requiring
target location prediction or tracking.
The concept of utilizing MAO to account for intra-fraction motion in IMRT of lung cancer under free
breathing is not new. 14–18 While Trofimov et al.14 introduced the theory of MAO for intra-fraction
motion, all prior investigators demonstrated MAO with small patient cohorts (less than 6 patients) in
proof of concept studies. Similarly, several authors have considered MAO methods for accommodating
rigid set-up uncertainties19–22, again with small numbers of patients. Both Trofimov et al.14 and Zhang et
al.16 compared ITV, tracking, gating, and 4D-planning, and found that MAO-methods are comparable to
idealized tracking and improve the ITV solution in proof of principle studies. One should note that the
accuracy of Zhang et al.’s16 study is limited since the 4D-dose estimate was accomplished via convolution
with a single image 3D-dose instead of DIR-based dose mapping and accumulation. Söhn et al.20
optimized 4D accumulated dose and also show similar objective achievement between gating and MAO
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(or 4D-planning). Together, these studies imply MAO can achieve plans superior to the ITV-method,
without reliance on prediction or tracking of tumor positions.
In further studies, Heath et al.21 compared an MAO approach with optimized margins and included
variations in respiratory motion by estimating tumor isocenter displacement based on tidal volume for 5
lung cancer patients. Heath et al.21 reported that MAO plans were degraded by respiratory motion
variation. Similarly, Nohadani et al.22 include uncertainty in the objective function to ensure that plan
objectives were not compromised by intra-treatment breathing variations for 2 patients23. Breathing
variation has the potential to create large geometric variations within the ITV and may lead to
unacceptable dose distributions24. Concerns about target motion probability density function (PDF)
stability during treatment have slowed clinical implementation of MAO. This study examines the effects
of PDF variation based on predictable and controllable factors during fractionated MAO delivery.
Since MAO incorporates both target and risk-structure motion PDFs in plan design, plans can be
delivered while a patient breathes freely and comfortably. In the optimization process, MAO designs a
non-conformal ITV-dose distribution which takes advantage of predictable intra-fraction motion
observed in individual breathing phases. This study compares MAO, which explicitly includes all 4DCT
phases in plan definition, and the ITV-method, under the hypothesis that inclusion of this information
will lead to superior treatment plans for lung cancer.

2. Methods
To quantify the potential dosimetric benefits of MAO compared to ITV-optimization for lung cancer
IMRT, plans were generated using both optimizations on a group of lung cancer patients. Following
optimization, target coverage and normal tissue sparing were evaluated and compared for each plan
based upon the 4D-dose. Inherent to ITV plans, dose differences estimated by single image 3D-dose and
4D-dose are reported. We also analyzed of the susceptibility of MAO and ITV plans to PDF variations.

2.1 Implementation of MAO
A research plugin interface to the Pinnacle treatment planning system (PINNACLE3 version 9.100, Philips
Medical Systems, Milpitas, CA) is used to implement MAO, including Pinnacles superposition/convolution dose calculation algorithm, the demons fast-symmetric DIR algorithm, and the
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built-in deformable dose accumulation algorithm. These processes were implemented from within
ORBIT objective functions and optimized using the quasi-Newton (QN) optimizer25. For each
optimization iteration, fluence was projected onto each anatomy (or respiratory phase image), dose was
calculated, then deformed along demons DVFs, and accumulated to the reference image (chosen as the
inhale phase). The 4D-dose was evaluated in the ORBIT objective function.
For a collection of N anatomies (Nana) or images, 4D-dose in voxel j in an arbitrary reference anatomy
(Djref) is expressed as

D ref
j =

∑

→a
wa u ref
D aj =
j

a∈N ana

∑ ∑w u
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a∈N ana i∈ Ap

ref → a
j

(b K )
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ij
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→a
where wa is the probability of the beam encountering the ath anatomy and u ref
is the DVF which acts
j

on voxel j in the reference anatomy, pointing to a location in the ath anatomy . The dose is expanded in
the latter half of equation 1 to include the ith beamlet weight (bi) summed over all beamlets in the
aperture (Ap). The dose deposition coefficients (or influence matrices) for anatomy a, beamlet i, and
voxel j are denoted  . The composite objective value (f) of n quadratic objectives (Nobj) for a region of
interest (ROI) with N voxels (Nvox) is expressed as

f=

∑ ∑ ω c (D
n n

n∈Nobjs j∈Nvox

ref
j

− Rxn, j )

2

(2)

Where ωn is the weight of the nth objective and cn includes Heaviside functions and proportionality
constants based on the prescription (Rxn,j). The beamlet update is calculated using the gradient of the
objective function at each dose voxel, and the Hessian is estimated through gradient differences,
consistent with the Broyden-Fletcher-Goldfarb-Shanno BFGS -method. These calculations are necessary
to determine the search direction. At each step size, 4D-dose is recalculated and is accepted if the
resulting objective function satisfies the Wolfe conditions.26
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The initial approximation of the Hessian in MAO
must include importance weighting for voxels
throughout the ITV (in order to include the CTV in
all phases), but the target objective is the CTV (not
the ITV) and only need to be defined in the
reference phase. Because the voxels of the
reference anatomy determine which voxels are
included in the objective function, many are
included in the gradient as either OAR or target,
when in fact this definition changes depending on
the individual phase. Several steps are taken to
ensure the entire ITV is considered in each MAO
iteration. The Hessian approximation defined in
the 3D, ITV-optimization problem is chosen as the

Figure 1. The flow diagram of multiple
anatomy optimization (MAO) is shown for a
simple, three phase phantom in which one
structure moves relative to another.

initial MAO estimate. Improvement in the initial
Hessian approximation by explicitly including the
influence matrices in all phases has the potential
to improve MAO convergence. All voxels in the
relative complement between the reference-CTV
and the ITV are always included in the

Figure 2. An ITV-optimized dose distribution
(top left) compared to an MAO solution
(bottom left).
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optimization problem by minimizing ipsilateral lung dose and the maintaining target coverage
throughout the optimization.
Intensity modulated fluence-based optimization is considered in this study, direct aperture optimization
(DAO) is a focus of future studies.
The fluence update is determined according to the flow diagram shown in Figure 1 for MAO with a
simple phantom example. The phantom includes three phases, and is designed so that in one of the
phases, the (moving) target and the (stationary) organ at risk (OAR) are aligned along beam paths. The
phantom ITV is the union of the moving CTV in all phase images, and the ITV-plan is optimized so that
95% of the ITV is irradiated to 70 Gy; the risk objective is a maximum dose of 45 Gy. The desired
solution is obvious, to reduce the fluence in the beamlets (3D beam elements) which intercept the OAR.
The ITV plan cannot reduce the OAR dose and also achieve ITV–D95 = 70 Gy because the objectives are
conflicting, however, they conflict in only one of the three phase images. In the MAO case, dose is
calculated on the moving target and knowledge of the motion drives the solution away from the risk
structure. The ITV- and MAO- optimized dose distributions are shown in Figure 2. This simple example
demonstrates the method of MAO and the potential for improvement in cases where objective
tradeoffs occur.

2.2 Patient Planning
Ten locally advanced non-small cell lung cancer patients (named P1-P10), each with a single 4DCT image
set collected on an internal review board-approved study of image-guided adaptive radiation therapy at
Virginia Commonwealth University, were used in this study. All subjects are lung cancer patients
receiving radiation therapy who gave informed consent. The patient images are imported into the
Pinnacle treatment planning system with physician drawn contours on each phase image. Registration
is performed using the Insight Toolkit (ITK) implementation of the demons fast-symmetric algorithm27 as
part of the Pinnacle treatment planning system. Displacement vector fields (DVFs) resulting from the
registration were produced at an isotropic resolution of 3 mm3. Propagated physician drawn contours
(from the reference maximum inhale phase to all other phases) are visually verified with the physician
drawn per-phase contours to ensure consistency of deformations. Dose voxels are designed at the same
resolution as the DVF and the dose-voxel grid encompasses the lungs in all phase images (~106 dose-
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voxels per image). Each plan consists of 7-9 co-planar beams, placed non-uniformly around the patient
to avoid both OARs and hot-spots in normal tissues not explicitly considered in the optimization. Four
different plan optimizations are performed for each patient with identical beam arrangements, three
ITV plans and an MAO plan.
The ITV is a union of the clinical target volumes (CTVs) on all phase images, with each CTV defined as a
5 mm isotropic expansion of the propagated GTV. Inter-fractional set-up error is not considered in this
study, so the planning target volume (PTV) is set equal to the ITV. The ITV-optimizations are performed
using three different input images, the 30% mid-ventilation phase, the average CT (with structures
defined from the 30% phase), and the maximum inhale phase (0% phase, with 0% structures). For the
ITV plans, the target objective is 70 Gy to 95% of the PTV (PTV-D95 = 70 Gy) with an objective weight at
least 100 times that of OAR objectives. The initial objectives include a maximum PTV dose of 80 Gy,
cord maximum dose of 40 Gy, for each lung V20 < 10%, esophagus V25 < 5%, and heart V30 < 5%, where
the OARs are defined on either the 0% or 30% phase, consistent with the input image phase.
The MAO plans consider the 4D-dose on the reference anatomy, therefore the PTV constraint becomes
a (moving) CTV constraint (CTV-D95 = 70 Gy, CTV maximum dose < 80 Gy) and OARs are considered in
each phase image. In some cases, the lung, esophagus, and heart objectives are impossible to achieve
simultaneously in ITV plans. For these cases, to achieve the target criteria in the ITV plans, volume
tolerances are adjusted at the listed dose levels by 5% increments until the objective does not dominate
the overall objective function, in other cases the OAR-objectives are reduced by 5% relative volume until
a non-zero objective score is encountered. The OAR objectives are designed to be difficult to achieve in
the ITV plans order to reduce normal tissue complication probability and show potential advantages in
MAO.
The maximum contour difference is defined between the ITV and 50% (maximum exhale)-CTV contour
and was measured along anterior-posterior (AP), lateral (LAT), and superior-inferior (SI) directions, as
shown in Table . The centroid CTV motion is also measured in the 3 principle directions, and this data
combined with the CTV volume, and the ratio of the two target volumes used in MAO- and ITV- planning
(CTV/ITV) is detailed in Table for each of the patients considered. The patients are ordered according to
the value of the Euclidean norm of the 3D-motion vector, ranging from 0.28 cm for P1 to 0.95 cm for
P10. Pearson correlation coefficients are used to examine the relationship between these patient-
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specific parameters and differences in 3D-dose and 4D-dose. Unlike the aforementioned studies14–18,
this work focuses on locally advanced NSCLC cases with modest 3D-motion (< 1cm in all cases)
Table 1. Patient Details
Contour deviation
(cm,maximum)

Patient

1
2
3
4
5
6
7
8
9
10

AP
0.9
0.5
1.5
0.3
1.5
1.6
1
0.6
1.4
1.9

LAT
0.7
0.7
0.8
0.3
2.3
1.6
1.1
1.2
0.7
2.9

Tumor Centroid Motion (cm)
SI
0.3
0.5
1
0.3
1.3
0.7
0.7
0.6
0.9
1.7

AP
0.15
0.21
0.21
0.08
0.16
0.08
0.30
0.32
0.44
0.36

LAT
0.07
0.13
0.28
0.24
0.19
0.07
0.41
0.25
0.15
0.16

SI
0.24
0.22
0.17
0.31
0.43
0.57
0.41
0.56
0.61
0.86

ITV
(cm3)

Ratio
(ITV/CTV)

221.5
294.8
401.8
60.2
174.6
174.4
232.6
105.1
173.1
442.4

0.83
0.89
0.84
0.78
0.70
0.81
0.70
0.80
0.79
0.82

2.3 Dosimetric Comparisons
For each of the patient cases, differences in single image approximations of dose (3D-dose) and the 4Ddose, calculated by dividing the ITV-plan monitor units on each of ten phases and accumulating dose to
the inhale phase, are reported. This includes mean structure dose and dose-volumes at dose levels
described previously. Differences between 3D- and 4D- dose are labeled as dose prediction errors
(DPEs). For a general dose or dose-volume measurement m, DPE is defined DPEm = Dm3D - Dm4D. Metrics
include mean dose (<D> and DPE<D>) and dose at fixed volume (i.e. D95 and DPED95). Similarly, for a
structure volume at a fixed dose level x (Vx), the volume prediction error (VPE) is defined as
VPEVx = Vx3D - Vx4D. Significance testing of DPE distributions are carried out using one-sided t-tests.
All analysis is performed on the 0% phase image (chosen as the reference image) on the physiciandrawn contours of this image. The inhale phase is chosen arbitrarily, but will have some effects on the
results. For example, the lung volume in inhale is up to 26% larger than the exhale lung-volume for
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these patient image sets, which has the potential to shift the DVH values. The ITV-based 3D- and 4Ddose are compared through DPE and VPE at the objective levels.
The ITV-based 4D-dose is also compared to the MAO-dose (which is inherently 4D). The differences in
target and OAR dose-metrics are used to estimate the potential advantages of our MAO approach. The
first comparison is between the final ITV and MAO plans at optimized MUs based on identical objectives
and objective weights and in general this will result in varying target coverage. In a second comparison,
the ITV and MAO plan monitor units are adjusted to a fixed target (4D-dose) D95 = 70 Gy, and the
potential for OAR sparing is examined.

2.4 Probability density variations in MAO
A source of variability in the 4D-dose estimated by equation 1 is due to variations in the anatomical
weight (wa) for each treatment phase in the time it takes to deliver each beam. Based on the daily
starting phase, the wa will vary during every beam of every fraction unless the treatment time of each
beam is coupled with a constant patient breathing period. This variation can be determined by the
monitor units per beam (MUb), dose rate (DR), and a breathing period (T). This predictable interplay
effect has been shown to average out over the course of fractionated radiotherapy8,9 but this may not
be the case for MAO dose distributions, where the total dose to the ITV is not necessarily conformal.
To estimate the effects of predictable interplay on MAO and ITV dose distributions, we evaluate Nana
images per breathing period (fixed at 10 for this study), a constant, reproducible breathing period
ranging from 3-6 seconds, and dose rates ranging from 400-1000 MU/min. This delivery is considered
over 30 fractions (Nfx), and the monitor units per beam (MUb) ranges from 4,000 to 10,000. With these
values, the expected number of anatomies, <nana>, seen by each beam is calculated according to
n

ana

=

M U b × N ana
N fx × D R × T

.

The calculation of the expected number of anatomies assumes a steady patient breathing pattern and
an accurate set of 4D simulation images with small temporal resolution with respect the dose
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significance level. For each optimized beam MU, the daily anatomical weightings (wa) during each
fraction can vary from a minimum value (wamin) to a maximum value (wamax) estimated by

 n

w amin = floor  ana 
 Nana 

nana ;

w amax = w amin + 1 nana
.

where the floor function is the integer component of the expectation value of the number of periods
sampled per beam (<nana>/Nana).
Dose and dose-response metrics are used to evaluate the effect of anatomic-weight variations on ITV
and MAO plans due to breathing interplay. The evaluation is based on the expectation value of CTV(D95, D95 ), and the variance in this value, σ. Following the formulation of Bortfeld et al.8, the expected
total physical dose after Nfx fractions is D% = N fx D with total dose variance σ% = N fxσ . The expected
total physical dose and the dose variance are used to estimate the equivalent biological dose,

D% E = D% +

σ% 2
α β + 2 D% N fx

assuming linear-quadratic cell kill with σ% small. An α β = 10 Gy is chosen for the NSCLC-CTV doseresponse model. The increase in equivalent biological dose with increasing dose variance is balanced by
the (possible) reduction in the expected physical dose if under-dosing occurs during individual fractions.

3. Results
3.1.

Dose prediction error in ITV plans

Figure 3 shows differences in 3D- and 4D-dose for ITV plans for each patient assuming equal probability
weightings for each of the ten phase images (wa=0.1). The distribution of DPE for mean dose (DPE<D>)
for all ITV plans ranges from -0.1 Gy to 1.8 Gy for the CTV (p=10-7) but values are relatively small (CTVDPE<D> > 1.7 Gy in 2 of 30 estimates). There is consistency in CTV-DPE<D> between the three different ITV
plans for nine of ten patients to within 0.5 Gy, but P4 shows a dissimilarity. The CTV-DPE<D> = 0.95 Gy in
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the 0% plan, and DPE<D> = 1.80 Gy in both the aCT and 30% phase plan. Figure 3 shows the aCT-DVH of
the 3D- and 4D-dose. The 3D-dose shows 92% of the ITV exceeds the 70 Gy (prescription) isodose, and
97% of the static CTV is covered by the 70 Gy isodose, however, the ITV volume is 25% larger than the
CTV volume, and in the aCT and 30% plan, 10% of the CTV volume falls below 70 Gy. The plan on the
inhale-phase is very similar in the ITV shoulder (92% volume at 70 Gy); however, the cold spots are
distributed so that DPE<D> is less than 1 Gy. The sign of DPE<D> indicates either over- or underestimation of accumulated dose by 3D estimates. Positive DPE<D> is observed for the CTV in 28 of 30
cases, overestimating mean dose to moving and deforming CTV by up to 1.8 Gy (2.5% of the prescription
dose). DPE<D> is independent of the ITV-

Figure 3. Dose-differences between 3D- and 4D- estimates are shown for CTV and OARs.
Three different ITV-plans on mid-ventilation phase (30%), the inhale phase (00%), or averageCT (aCT) create three values of 3D-dose for each structure in each plan. Compared to
accumulated dose over all phases, the CTV- mean dose is overestimated and OAR- mean dose
is underestimated in a majority of cases considered. Differences in D95 are noticeably larger
than differences in mean dose.
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planning image, with mean DPE<D> of 0.5 Gy for plans on both 0% phase (± 0.4 Gy, p=0.002) and 30%
phase (± 0.4 Gy, p=0.007). For plans on aCT, mean DPE<D> = 0.7 Gy ± 0.4 Gy (p=0.001). Using two-sample
t-tests between the three distributions, only the relationship between the 0%-phase and aCT plans show
p < 0.1.
Negative DPE<D> is observed in 80
of 120 OAR measurements with
magnitude of OAR-DPE<D> less
than 1 Gy in 116 of 120
estimates. Ipsilateral lung VPEV20
ranges from -3.2% to 3.5%;
contralateral lung VPEV20 similarly
ranges from -2.1% to 3.5%.
Esophagus VPEV25 ranged from 0.2% to 1.3% in the patients
considered, and heart VPEV30
ranges from -3.2% to 1.2%. DPE
for maximum cord dose are
negligible in all cases. VPE at
objective dose levels exceeds 3%
in 3 of 150 cases, with only

Figure 4. DVH for an ITV plan for Patient 4 showing single
image dose on average CT (3D-dose) and accumulated dose
(4D-dose). The 3D-dose, using the static CTV contour, gave
CTV-D95 = 70.4 Gy, however 4D-dose gave 66.7 Gy. In most
of the patient cases considered the OAR doses are similar in
3D- and 4D- estimates.

ipsilateral lung VPEV20 showing
statistically significant
differences (p=0.03) from a
normal distribution about zero.
A similar trend is observed in

CTV-DPED95 as with DPE<D> (shown in Figure 3). In 8 of 10 patients considered, CTV-D95 is overestimated
in all three ITV-plans compared to the 4D-dose CTV-D95. In 4 of 10 cases, DPED95 is greater than 3% of
the prescription dose in all three ITV plans including P1, indicating even small tumor motion may be
susceptible to DPE. The 4D-dose CTV-V70 also shows consistent underestimation by 3D-ITV plans, with
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VPEV70=3.4% ± 4.9% (p=10-4), 7 of 30 plans fail to achieve 4D-dose CTV-V70 > 90%. Different ITVplanning images result in similar VPE V70 (p > 0.2 in all comparisons) showing DPE in ITV planning is
independent of planning image. DPE in ITV plans is not correlated to 3D-motion of the CTV (r2 = 0.002)
or CTV to ITV ratio (r2 = 0.124).

3.2.

MAO compared to ITV plans

The volume of CTV at prescription isodose (V70) is shown in Figure 5 for all plans and all patients. MAO
improves CTV-V70 compared to at least one ITV plan for each patient considered. In other cases, the
ITV plan results in a 4D-dose exceeding prescription (e.g P3) and MAO reduces the CTV isodose in order
to spare OARs. Both P6 and P9 show improvements through MAO planning, ipsliateral lung V20 and
heart V30 is less than or equal to all other plans, while also maintaining increased target V70 (in all
plans) and D95 (in 4 of 6 plans). In most comparisons of MAO and ITV plans, the reduction in OAR dosevolume levels is small (average ipsilateral V20 decrease is 1.5%±1.1%). In other cases, there was a more

Figure 5. The CTV volume at
prescription dose (70 Gy) based on
the 4D-dose, assuming equal phaseweightings for each of the plans
considered. In seven of ten patients
considered, at least one plan fails to
deliver 70 Gy to 90% of the CTV,
however the MAO solution can
ensure accumulated dose meets
prescription.
pronounced difference, for example in P3,
the MAO plan results in V70 = 94.9% of the CTV, compared to the 30%-ITV plan with V70 = 96.4%. In
this case, by reducing the target V70 to prescription MAO reduces ipsilateral mean lung dose is reduced
by 2.2 Gy (a reduction in V20 of 7%) even though 3D motion for this case is just 0.39 cm.
Overall, MAO improves V70 by an average of 3.5% (±4.3%, p=0.01) compared to ITV plans at optimized
MUs. Increased D95 with MAO compared to ITV planning is not significant, on average 0.35 Gy ± 1.27
Gy (p=0.8), but is greater than 1 Gy in 8 of 30 cases. Two of the DVH’s are shown in Figures 6 and 7 for
patients 6 and 10, respectively. The MAO- and ITV- DVH comparison for these two patients display
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common features observed with many of the ten patients, notably, increased CTV coverage in the MAO
plan with similar dose-volumes for OARs.

Figure 6. Accumulated dose DVH
for Patient 6 based on delivering
the 30%-ITV plan and the MAO
plan. The ITV is not covered in
the MAO plan (as it is not an
objective), but the CTV coverage
is improved while reducing
ipsilateral lung and heart doses.

Figure 7. Accumulated dose DVH for Patient 10 based on delivering the 30%-ITV plan and the
MAO plan. MAO increases CTV-D95 to prescription, while simultaneously reducing ipsilateral
lung dose.
In order to show the potential to spare organs at risk in MAO, the 30%-ITV plan and the MAO plan
monitor units are normalized so that 4D-dose CTV-D95 = 70 Gy. In this set of normalized plans, OAR
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volume sparing at objective dose levels is evident in five of the ten cases, P3, P4, P6, P7, and P10, as
shown in Figure 8. In the other five cases the combined OAR-volume sparing at objective dose levels is
less than 2%. The potential for OAR sparing in MAO is not trivially correlated to 3D-motion (r2 = 0.08, p =
0.8). The lateral motion showed a weak correlation (r2 = 0.42, p = 0.2), the largest CTV motion is
measured in the lateral direction for P3 (0.28 cm) and P7 (0.41 cm) and MAO reduces total of all OAR
volumes at prescription by 16.3% and 5.9% for these cases. In all other cases, the largest CTV motion
direction is superior inferior and the 3D-motion for the CTV for P4, P6, and P10 is dominated by SI
motion.

Figure 8. At fixed CTV-D95, the decrease in relative volume of OARs at objective dose levels is
shown using the MAO approach, compared to the 30%-ITV plan. There is potential to spare
organs at risk using MAO for patient 3, 4, 6, 7, 8, and 9.

180

3.3.

Probability density variations in MAO

For 10-phase images per breathing period, on any given treatment day, the individual anatomical
weightings (wa) range from approximately 0.09 to 0.11 per phase image if the patient breathes
consistently with the pattern observed during simulation. This variation (10% of the nominal value) is
estimated based on simulations of the anatomical weights and their standard deviation for 30 fractions.
These values bound all scenarios considering the breathing period (T=3-6 sec), dose rate (400 – 1000
MU/min), and beam monitor unit variations (4,000-10,000 per beam). Even in an extreme scenario (i.e.
4,000 MU beam delivered at 1,000 MU/min to a patient with a 5 second breathing period) sampling a
random starting phase over 30 fractions results in an average anatomical weight ranging from 0.094 to
0.106.
Based on these findings, the sensitivity analysis of MAO and ITV dose distributions to PDF variation is
carried out considering three scenarios: nominal weighting (wa=0.1) on all phases, distribution of the
maximum weights (wamax = 0.11) on the five phases surrounding inhale (80% - 20%), and distribution of
the minimum weight (wamin = 0.09) on the five phases surrounding inhale. The three dose values are
used to calculate the expected dose and dose variance for the CTV.
Both P1 and P3 show negligible differences in dose resulting from equal delivery to all phases (wa=0.10)
and the other two scenarios considered, the variance in CTV-D95 is 0.01 Gy for both ITV and MAO plans
so that the effective dose approximately equals the physical dose. For P3, the range of dose differences
in the considered scenarios are -4.02 Gy to 2.12 Gy for the MAO plan and -4.2 Gy to 1.93 Gy for the ITV
plan when considering the entire dose-volume, but these differences occur outside the ITV.
Increased sensitivity to PDF variation is observed for the MAO dose-distribution for P6, with a CTV-D95
standard deviation of 1.4 Gy in the MAO plan and 0.6 Gy in the 30%-ITV plan. A coronal slice of the
optimized MAO and ITV dose distributions are shown in Figure 9. The dose shows the SI motion is
incorporated in the MAO solution for this patient with hotspots (or horns) on the superior and inferior
borders of the target. In the case of P7 or P10, where the standard deviation in D95 is 0.2 Gy and 0.01
Gy, respectively, both MAO and ITV plans are robust to PDF variations considered. The average D95 for
P1, P3, P7, and P10 is equal to the D95 based on nominal weightings (to within 0.10 Gy) and the
biological dose does not differ from the physical dose by more than 0.10 Gy in any of the cases
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considered, implying the MAO solutions are robust to PDF variations occurring due to dose-rate and
breathing interplay. However, the effects of motion along a principle axis (i.e. P6) were more
pronounced than a distribution along multiple axes. The dose variation over the entire dose-grid is
greater in the MAO distributions, but dose variance due to breathing interplay does not affect the
biologic equivalent dose in the cases considered.

Figure 9. Coronal slice of the MAO dose distribution (left) and the ITV dose distribution (right)
calculated on a single anatomy (inhale), where the CTV is drawn in black. The MAO dose
distribution (left), creates CTV- hot and cold spots in individual phase doses for this patient to
improve accumulated dose, this plan is more susceptible to interplay effects than any
considered.

4. Discussion
Differences in 3D-and 4D-dose CTV-D95 exceed 2.5% in at least one ITV-plan for 6 of the 10 patients
considered. For mean dose simulations, DPE<D> is consistent with the findings of Rosu et al.4 and GlideHurst et al.3 who have shown DPE<D> to be within ±3% of 4D-estimates. The DPE<D> and DPE based on
other dose metrics which sum dose values over a region of interest (e.g. equivalent uniform dose)
should be small under approximate conservation of mass and energy in different considered anatomies.
However, when considering dose-volume metrics, cold spots in the ITV have the potential to create a
relatively larger cold spot in the (smaller) CTV volume.
The value of CTV-DPE in an ITV plan depends on the motion of the CTV (or the CTV-PDF) and the dose
distribution within the ITV; implying that dose differences are both patient- and plan- specific. Even in
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cases of small motion the CTV-D95 can potentially be compromised, as shown for P1 and P4. A
completely conformal dose within the PTV will result in zero DPE under the assumption of conservation
of mass and energy in multiple anatomies. In other words, there is no motion-PDF which will alter the
CTV dose if the PTV dose is completely uniform in all breathing phases. Uniformity within the PTV,
however, is often relaxed to spare OARs creating the potential for degradation of the conformality of
the moving CTV. For OARs, the 4D-dose was observed to be larger than 3D-dose in most cases, but this
difference is less than 3.2% for lung, heart, spinal cord, and esophagus for all patients and all ITV-plans
considered. Mean dose 3D- and 4D- differences for OARs are less than 1.5 Gy in all estimates.
A simple evaluation of a worst case scenario in 3D-planning of moving anatomy can indicate the
possibility of large CTV-DPE. Rather than evaluate the CTV coverage based on a static contour, the CTV
coverage is robust against DPE when, for each voxel of the CTV, the minimum dose in the PTV is
sampled. A worse-case sampling of the PTV dose distribution will establish a limit on DPE and can be
used to ensure an un-acceptable under-dosing of the CTV cannot occur in an ITV plan. A similar method
was proposed by Niemierko and Goitein28 in sampling dose distributions. The relatively small
dose/volume differences in 3D- and 4D- dose for OARs can be accounted for through tolerance levels in
OAR objectives. With a worst case sampling and additional OAR tolerance, new methods of
optimization are not required clinically, and will ensure target coverage is not compromised.
In this study, intensity-based optimization of accumulated dose is performed within a commercial
treatment planning system. Others have proposed similar methods in proof of principle studies,
especially in cases of large CTV motion14–18. This work specifically looked at differences in 3D- and 4Ddose, not only to overcome ambiguity between the two, but to investigate the advantage of phasespecific dosimetry in MAO. This study includes cases of moderate CTV motion which may be more likely
to be encountered clinically. MAO can ensure accumulated dose meets the planning objectives based
on a known PDF. For five of ten patients, the MAO solution shows some advantages compared to ITV
planning. The advantage of MAO is not well correlated to 3D- motion or the size of the CTV. The ITV
plan assumes a uniform distribution of CTV voxels throughout the ITV, so that if motion is distributed
uniformly, the CTV-PDF may resemble a uniform distribution and may explain why the MAO results in a
plan nearly identical to ITV in five of the patients considered. Without some distinguishing features in
the CTV-PDF, there may not be advantages in using the MAO technique.
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There are limitations to MAO, and there are many hurdles to overcome in order to move this technology
into clinical use. In order to implement the method of MAO described herein clinically, calibration of an
accumulated, 4D-dose algorithm with delivered dose to mobile, deforming structures using a realistic
deformable phantom is necessary (see, for example Kashani et al.29). Creation of a PTV in order to
account for set-up error is another obstacle, however the MAO software is interfaced with methods to
optimize margins to account for both random30 and systematic31 errors. Of these challenges, the
sensitivities of the MAO dose distribution with respect to anatomical changes during each treatment
and over the course of fractionated radiotherapy (including tumor regression) will require consideration.
Because MAO depends directly on the phase images and the DVFs connecting them, the technique may
be sensitive to realistic anatomic variations, at least when compared to the more conformal ITV
solutions.
The effects of fractionated interplay is considered in this study, however the effect of irregular breathing
may be much more significant. The probability of encountering the phase images observed in 4DCT
during treatment may alter anatomical weights (in equation 1) by more than 10%. The effect of
breathing variation is a focus of future studies. MLC interplay effects (which vary the anatomical
weighting for each aperture) are also a concern. MLC interplay can be directly incorporated in the MAO
solution through DAO including a high frame-rate of per-aperture dose calculation. The solutions
presented herein are based on fluence optimization, not MLC conversion. Generalizing the fluence
optimization to multi-aperture DAO will require sensitivity analysis with respect to varying anatomical
weights, which grows as the delivery time of each aperture is reduced. It is plausible that the MLC
delivery of the plan must be coupled to the patient specific motion in cases of limited treatment time for
each aperture, which is especially relevant to arc-based therapy (see for example Ma et al.32 or Chin and
Otto33). Court et al.34 have investigated MLC sequencing to ensure the interplay effect results in dose
distributions within a known tolerance, and such a method may be applicable to MAO dose
distributions.
The current implementation of MAO takes approximately 20 hours per patient using a single core x86
processor. Each optimization iteration requires several minutes, as dose is calculated for 7-9 beams on
10 images multiple times during each iteration, with calculation time on a single core for each beam
ranging from approximately 3-6 seconds. Using a pencil beam dose calculation on multiple CPU cores
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(i.e. 8 cores) will speed up this calculation by a factor of 40 or more, but will sacrifice accuracy in
heterogeneous lung. The preferred method of dose calculation to pencil beam may be GPU-based
superposition-convolution35. Of the total time for optimization, approximately 70% was spent in dose
calculation on the representative anatomies, with the other 30% of time spent on dose accumulation
and data transfer. Because of DIR and minimization of optimization objectives, however, the method
relies only on a single contour set and a beam arrangement. User interaction is minimal, so that the
resulting plan may approach a best-case scenario in terms of target coverage and OAR sparing and can
be optimized off-line.

5. Conclusions
Multiple anatomy optimization has been implemented in the Pinnacle treatment planning system for
free breathing radiotherapy of lung cancer. The optimization explicitly includes accumulated dose on
multiple anatomies as presented in 4DCT simulation images. The method shows potential advantages
compared to ITV planning for half of the patients considered, and does not require real-time tracking or
prediction. The solutions are robust to breathing interplay, implying high dose rates can be used in
traditional fractionation.
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Appendix B

Dose Differences in ITV Planning of Time Dependent
Anatomy

W.T. Watkins1, J. A. Moore2, B. Cai1, N. R. Anderson1, C. Dial1, G. D. Hugo1, J. V. Siebers1
1

Virginia Commonwealth University, Richmond, VA

2

Johns Hopkins University, Baltimore, MD

Purpose / Objectives. Tumor motion and deformation create ambiguity in target dose coverage
when prescribing to an internal target volume (ITV). This work quantifies dose differences
between single image dose approximations and deformed, accumulated dose for five lung
cancer patients for several different measures of target coverage.

Materials / Methods. IMRT plans are developed to deliver 70 Gy to 95% of the ITV volume on a
mid-ventilation image (mid-vent) and on an average CT image (aCT) for five lung cancer
patients. Dose calculations are performed for delivery to each of ten phase-sorted 4DCT
images, and deformable dose accumulation is carried out utilizing a fast-symmetric Demons
algorithm for registration. The accumulated dose distribution (or 4DD) is compared to the single
image dose (or 3DD) through five metrics, the relative target volume at prescription isodose,
minimum dose, and gEUD for a = 1, -5, and -20 to represent mean dose, radiosensitive tumor
coverage, and aggressive tumor coverage, respectively. Dose measures are considered for the
gross tumor volume (GTV) and a 5 mm isotropic expansion of the GTV to represent the clinical
target volume (CTV) in each of the plans.
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Results. In nine of ten plans, CTV prescription isodose volume is overestimated in 3DD
compared to 4DD (mean, 1 standard deviation of 9.9% ± 9.7%, range of -5.1% to 19.8%). Mean
dose differences (gEUDa=1) in the CTV are 1.55 Gy ± 1.20 Gy and are overestimated in all ten
3DD calculations (range of 0.2 Gy to 3.8 Gy); however mean GTV dose differences are not
significant (0.78 Gy ± 1.32 Gy, p=0.0948). Increasing the importance of cold-spots within the
target, the differences in 3DD and 4DD become patient specific, with 3DD overestimating CTVgEUDa=-5 and GTV-gEUDa=-5 in five of ten plans. Measured differences between 3DD and 4DD for
gEUDa=-5 range from -6.5 Gy to 3.8 Gy for CTV, and from -1.1 Gy to 3.7 Gy for GTV. Measured
gEUDa=-20 is also patient-specific for both CTV (range -3.9 Gy to 9.6 Gy) and GTV (range -9.9 Gy
to 2.3 Gy) and the magnitude of observed differences increased with decreasing a. As the value
of a is decreased in gEUD computations, the correlation with minimum target dose increases
from 0.658 for a=-5 to 0.900 for a=-20. Planning on aCT decreases gEUD differences compared
to plans on mid-vent in 12 of 15 CTV measurements, and in 10 of 15 GTV measurements.

Conclusions. Differences in 4D-accumulated dose and 3D dose on a single image are evident
from dose volume histogram levels. However, for mean dose these differences are veiled,
which is expected since this is a summation of similar dose values, assuming only slight
deviations of conservation of mass and energy among different 4D images. When magnifying
the importance of low dose voxels decreasing a in gEUD, differences in 3DD and 4DD become
patient and plan specific, and should be considered in radiotherapy planning.
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Appendix C

The Effects Of Interplay On Accumulated Dose In High-dose
Rate Stereotactic Body Radiotherapy Of Lung Cancer

W. Watkins*1, W. Y. Song*2, G. D. Hugo*1, E. Weiss*1, J. V. Siebers*1.
1

Virginia Commonwealth University, Richmond, VA

2

University of California San Diego, San Diego, CA

Purpose/Objectives. To determine the dosimetric effects of beam-delivery and breathing-phase
interplay as a function of dose rate for lung cancer stereotactic body radiation therapy (SBRT).
Methods/Materials. For four lung cancer patients who underwent 4DCT and received SBRT under freebreathing conditions, 4*12 Gy/fraction is prescribed to 95% of the planning target volume (PTV), defined
as a 3-5 mm expansion of the internal target volume. The plan is optimized on a single planning image
(three on average-CT, one on a single phase). For each patient, this study estimates accumulated dose
to 95% of a reference-phase GTV plus a 3-5 mm margin (D95acc). In one approximation of D95acc, the
dose is assumed to be independent of beam-on time, so that dose is delivered to the same anatomy
captured in 4DCT (i.e. equi-weighted respiratory phase images). This approximation of D95acc is
compared to the planned PTV-D95. In reality, dose is dependent on the 4DCT phases encountered
during treatment which in turn depends on treatment dose rate, per-aperture MUs, and the interplay of
beam delivery with patient-specific breathing patterns. In order to estimate the effects of interplay on
D95acc, ten deliveries are simulated per patient by randomly sampling patient-specific breathing patterns
for durations determined from per-beam MUs and dose rates 1000, 1400, and 2400 MU/min. This
methodology assumes a conformal delivery (i.e. one aperture per beam). Differences between D95acc
for each simulated delivery and the standard deviation in simulated D95acc are reported.
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Results. Using the equi-weighted CT acquisition phases, the (nominal) D95acc is greater than the planned
dose to the PTV by 0.1 Gy, 1.3 Gy, 1.3 Gy, and 2.8 Gy for the 4 patients considered. Beam-on times
range from 2.7 seconds (at 2400 MU/min) up to 22.6 seconds (at 1000 MU/min). Including interplay,
the maximum difference between the 10 estimates of D95acc is less than 0.71 Gy for all patients. The
standard deviations of dose between the 10 simulated deliveries are < 0.11 Gy when delivered at 1000
MU/min; < 0.12 Gy when delivered at 1400 MU/min; and < 0.26 Gy when delivered at 2400 MU/min.
The average D95acc of the 10 simulated deliveries for each dose rate differ by < 0.09 Gy for all patients;
and average D95acc is greater than or equal to the nominal D95acc for ¾ patients (by up to 1.5 Gy).
Conclusions. In the cases considered, D95 to the moving target is approximately independent of beamon time. Interplay between beam-on time for high dose-rate treatment (up to 2400 MU/min) and
patient-specific breathing results in target dose variations < 0.71 Gy assuming one aperture per beam.
Further studies are needed to ensure interplay effects do not compromise intended treatment in
dynamic IMRT delivery.
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Appendix D

Dose To Mass In Lung Cancer Radiation Therapy

W.T. Watkins1, J. A. Moore2, G. D. Hugo1, J. V. Siebers1
1

Virginia Commonwealth University, Richmond, VA

2

Johns Hopkins University, Baltimore, MD

Purpose. To integrate mass and density information in structure definition, in dosimetric evaluation,
and in intensity-modulated radiotherapy (IMRT) plan optimization for lung cancer radiotherapy.
Methods. Four-dimensional computed tomography (4DCT) image sets for 8 lung cancer patients are
analyzed in this study. An expert physician has delineated ipsilateral lung and gross tumor volumes
(GTVs) on all phases of several of the patient-image sets. Mass and volume of lung and GTV, as
delineated by the physician in the phase-sorted 4DCT images, are compared to deformed contours
defined through propagation of inhale-phase contours according to deformable image registration (DIR).
In order to incorporate mass in dosimetric evaluation, dose-volume histograms (DVHs) are compared to
dose-mass histograms (DMHs) for each patient using (DVH-based) IMRT optimized-dose distribution on
the inhale phase image and on the average-4DCT density. For these same plans and images, plans based
on DMH-optimization are compare to DVH-based plans.
Results. The coefficient of variance (CV) of ipsilateral-lung mass, defined across different phases of each
4DCT image set, is less than 5.6% for physician contours and less than 2.4% for all DIR-contours. GTV
mass across respiratory phases is also approximately constant, with physician contoured CV < 4.7% in all
image sets and DIR-based CV < 3.5% for 7/8 patients. In one case which included visible artifacts near
the GTV, DIR resulted in a relatively large mass variation (CV > 8.5%). Incorporating mass into dosimetric
evaluation revealed differences between DVH and DMH less than 3% for the spinal cord, heart, and
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esophagus across all dose levels. In the lungs and targets, differences between DVH and DMH often
exceed 5%. Differences between lung DVH and DMH were normally distributed, showing plan and
patient dependence. In optimizing DMH levels in IMRT, target and ipsilateral lung doses are adjusted to
account for large differences in dose to massive regions within each structure .
Conclusions. Incorporating mass in lung cancer radiation therapy; in delineation, evaluation, and plan
optimization, offers potentially useful information.

1. Introduction
The dose volume histogram (DVH) is an integral component in modern radiotherapy (RT) planning and
evaluation. The DVH was first introduced as a proportion of posterior rectal wall as a function of dose
by Shipley et al (1979) whose stated aim was “to develop practical clinical techniques for the delivery of
a well-localized beam.” They unquestionably succeeded in this aim, but it is interesting to note that the
first DVH plotted the relative volume of posterior rectal wall at dose, not the relative volume of the
entire rectum (including contents) as is commonly done today. The entire rectum is composed of both
functional and non-functional sub-units. Nioutsikou et al (2005) describe the inherent assumption that
each voxel (of equal volume) has equal importance in DVH evaluations. Combine this assumption with
prospective cell-kill models (e.g. linear-quadratic model) which rely fundamentally on the number of
cells irradiated, and there is an evident disconnect between DVH measures and radiation damage.
The current standard to estimate prospective radiation damage is based on the linear-quadratic model,

(

)

where the surviving fraction (N/N0) of cells is estimated according to N N0 = exp −α D − β D 2 . In
parallel organs, the number of surviving functional sub units (FSUs) of an organ will determine the
complication probability (Niemierko and Goitein 1993). Under the assumption that FSU density is
directly proportional to physical density, the biologic effect of an equal dose delivered to reduced mass
is directly proportional to a reduction in complication or control probability. This assumption does not
require all cells in a voxel to function equally; it requires the relative proportion of FSUs to be directly
proportional to voxel density. In normal tissues, there is an added advantage in delivering radiation
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through less massive regions, i.e. a reduction in radiation path length will reduce the delivered dose
through normal tissue.
Consider the integral dose (Carlsson 1963, Attix 1991), dose integrated over a structure mass composed

∫

of n voxels is D dm =

En

∑m
n

n

mn = ∑ E n = E abs . The integral dose in a structure of mass elements is
n

∫

the absorbed energy. Integral dose within n volume elements is D dV =

∑D

n

n

mn

ρn

=∑
n

En

ρn

, or the

sum of energy absorbed per unit density (ρ) of each voxel. This quantity (integral dose over volume) is
meaningful in homogenous media, where energy per unit density is directly proportional to the energy
absorbed. Fundamental limitations of radiation delivery have been described based on conservation of
integral dose in spherical shells (e.g D’Souza and Rosen 2003 or Reese et al 2009); however, in
heterogeneous structures dose is not conserved among different beam/delivery conditions. Specifically,
delivering a larger proportion of fluence through a region of lower density will reduce the dose in such a
spherical shell. We hypothesize that consideration of structure mass in plan development through the
dose-mass histogram (DMH) has the potential to lead to reduce integral dose to normal tissues and will
result in a superior RT plan.
The differences in DVH and DMH are clear in theory but the magnitude of such differences may not be
clinically significant. There is evidence that outcome (or toxicity) correlates with dose-volume
parameters for many organs, without consideration of mass. Mavroidis et al (2006), commenting on the
work of Nioutsikou et al (2005), showed for numerical phantoms with Gaussian dose distributions the
differences between DVH and DMH are greater than 5% in lung. For a pair of tangential photon fields in
a breast cancer case, they also show clinically-significant (> 5%) differences between DVH and DMH in
the lung. This study examines the magnitude of DVH and DMH differences for eight lung cancer patients
based on intensity modulated RT (IMRT) dose distributions. Two different planning images are
considered, a plan optimized on the inhale phase of 4DCT (representing idealized gating or breath-hold
therapy) and a plan optimized on the average CT (aCT) density representing free-breathing treatment.
These plans are optimized based on dose-volume objectives.
For the same eight patients, DMH-based IMRT optimization is performed and compared to the DVHbased plans. The same planning images are used in DMH optimization, with objectives trivially
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transformed from DVH to DMH levels. Volume and mass at fixed dose levels, as well as dose at fixed
volume and mass, are compared for targets and organs at risk (OAR). DMH-based plan optimization has
the potential to preferentially reduce radiation path lengths through normal tissues in order to reduce
normal-tissue dose and ensure massive regions of targets are treated.
Both of the planning approaches investigated in this study are idealized. The aCT density is never
physically encountered, but instead represents a mass-probability distribution averaged over the
breathing cycle. Single-phase gating or breath-hold, as considered in the inhale-phase optimization, is
difficult (or impossible) to achieve clinically. A better approach may be to optimize dose to structure
mass, as represented in individual phases of 4DCT. A hurdle in achieving this multiple-anatomy
optimization (MAO) is structure definition in multi-phase images and reliable deformable image
registration (DIR) between phase images. The first step in implementing a mass-based MAO is to
consistently define structures in multiple anatomies and mass evaluation has the potential to aid in this
process.
During respiration anatomic mass is approximately constant, and inclusion of this information may
result in more consistent structure definition. Prior to considering DMH and DVH differences, and DMHoptimization, this study reports mass and mass-conservation in delineated structures as defined in
different breathing phases of 4DCT. Delineating structures in all phases of 4DCT is a time-consuming
task but can be done relatively quickly using DIR and contour propagation. If mass is conserved in 4DCTphase images, evaluation of structure mass in different phases of 4DCT is a quantitative measure of
intra-observer delineation consistency.

2. Methods and Materials
2.1 PATIENT DETAILS
Eight locally advanced, non-small cell lung cancer patients who received 4DCT are considered in this
study. For each patient, a single simulation 4DCT is used for planning and evaluation. All (eight) of the
image-sets include physician-delineated gross tumor volume (GTV) on all phase images (ten phases).
Five of these image sets include physician contours of OARs on all phases, including the ipsilateral lung
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contour. Each of these patients display moderate GTV motion and a range of GTV volume from 17.4 cm3
to 189.2 cm3, detailed in Table 1.
Table 1. Patient details. The gross tumor volume (GTV) and the lung are defined in the inhale 4DCTphase.
GTV:

Lung:

3D-Motion (cm) Volume (cm3) Mass (g) Volume (x103 cm3) Mass(g)
P1

0.39

189.20

193.20

1.18

464.09

P2

0.40

17.40

15.68

1.02

413.08

P3

0.28

79.89

74.51

2.96

881.91

P4

0.58

60.80

55.94

1.91

715.95

P5

0.69

32.60

30.06

2.40

675.30

P6

0.50

39.20

36.24

2.26

632.31

P7

0.77

53.00

44.99

2.58

802.40

P8

0.95

185.20

166.78

3.79

948.99

2.2 EVALUATION OF MASS AND VOLUME IN 4DCT
For ipsilateral lung and GTV, both volume and mass as a function of respiratory phase are reported for
each patient based on a single 4DCT image sets. The contoured mass will remain constant during
respiration if the images and delineated structures are an accurate representation of actual, physical
patient anatomy. Volume physically varies during respiration, especially for elastic tissues in lung (Zhao
et al 2011). The volume variation can be expressed through the tissue fiber strain. This quantity is
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estimated for both lung and GTV according to Carton et al (1964) as ε = (V2 V1 )

1/ 3

− 1 , which physically

represents structure deformation of an equivalent sphere in one dimension.
A physician has contoured lung and GTV on all phases of 4DCT for five patients (named contoured
structures); the DIR-propagated contours (named deformed structures) are initiated with the physiciancontour on the inhale phase and are deform it to nine other 4DCT-phases. The deformed structures are
propagated according to demons- deformation vector fields (DVFs), calculated using the Insight Tool Kit
(ITK) and implemented in a research version of the Pinnacle3 (Philips Healthcare, Andover, MA)
treatment planning system (version 9.100). The GTV and ipsilateral lung mass and volume in contoured
and deformed structures are used to evaluate intra-observer delineation consistency for the patient
cohort.
Physical volume variations will occur between structures in different respiratory phases due to tissue
elasticity. Mass differences between structures defined in different breathing phases, in this work, is
assumed to be due to contour delineation errors. Using mass as a surrogate for spatial discrepancies,
consider two spheres with volumes V1 and V2 (and radii r1 and r2). Sampling from similar density arrays,
the differences in total mass (∆M) of the two spheres can be cast into spatial estimates of delineation
consistency by volume differences, ∆V = V1-V2. For two spheres, if ∆V is 10% of V1, then r2 is within 3%
of r1. For example, if a sphere with radius 3 cm (V1=113 cm3) increases by 10% volume, the spatial
change in radius is less than 0.1 cm. However, if the sphere is deformed to a spheroid, so that the
spatial discrepancy occurs over a fraction f of the original surface (V2 = f V2 + (1-f) V1 and ∆V = f(V1-V2)
then the spatial discrepancies grows with decreasing f. For example, a 10% volume change due to
deformation over 1/4 of the original volume (f=1/4) results in a spatial difference between r1 and r2 of
16% (or 0.5 cm for r1 = 3 cm).
The estimation of contour delineation consistency assumes a constant mean density ( ρ ) between
structures in different phases, so that ∆M ρ = ∆V . The fractional volume of deformation is arbitrarily
chose as f=1/4 in all evaluations. Based on a sphere (radius r1) with volume equivalent to the volume of
1

 3
 3
the GTV (VGTV) defined in the inhale phase, r1 = 
VGTV  . The corresponding spatial discrepancy, ∆r,
 4π

based on an observed mass difference (∆M) is
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∆M ρ = ∆V
 3 (1 − f )V1 − ∆V 
∆r = r1 − 

(1 − f )
 4π


1

3

The mean density ( ρ ) is estimated as the ratio of average mass and volume computed in all phases for
each patient, and ∆r is reported for GTV and lung based on physician and deformed contours.

2.2 DOSE-TO-VOLUME AND DOSE-TO-MASS METRICS
Relative volume and mass differences at varying dose levels, for each plan, are evaluated for all regions
of interest (ROIs) at all doses. Specific values of volume and mass at dose include planning target
volume (PTV) V70/M70, lung V20/M20, esophagus V25/M25, heart V30/M30, and spinal cord maximum
dose. At dose level x the differences between Vx (relative volume at dose) and Mx (relative mass at
dose) are reported.
DVH and DMH differences are due to two potential factors, accuracy of heterogeneous dose calculation
and relative volume and mass differences in the heterogeneous, irradiated volumes. The same dose
calculation algorithm is used in DVH and DMH measures; the adaptive convolve option in the Pinnacle3
TPS, so the effects of accurate dose calculation are not considered in this study. In a structure S of
volume Vs composed of n voxels of fixed volume v, DVH is a measure of relative volume at dose D; or the
relative number of voxels at dose D (nD).

DVH(D) = ∑v VS {D − Di }+ = nD n .
i∈S

DMH considers the total mass of structure S (or MS) and the mass of each voxel (mi), returning the
relative density of the tissue in S at dose D, S(D).

DMH (D) = ∑ mi MS {D − Di }+ =
i∈S

∑

i∈S( D )

ρi

∑ρ

i

.

i∈S

DVH and DMH levels are compared on two image sets for each patient considered, the inhale image
and the aCT density using IMRT dose distributions.
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2.3 DVH AND DMH OPTIMIZATION
For each patient considered, DVH- and DMH- based IMRT optimization is carried out. The dose
calculation and mass sampling is performed with dose and image voxels of 0.3x0.3x0.3 cm3 (the images
are re-sampled at the dose distribution) within the Pinnacle3 TPS. The resulting four optimized plans per
patient (2-DVH plans, 2-DMH plans) are compared. The inhale-plan density values result in well-defined
(visible) image contrast; the aCT blurs the structure densities according to 10 phases of the respiratory
cycle and obscures structure boundaries in many cases.
DVH plan objectives include 70 Gy to 95% of the PTV-volume and a maximum dose less than 80 Gy,
while minimizing lung V20, esophagus V25, heart V30, and maximum dose in the spinal cord less than 40
Gy. DMH optimization utilizes the same beam angles and objective weightings evaluated at relative
mass levels; 70 Gy to 95% of the PTV mass (M70) and minimization of the relative mass of risk structures
at the same dose levels (M20 for lung, M25 for esophagus, M30 for heart). In the inhale plan, the PTV is
defined as the GTV surrounded by a 1 cm margin. In the aCT plan, the PTV is a 1 cm expansion about the
internal target volume (ITV) – the union of the GTV in all phase images.
The dose-volume objectives are chosen based on outcome evidence primarily from QUANTEC
(Quantitative Analysis of Normal Tissue Effects in the Clinic) reports (summarized in Marks et al 2010b).
For lungs, 20 Gy (V20 and M20) is chosen based report of Marks et al (2010). For the heart, 30 Gy is
chosen based on the studies of Wei et al (2008) and according to the report of Gagliardi et al (2010),
who show V25 > 10% of the heart results in a non-zero NTCP. The V25 & M25 level is used to estimate
risk in the esophagus, which is chosen based on two studies; Belderbos et al (2005) indicate V35 as a
dosimetric predictor of Grade 2 acute esophagitis at all volume levels for 156 patients, Wei et al (2008)
indicate V20 as a predictor of Grade 3 acute esophagitis at volumes exceeding 35% of the organ in in a
215 patient study. The spinal cord is evaluated at a max dose of 40 Gy, with expectations that DVH and
DMH differences will be negligible when evaluated at a point (or for all maximum and minimum dose
objectives).
The differences in relative volume and relative mass at defined dose levels, DVH(D) – DMH(D), will result
in differences between DVH- and DMH- plans due to changes in trade-off consistency. In DVH-plans,

199
objectives are minimized until a trade-off is encountered between conflicting volumes at dose. An
optimized DMH-plan will achieve tradeoff consistency between mass at dose (or DMH) levels. Another
source of differences in DVH and DMH plans is explicit consideration of mass in the DMH measure. DVH
optimization may encounter reduced radiation-path lengths through OARs because they reduce the
objective function, whereas DMH explicitly penalizes higher density regions of OARs at dose levels.

3. RESULTS
3.1 MASS AND VOLUME VARIATIONS IN 4DCT IMAGES
Lung volume is expected to be at maximum near inhale and at minimum near exhale, but for two of the
4DCT-image sets considered there was not a clear volume/ breathing-phase relationship. The total lung
volume did not vary in a predictable way for P1 and P2. Figure 1 shows relative lung mass and volume
for P2, based on physician and deformed contours. Lung mass deviations > 5% are observed in both sets
of contours. For the physician contours, maximum ∆M = 36.7 g resulting in ∆r = 0.47 cm; in deformed
contours maximum ∆M = 28.8 g with ∆r = 0.36 cm. The P2-4DCT dataset has recognizable 4DCT sorting
artifacts (including ‘floating diaphragm’) visually evident in many of the phase images. Compromised
lung function and alectasis are evident in the images for P1. For this case, deformed contours indicate
small volume changes (less than 18 cm3 of air intake, a 1.5% volume change) and mass conservation to
within 11.2 g (2.4% of the mass at inhale). The physician contours, in this challenging case, indicate > 6%
volume variation and mass changing by > 10% (> 50 g) between different phases in the lung. Using the
calculated average density of 0.38 g/cm3, the spatial discrepancy over ¼ of an equivalent sphere is ∆r =
0.38 cm when ∆M = 55 g for the physician contours of P1.
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Figure 1. Relative mass and volume of lung for P2 with respect to the physician contour defined in the
inhale (00%) phase for physician-defined and deformed- contours. Image artifacts are visually evident
in this case and contribute to mass variations >5% in both physician and deformed contours.
Figure 2 shows the mean and two standard deviations (to show inter-patient variation) for relative mass
and volume as a function of respiratory phase for three lungs (P3-P5). This data includes both physician
and deformed contours and allows a direct comparison of intra-observer delineation consistency
between the two. The deformed contours conserve total lung mass more consistently than physician
contours for these cases based on standard deviation of the average relative mass. Statistics for each
ipsilateral lung are summarized in Table 2, showing mean volume and mean mass, and the coefficient of
variation (CV) among structures in different phases for ipsilateral lung and GTV for each patient.
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Figure 2. Relative lung mass and volume for 3 patient image sets, based on evaluation of physiciandelineated and Demons-deformed contours. The deformed volumes result in a more consistent mass
throughout the respiratory cycle.
Table 2. Lung volume and mass, with the coefficient of variation (CV), defined by physician contours
and deformed structures.
Lung

Mean Volume (CV) / cm

3

Mass (CV) / g

contoured

deformed

contoured

deformed

P1

1134.4 (3.0%)

1186.5 (0.4%)

433.9 (5.6%)

470.3 (0.8%)

P2

1001.2 (6.6%)

987.5 (2.2%)

415.1 (2.7%)

425.9 (2.1%)

P3

2758.6 (6.3%)

2752.3 (5.7%)

867.0 (2.0%)

879.0 (1.8%)

P4

1701.4 (7.5%)

1705.7 (8.8%)

720.7 (3.6%)

724.9 (1.7%)

P5

2291.1 (5.0%)

2251.5 (4.5%)

658.6 (2.0%)

658.6 (0.8%)

P6

-

2147.7 (3.7%)

-

634.7 (2.1%)

P7

-

2438.2 (5.2%)

-

788.2 (2.4%)

P8

-

3602.0 (3.4%)

-

952.0 (0.8%)
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Gross tumor volume and masses, together with the coefficient of variation are listed for each patient in
Table 3. Relative GTV mass and volume for P8 is shown in Figure 3. In this case, the physician contoured
mass and volume shows phase dependence similar to the lung (for P8-GTV, physician maximum ∆M =
15.6 g, ∆r = 0.16 cm, deformed maximum ∆M = 6.7 g, ∆r = 0.06 cm).
The deformed contours on P7 show GTV volume and mass varies by >8% in deformed contours between
phases. The relatively large variation in GTV mass for P7 indicates a failure in DIR (P7 physician
maximum ∆M = 2.8 g, ∆r = 0.06 cm, P7 deformed maximum ∆M = 12.4 g, ∆r = 0.33 cm). A coronal slice
of the inhale-phase image for P7 is shown in Figure 4. This phase is the reference image, from which all
DVFs and deformed contours are generated. The sorting artifacts near the superior and inferior border
of the contoured tumor, as pointed out in Figure 4, are a possible cause of the observed mass deviations
in the deformed GTV structures. DIR shows larger mass variation with decreasing GTV-mass, i.e. a weak
negative correlation was found between GTV volume and DIR-based mass CV across all phases (r=-0.47)
and maximum mass differences across all phases (r=-0.46). There was no clear correlation in the
physician-based mass CV and GTV size.
Table 3. Gross tumor volume and mass,
with the coefficient of variation (CV),
defined by physician contours and
deformed structures. *The GTV for P7
was copied from the inhale phase to all
other phases.

GTV

Mean Volume (CV) / cm
contoured

3

deformed

Mass (CV) / g
contoured

deformed

P1

180.6 (2.5%)

191.9 (0.1%)

184.0 (2.4%)

195.0 (1.0%)

P2

17.3 (1.0%)

19.1 (4.5%)

15.3 (1.9%)

16.9 (3.5%)

P3

76.6 (2.8%)

83.0 (2.1%)

71.8 (2.7%)

75.7 (2.0%)

P4

58.2 (2.2%)

64.9 (3.2%)

54.7 (1.6%)

59.0 (2.5%)

P5

32.2 (5.0%)

33.3 (3.0%)

29.6 (4.6%)

30.1 (3.0%)

P6

42.7 (4.6%)

41.5 (3.5%)

37.9 (2.1%)

37.7 (2.0%)

P7

53.0 (0.0%*)

54.2 (9.4%)

43.6 (2.5%)

45.1 (8.6%)

P8

178.8 (4.3%)

189.7 (1.4%)

164.0 (3.0%)

170.4 (1.3%)
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Figure 3. Relative volume and mass for the GTV of patient 8. The physician contours show a phase
dependence which is typical of the lung (at minimum in exhale, at maximum in inhale).
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Figure 42. An inhale-phase coronal slice for P7. The sorting artifacts near the superior/inferior
borders of the tumor result in >10% mass deviations in deformed GTV structures in different
respiratory phases.

3.2 DVH AND DMH DIFFERENCES
DVH-based plans, optimized for delivery on both the inhale-phase image and the aCT are used to
evaluate DVH and DMH differences. The differences in relative volume and relative mass at all dose
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levels (DVH-DMH) are less than 3% in the spinal cord and the heart for all patients (8) and DVH-plans
(16) considered. For the esophagus, 1 of 8 patients show relative mass/volume differences exceeding
3% at doses above 2 Gy. In the ipsilateral lung, differences in relative mass and volume exceed 3% in 3
of 8 inhale-based plans, and in 6 of 8 aCT- plans at dose levels ranging from 10-20 Gy. The targets
(including GTV, ITV, and PTV) show differences exceeding 3% in both inhale and aCT plans for all patients
near the prescription dose. The PTV dose at 95% volume (D95V), when compared to PTV dose at 95%
mass (D95M), differ by up to 15.7 Gy for P3, implying cold spots occur in massive regions of the PTV for
this patient. For 5 of 8 patients considered, differences in D95V and D95M are less than 1 Gy, but for three
patients these differences exceed 2 Gy in at least one of the two plans considered. Figure 5 shows the
difference between relative volume and relative mass at prescription dose levels for both lungs and PTV
on each of the images considered. For the GTV (in inhale plans) and ITV (in aCT plans), the results are
similar to PTV, with differences occurring near the prescription dose.
Figure 6 shows the DVH and DMH for the aCT-plan for P1. In this case, relative lung mass at dose is
greater than the DVH levels by at least 5% for doses ranging from 20 Gy–70 Gy. This is the only case
which shows differences in esophagus DVH and DMH > 3% of the DVH value.

Figure 5. (DVH-DMH) Average DVH and DMH differences planned and evaluated on the inhale phase
image, with the PTV defined as a 1 cm expansion of the GTV. The only structures of potential
significance in all cases considered are the lungs, GTV, and PTV.
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Figure 6. DVH (solid) and DMH (dasheded) values for P1 for a plan optimized on the average-CT. The
optimization objectives shown as solid triangles. The relative mass at dose is higher than dose-volume
levels for ipsilateral lung, esophagus, and for the PTV. This is the only case which shows >3%
differences in esophagus, and these differences are far below the esophagus objective

Average DVH and DMH differences based on inhale- and aCT-images/plans across the 8-patient cohort
at objective dose levels are shown in Table 4. Population average differences are normally distributed
and are small for esophagus, heart, and cord. For lungs, relative volume and relative mass differences at
20 Gy ranges from -0.07 to 0.03 at 20 Gy on the inhale plans, and from -0.04 to 0.07 on aCT plans. These
DVH and DMH differences have potential to impact plan optimization and outcome evaluation. For the
GTV and PTV, DVH at prescription dose is consistently greater than the DMH in all inhale-plans, and in
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6/8 aCT-plans. This implies that cold-spots in the target occur in regions of high density in these plans.
At the prescription dose level (70 Gy), the PTV-DVH > PTV-DMH in 14/16 plans. Ipsilateral lung did not
show a consistent trend in DVH and DMH differences.
Table 4 Differences between relative volume and relative mass at objective dose levels,for IMRT plans
on inhale and on average-CT. The average (µ), standard deviation (σ), and the p-value (p) calculated
from a student’s t-test. The dose-levels are specified following the V and M in the metric, e.g. V25 is
volume receiving 25 Gy.
Inhale-Plan

aCT-Plan

µ

σ

p

µ

σ

p

Esophagus (V25-M25)

-0.0013

0.0048

0.5

0.00015

0.004

0.9

Heart (V30-M30)

0.0023

0.002

0.02

0.0021

0.0019

0.02

Cord (V40-M40)

-0.00064

0.0015

0.3

0.0003

0.00085

0.4

Left Lung (V20-M20)

-0.0099

0.027

0.3

0.0022

0.024

0.08

Right Lung (V20-M20)

-0.0032

0.023

0.7

0.021

0.034

0.1

GTV / ITV (V70-M70)

0.047

0.023

0.0006

0.029

0.03

0.03

PTV (V70-M70)

0.026

0.025

0.02

0.016

0.031

0.2

3.3 DVH AND DMH OPTIMIZATION
Differences in volume and mass at prescription dose levels yield different optimized solutions based on
tade-off consistency between objectives. An example of the adjustments when considering DMH,
instead of DVH, is shown in Figure 7 for the aCT-plan of P4. Both lung V20-M20 (=0.046) and PTV V70M70 (=0.063) are greater than zero, so the DMH-optimized plan increases lung-mass at 20 Gy in order to
ensure PTV-mass coverage at 70 Gy. The converse is true for P1, shown in the previous section. For this
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plan, for both lung and PTV, DMH > DVH at objective dose levels so that DMH-optimization reduces both
PTV-dose at mass and lung-dose at mass, in order to reduce the objective function.

Figure 7. DVH (solid) and DMH
(dashed) curves resulting from
DVH-optimization (thin) and
DMH-optimization (thick) for P4.
Because lung DMH<DVH, the
DMH-optimized plan results in
better PTV coverage. Dose to
95% of the PTV-mass is
increased from 69.3 Gy in the
DVH- optimized plan, to 71.1 Gy
in the DMH- optimized plan.
In 13/16 DVH-optimized plans,
cold-spot distributions in dense PTV sub-volumes result in V70 > M70 and led to increased PTV-mass
coverage in DMH-optimized plans. However, the difference in dose to 95% volume (PTV-D95V) and dose
to 95% mass (PTV-D95M) between DVH and DMH plans is less than 2 Gy in 6 of 8 inhale-plans, and in 6 of
8 aCT-plans (and in both aCT and inhale plans in 5 of 8 patients considered). This was not the case for
P3, where PTV-D95M increases from 49.7 Gy to 58.4 Gy. This 8.7 Gy increase in mass-coverage is
achieved by increasing PTV-D95V by just 3.2 Gy (from 65.4 Gy in the DVH-plan to 68.6 Gy in the DMHplan). A different trend was observed for P1, where lung DMH > DVH by 15.7% of the DVH value in the
inhale-plan and by 9% in the aCT-plan. By optimizing DMH for P1, PTV-D95V is reduced by 12.6 Gy in the
inhale plan and by 8.5 Gy in the aCT plan, resulting in reduced lung mass and volume at dose (by 9-14%
of DVH-optimized values); however, PTV-D95M is reduced by just 2.5 Gy in the inhale plan (69.4 Gy to
66.9 Gy) and by 1.8 Gy (68.8 Gy to 67 Gy) in the aCT-plan. The comparison of DVH and DMH optimized
inhale-plans for P1 is shown in Figure 8. A large reduction in PTV-volume at dose allowed significant
sparing while maintaining an acceptable PTV-mass at prescription dose.
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Figure 8. DVH (solid) and DMH (dashed) curves resulting from DVH-optimization (thin) and DMHoptimization (thick) for P1. DMH-optimization reduces dose at 95% PTV volume by 12.6 Gy compared
to DVH-optimized levels in order to reduce ipsilateral lung mass at 20 Gy. Even though the PTVvolume is clearly under-dosed, the dose at 95% of PTV mass is 66.9 Gy.

4. DISCUSSION
The current standard for simulation of lung cancer patients is 4DCT; under the assumption that 4D
information will improve the quality of plans and associated risk/benefit analysis. In a first stage
towards this goal, anatomical structures must be well defined with minimal inter- and intra- observer
contouring variability (Louie et al 2010). Evaluation of structure mass in different phases of 4DCT has
the potential to lead to more consistent structure definition, and using DIR to define structures will
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reduce the physician delineation workload by a factor of 5 or more. In this work, consistent GTV mass
across different breathing phases using demons DIR is observed for 7/8 patients; and compared to
delineated structures the deformed GTV shows smaller mass variation in 5/8 4DCT image set
(comparable mass conservation in two more cases). In 1 image set, however, DIR failed to preserve
mass across respiratory phases due to image-artifacts – that is, mass-based evaluation of structures
identified registration problems that require attention. If structure definition can be improved, which
certainly requires careful steps to ensure 4DCT images are free of artifacts, structure density as reported
in 4DCT has the potential to be correlated to function (Ma et al 2009). If artifacts are present, which
have been shown to be prevalent in 4DCT image sets (Yamamoto et al 2008), the findings of this study
suggest they can be identified through DIR-contour propagation and mass analysis.
For lung, density may not correlate well with lung functionality, very low density parenchyma may be
significant to oxygen exchange. Lung on CT is primarily composed of a mixture of blood vessels, blood,
and air, with functional alveoli difficult or impossible to identify. Several authors have incorporated lung
perfusion imaging in plan optimization (Seppenwoolde et al 2002, Christian et al 2005, McGuire et al
2006, Shioyama et al 2007, Lavrenkov et al 2007, Munawar et al 2010) and beam angle optimization
(McGuire 2010) to reduce dose to functional lung. Castillo et al (2010) have considered methods to
produce ventilation images from 4DCT data sets, and have shown that neither the Jacobian determinant
of the DVF nor the fractional air content of each voxel correlates well with perfusion imaging, with dice
similarity coefficients less than 0.4 in six of seven cases. In this study, mass is used as a surrogate for
voxel importance in optimization for lung cancer. The method proposed here can take advantage of
reduced radiation path-lengths through tissue, regardless of functionality. By preferentially treating the
tumor through lower density normal tissue, more unit incident fluence is delivered to the tumor.
However, using mass (and density) as a surrogate for cell importance can be replaced by some other
indicator of functionality (e.g. perfusion) if one is available.
Comparison of dose-at-volume (using DVH) with dose-at-mass (using DMH) shows differences in lung
volume at fixed dose often exceed 5% and exceed 2Gy at fixed volume or mass. The study of Mavroidis
et al (2006) shows similar results. It is possible that these differences have a one-to-one
correspondence with uncertainty in outcome data relying on the DVH (Lyman 1985), based on the
linear-quadratic prospective model of cell-kill. This study shows DVH and DMH in both lung and lung-
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cancer targets can vary by >10%, and the sign of this difference is patient and radiation-path dependent.
For a set of voxels composing a given volume, the subset of irradiated voxels may have a different mean
density than the entire structure mean. No conclusive generalization can be made about DVH and DMH
differences; the irradiated volume may be more dense than the structure mean (and DMH>DVH) or less
dense than the structure mean (with DMH<DVH).

5. CONCLUSIONS
The results of this study show the utility of structure mass in structure delineation, in dose evaluation,
and in RT plan optimization. Relying on the premise that mass is constant during respiration, evaluation
of structure mass defined on different respiratory-phases measures intra-observer delineation
consistency. Using DIR to define contours often results in more consistent structure mass between
phases compared to physician contours, but DIR failed in the presence of image artifacts. In dose
evaluation using the DMH, density of the irradiated tissue is explicitly included in evaluation, rather than
consider the entire structure which may include non-functional sub-units, the density of irradiated tissue
is explicitly included inmass-based evaluation. Finally, optimizing RT plans using mass (and the DMH)
has the potential to reduce radiation path lengths by treating less dense regions of normal tissue as well
as increasing importance in massive regions of the target.
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Appendix E

Multi-criteria Optimization for Real-Time Planning of
Lung Cancer Radiotherapy

W.T. Watkins1, W.Y. Song2, E. Weiss1, J.R. Merrick1, G. D. Hugo1, J. V. Siebers1
1

Virginia Commonwealth University, Richmond, VA

2

University of California San Diego, La Jolla, CA

Purpose. Multi-criteria optimization (MCO) is implemented for planning lung cancer radiotherapy
treatments to clarify patient-specific tradeoffs and allow real-time plan decision making.
Methods. For four locally advanced lung cancer patients (Pt1-Pt4), a basis set of MCO plans are
constructed and compared to plans determined from fixed-objective (FO) optimization for organs at risk
(OARs). All optimized plans include constraints on target-D95>70 Gy and spinal cord Dmax<45 Gy. Five
MCO basis plans are designed per patient through weight variation of four non-zero dose-volume
objectives (DVOs) for ipsilateral lung (iLung), contralateral lung (cLung), heart, and esophagus. The five
basis plans are optimized according to: (1) simultaneous minimization of four OAR-DVOs and (2-5)
weight variation for one OAR-DVO.
Results. Patient-specific tradeoffs between OAR objectives are revealed with MCO which are not
evident in FO-optimization. For Pt1, MCO basis plans vary iLung-V20 from 46% to 65% and show that
V20<46% is not achievable; the FO iLung-V20 is 54%. For Pt2,the FO-plan trades off a 1% reduction in
iLung-V20 for a 29% increase in esophagus-V20. An interpolated MCO plan, in this case, takes advantage
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of this tradeoff to reduce esophagus V20 by from 41% to 8%. Pt3 shows increasing heart-V20 by 35%
(from 20% to 55%) results in a 7% (34%-27%) reduction in iLung-V20. With Pt4, MCO reveals a tradeoff
between the two lungs; varying iLung-V20 from 23% to 30% corresponds to cLung-V20 varying from 23%
to 17%. The FO plan treats cLung up to the V20 objective (to 29%) without penalty. MCO shows the
ability to reduce OAR dose-volumes, but often led to increased PTV hotspots.
Conclusions. Analysis of MCO plans clarifies conflicting objectives and exposes inherent limitations due
to patient geometry. Real-time decision making is possible with a small set of MCO plans, and achieves
plans which are superior to FO-optimization.
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